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ABSTRACT
The work presented in this thesis focuses on the development of polymerase chain 
reaction (PCR) assays for diagnosis and differentiation of equid herpes viruses-1 and -4 
(EHV-1 and EHV-4) infections in suspected field cases and contact animals and in 
experimentally infected specific-pathogen-free (SPF) foals. The technique has been 
applied to study the pathogenesis of EHV-1 and EHV-4 infections in these foals. Further, 
the effect of homologous (EHV-1:EHV-1) challenge on nasal virus excretion and 
duration of viremia has been studied. Studies on heterologous (EHV-4:EHV-1) challenge 
have also been conducted with one objective being to determine whether challenge virus 
could reactivate virus inoculated to produce primary infection (reactivation of EHV-4 by 
EHV-1 in this instance). Following secondary challenge (homologous or heterologous), 
dexamethasone administration was performed in order to reactivate latent virus(es). The 
chapterwise details of the thesis are as follows:
Chapter 1 describes the general features the family Herpesviridae structure of 
herpesvirion, genomes of herpesviruses, classification of herpesviruses, their replicative 
cycles and latency. A brief account of various equid herpesviruses (equid herpesviruses-1 
to -8) is given and the literature on various aspects of EHV-1 and EHV-4 has been 
reviewed comprehensively.
The general materials and methods used throughout the course of study are described in 
Chapter 2.
Chapter 3 gives an account of polymerase chain reaction (PCR) and its application in 
various fields of science. The EHV-l/EHV-4 PCR assay is detailed. Type common 
primers derived from the conserved regions of homologues of HSV genes encoding
xvii
glycoproteins gH and gC and a nested set comprising a primer derived from thymidine 
kinase (tk) gene and three from the gH gene have been used to amplify specific regions of 
EHV-1 and EHV-4. The targets for amplification in the PCR assays were: tissue culture 
supernatants from EHV-1 and EHV-4 infected cultures and recombinant plasmic DNAs 
containing EHV-1 and EHV-4 target. The amplified products could be distinguished by 
type-specific probes selected from the divergent regions of the genes and internal to the 
primers. Reaction conditions were optimised and assay sensitivity assessed.
Chapter 4 describes the use of PCR techniques to the detection of EHV-1 or EHV-4- 
specific DNA in nasopharyngeal swab samples from suspected field cases and their in­
contacts. The primers used in the PCR assay were: inner gH, nested set and gC. The 
assays were conducted blind and later decoded and compared with virus isolation data. 
Of 98 samples, 91 of which were EHV-1 and EHV-4-negative and 7 positive, all 7 
positives were confirmed by PCR and 5 virus-negative were PCR-positive. The results 
indicated that PCR is a sensitive and rapid technique for the diagnosis of EHV-1 and 
EHV-4 infections.
The studies on the experimental infections of specific-pathogen-free (SPF) foals are 
described in Chapter 5. The experiment was conducted in three phases: primary
infection, secondary infection/challenge and reactivation. Two groups of two SPF foals 
were infected by inoculating 10^ pfu of EHV-1 strain Ab4 or EHV-4 strain MD 
intranasally. Nasal secretions and peripheral blood leucocytes (PBMCs) were collected at 
days -2, 1, 3, 5, 8, 11 and 18 post-infection (p.i.) and analysed by PCR. Results were 
compared with the virus isolation and co-cultivation data. The latter work was carried 
out by research group at Cambridge led by Dr Hugh Field. Rectal temperatures as high as 
106F were recorded in EHV-1 infected foals and classical signs of EHV-1 induced
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disease were observed. The EHV-4 infected foals exhibited a mild disease. EHV-1 
specific DNA was detected in the nasal secretions of the EHV-1 infected foals til day 18 
post-infection, the day of last sampling. In the PBMCs of EHV-1 infected foals, EHV-1 
specific DNA was detectable till day 11 p.i. At the peak of infection at day 5 in one foal 
and at day 8 in another foal. 5 x 10^ and 5 x 10^ PBMCs respectively gave a positive 
signal in PCR assay. Nasal virus excretion by virus isolation was demonstrable till day 
11 p.i. in both the EHV-1 infected foals. EHV-1 viraemia was observed by infectious 
centre assay at days 3, 5 and 11 in one foal and at day 11 post infection in another. The 
EHV-4-specific DNA in EHV-4 infected group was detectable till day 18 and 15 
respectively in the nasal secretions of the two foals. EHV-4 specific DNA was detectable 
till day 15 p.i.: the infection was mild throughout as 5 x 10^ cells gave a positive signal in 
PCR assay. In another foal, EHV-4 specific DNA was detectable till day 11 p.i. in the 
PBMCs, the peak of infection observed at day 11 when 5 x 10^ cells gave a positive 
signal. No infectious centre was demonstrated in co-cultivation studies of leucocytes of 
EHV-4 infected foals indicating thereby that the assay is less sensitive as compared to 
PCR. Our studies provide definitive evidence of EHV-1 and EHV-4 specific DNA 
sequences in PBMCs of foals infected under specific pathogen-free conditions, following 
primary infection with EHV-1 and EHV-4.
For secondary EHV-1 infection/challenge, a dose of 10^ pfu of the virus by intranasal 
route was inoculated in both the groups of foals. Following secondary challenge, no rise 
in body temperatures of EHV-1: EHV-1 infected foals was observed and the clinical signs 
were very mild in comparison to those observed during acute primary infection. A slight 
elevation in the rectal temperature of one of the EHV-4:EHV-1 infected foals was 
observed at day 7. The clinical disease in this group was milder. The homologously 
challenged foals had viruses in their nasal secretions at day 1. EHV-1 specific DNA was
detectable in 5 x 10  ^PBMCs at day 3 in one foal in this group and in 1 x 10^ cells at day 
12 p.i. in another foal. In heterologously challenged foals (EHV-4:EHV-1), EHV-4 
specific DNA was detectable in 5 x 10^ cells of both the foals two days prior to challenge 
i.e. 82 days after primary infection. Following EHV-1 challenge in one foal EHV-4 DNA 
was detectable in pellets of PBMCs containing 1 x 10^ and 5 x 10^ cells at days 1, 3 and 
5 and in 1 x 10^ cells at day 8 but not subsequently. EHV-1 DNA was detectable in up to 
1 x 105 cells at day 8 and 5 x 10^ cells at days 12 and 17. In another heterologously 
challenged foal, EHV-4 DNA was amplified from 5 x 1 0 ^  cells 2 days prior to challenge 
from 1 x 105 cells at day 5 and from 1 x 10^ cells at day 8 post challenge: EHV-1 DNA 
was detected in 5 x 1()4> 5 x 10^, 5 x 10^ and 1 x 10^ cells of this foal at days 5, 8, 12 
and 17 respectively.
EHV-1 specific DNA was not detectable in nasal swab samples and PBMCs of EHV-1: 
EHV-1 infected foals following the two treatments of dexamethasone on days 29 and 30 
post secondary challenge, although nasal aspirate samples were positive. In the case of 
EHV-4:EHV-1 infected foals EHV-1 and EHV-4 DNA was detected in nasal swabs from 
one foal and leucucytes of both foals. Nasal aspirates were positive for EHV-1 DNA. No 
virus was recovered by cocultivation of leucocytes from any foal.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 HERPESVIRIDAE
1.1.1. General Description
Herpesviruses are infectious agents which are highly disseminated in nature and infect a 
number of vertebrate species. They are among the most important causes of viral diseases 
of man and domestic animals. Over 100 herpesviruses have been at least partially 
characterised (Roizman and Baines, 1991). They are genetically complex and possess 
large, linear, double-stranded genomes with a base pair composition of 32 to 75% G+C. 
All the members of the family share a typical architecture: the virions of various 
herpesviruses cannot be differentiated by electron microscopic examination. Although, all 
herpesviruses share the property of maintaining a state of latency in their hosts, they show 
considerable diversity with respect to their host range and other biological properties. In 
fact, few virus families exhibit as much variation as the members of family Herpesviridae. 
Six human herpesviruses have so far been characterised, namely, Herpes simplex virus-1 
(HSV-1) and 2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr Virus (EBV), human 
cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6). Recently, another human 
herpesvirus, HHV-7 has been isolated from human lymphocytes (Frenkel et al. , 1990) and 
saliva (Black et al, 1993). In domestic animals, at least one major disease of each species 
is caused by a herpesvirus.
Herpes simplex virus-1, one of the most intensively studied of all viruses, is regarded as 
the prototype of the Herpesviridae. In humans, infection with HSV-1 typically occurs 
during the first six years of age as a consequence of exposure to an adult or child secreting 
virus. The disease, which usually occurs as mild stomatitis is often indistinguishable from 
other diseases of childhood. A proportion of those infected exhibit recurrent lesions 
containing virus, usually at the mucocutaneous junction of the lip. HSV-1 may play some 
role in Alzhemier's disease (Jamieson et al., 1992). In the case of HSV-2, infection occurs 
either at birth or more commonly after the age of consent. The virus is transmitted
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through sexual contact and primary lesions and recrudescences usually occur at or near 
genital organs and may also occur in the mouth. Both HSV-1 and HSV-2 may also be 
implicated in encephalitis and keratoconjunctivitis (Stanberry, 1992). Patients 
compromised either by immune therapy, underlying disease, or malnutrition are at 
increased risk for herpes simplex virus infection.
Varicella zoster virus (VZV) causes chicken pox (varicella) upon primary infection and 
shingles (herpes zoster) after reactivation of the latent virus from dorsal root ganglia. 
Chicken pox is a highly contagious but commonly mild disease, usually of children, 
whereas shingles is a local vesicular lesion caused by reactivation of the virus within a 
dermatome and is extremely painful. VZV infections may have serious consequences in 
immunocompromised individuals. The virus can cause neurological complications such as 
post-herpetic neuralgia (Kennedy, 1987; Mahalingham et al., 1993).
EBV is a causative agent of infectious mononucleosis (Katz et al., 1986). It is also 
associated with Burkitt's lymphoma (Epstein et al., 1964), nasopharyngeal carcinoma 
(Raab-Traub et al., 1987), Sjogrens's syndrome (Fox et al., 1986), lymphomas in 
immunodeficient individuals and rheumatoid arthritis (Sculley et al., 1986). EBV is also 
involved in Hodgkin's disease (Jarrett et al., 1991, Jarred and Onions, 1992). This virus 
can cause indefinite in vitro proliferation of lymphocytes, a process termed 
immortalisation, and this property underlies its role in lymphoproliferative disorders.
HCMV infections are often subclinical but distinct syndromes have been associated with 
the infections. HCMV has been estimated to be responsible for about 7% of infectious 
mononucleosis cases (Horwitz et al., 1977). In infants, a potentially fatal condition known 
as cytomegalic inclusion disease follows infection of the foetus (Stagno et al., 1977). 
Primary or reactivated HCMV infection of immunocompromised individuals and
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infections of neonates may result in prolonged fever, hepatitis, myalgia and or pneumonia 
(Ho, 1982).
HHV-6 has been isolated from peripheral blood mononuclear cells of patients with AIDS 
and leukaemia/lymphoma (Salahuddin et al., 1986; Becker et al., 1989). The virus causes 
a febrile condition, exanthem subitum, in young children (Yaminishi et al., 1988). The 
virus is tropic for CD4+ T cells (Ablashi et al., 1987) and induces apoptosis in 
macrophages (Knox and Carrigan, 1992). HHV-6 has been isolated from over 85% of 
normal healthy individuals (Harnett et al., 1990). Following primary infection, individuals 
persistently harbour the virus in the oropharynx, salivary gland and peripheral blood 
(Jarrett eta l., 1990).
Herpesviruses can cause diseases in domestic animals, resulting in considerable economic 
losses. Bovid herpesvirus-1 (BHV-1) causes infectious bovine rhinotracheitis, a 
respiratory condition; infectious pustular vulvo-vaginitis in cows and balanoposthitis in 
bulls, venereally transmitted conditions; abortion, conjunctivitis and a fatal systemic 
infection in new bom calves (Ludwig, 1983). Another bovid herpesvirus, BHV-2, is 
responsible for bovine mammilitis, a condition characterised by lesions on the udder and a 
severe generalised cutaneous condition, pseudo-lumpy skin disease. A reduction in milk 
yield occurs in cows infected with BHV-2 as a result of mastitis and difficulty in milking.
Pseudorabies virus (PRV, suid herpesvirus-1) is the aetiologic agent of Aujeszky's disease 
in pigs, a disease of great economic importance world-wide. (Gustafson, 1986). Up to 50% 
of pregnant sows may abort over a short period of time due to spread of infection from 
carrier animals. In young pigs, the virus causes a severe meningo-encephalitis resulting in 
heavy mortality. Adult pigs usually survive infection, but the virus can cause fever and 
pneumonia resulting in significant weight loss and poor growth rates. Pigs can transmit 
the virus to a diverse range of secondary hosts such as cattle, sheep, goats, dogs, cats and
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many feral species. PRV has recently been isolated from the brain of a mare showing 
neurological signs and on inoculation into foals the virus reproduced Aujezky's disease 
(Kimman et al., 1991).
Marek's disease virus (MDV) causes a progressive lymphoproliferative disease in poultry 
throughout the world. Prior to the introduction of vaccination, it was the most common 
lymphoproliferative disease of chickens causing heavy annual losses. Although 
vaccination against Marek's disease has dramatically reduced the incidence of the disease 
it has not reduced the incidence of infection and, because of the continuing losses from 
disease and the cost of vaccination, it remains the most economically important disease of 
chickens. MDV can transform T lymphocytes. The lesions of Marek's disease result from 
the infiltration of these lymphocytes into nervous tissue. The virus can induce T cell 
lymphomas in chicken (Payne, 1982).
Herpesvirus of turkeys (HVT), which is antigenically related to MDV, produces no 
apparent disease in chickens and turkeys and has been successfully used in chickens to 
prevent tumours caused by MDV (Purchase et al., 1972).
Infectious laryngeotracheitis virus (ILTV) causes an acute and contagious disease of 
chickens which is characterised by depression, conjunctivitis, sneezing and in severe cases 
gasping, laboured breathing and death due to asphyxia (Jordan, 1990). Economic losses 
result from heavy mortality and lowered egg production. Immunisation with live- 
attenuated vaccines protects birds against clinical disease but does not protect against 
infection with virulent strains or the establishment of a latent state.
Equid herpesviruses-1 and -4 (EHV-1 and EHV-4) are responsible for various clinical 
syndromes like upper respiratory tract disease, abortion and neonatal foal mortality, and
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neurological disease (Allen and Bryans, 1986) and are described in greater detail in 
section 1.3.
1.1.2 Structure of the herpesvirion
In negatively stained preparations, the size of the herpesvirus virion varies from 120 nm to 
300 nm in diameter (Roizman and Furlong, 1974). This variability in the size is due to 
differences in the amount of tegument and the integrity of the envelope. The virions of all 
members of the family Herpesviridae share structural features: the virion consists of four 
structural components, the core, capsid, tegument and envelope. The core, the innermost 
component, is believed to consist of a fibrillar spool on which the DNA is wrapped with 
the ends of the fibre anchored to the underside of capsid shell. However, a recent study 
does not support the presence of a spooled structure in HSV-1 and suggests that virion 
DNA is packed in bundles of parallel duplex DNA strands in a locally ordered manner 
(Booy et al., 1991). The capsid (100-110 nm) is an icosahedron with 150 hexameric and 
12 pentameric capsomers. The hexameric capsomers contain a hole running halfway 
through the long axis. The structure between the capsid and the envelope, termed the 
tegument, consists of an amorphous material that is often asymmetric in distribution and 
its thickness may vary depending on the location of the virion in the infected cell. The 
envelope, which consists of a bilayer lipid membrane, is the outermost component. Surface 
spikes composed of glycoproteins which differ in size, morphology and distribution 
project from the envelope (Stannard et al., 1987). The envelope glycoproteins serve as 
targets for both humoral and cell-mediated immune responses. Fc receptors for 
immunoglobulin G may be present in the virion envelope and on the surface of the 
infected host cell (Dubin et al., 1990; Litwin et al., 1990). The structure of the 
herpesvirus virion is schematically represented in Figure 1.1.
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Figure 1.1 
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Figure 1.1 Schematic representation of a herpesvirus virion.
1.1.3 Herpesvirus Genomes
The herpesvirus genome is a single linear double-stranded DNA molecule of molecular 
weight 80-150 x 106 daltons and base composition of herpesvirus DNAs varies from 32-75 
G+C moles per cent (Honess, 1984). The genome sizes of the herpesviruses range from 
approximately 120 to 235 kilobase pairs (kbp). In general, the cytomegaloviruses have 
larger genomes and viruses with smaller genomes, such as VZV, are found among the 
alphaherpesviruses. The genomes contain terminal and internal repeat sequences which 
may be repeated directly or in an inverted manner. The repeats were detected initially by 
studying annealed single-strand DNA by electron microscopy. Because of the variability 
in the numbers of reiterations, the size of the genome of a given herpesvirus may vary by 
more than 10 kbp among isolates. Spontaneous deletions are reported to occur, 
particularly when viruses are passaged outside their natural host or in heterologous cells in 
vitro (Allen et al., 1983a; Studdert et al., 1986; Koch et al., 1987). The complete genomes 
of HSV-1 (McGeoch et al., 1988), VZV (Davison and Scott, 1986), HCMV (Chee et al., 
1990), EBV (Baer et al., 1984), EHV-1 (Telford et al., 1992) and CCV (Davison, 1992) 
have so far been sequenced and more are underway.
1.1.4 Classification of Herpesviruses
New viral isolates are identified and included in the family Herpesviridae on the basis of 
the architecture of the virion, but members within the family cannot be differentiated by 
electron microscopy. A classification system would ideally allow the properties or gene 
functions of new or less characterised viral isolates to be predicted by comparison with 
those of related, well characterised viruses. Herpesviruses have undergone considerable 
divergence with respect to their antigenic and biological properties, as well as the genetic 
contents of their virions. Serology has been useful in determining the antigenic 
relationships between closely related herpesviruses, e.g. HSV-1 and HSV-2, but it may not 
effectively detect relationships among the less related members even of the same 
subfamily. On the basis of biological properties, the family has been divided into three
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subfamilies (Roizman, 1982). With the availability of gene mapping and sequence data, 
criteria such as conservation and colinearity of genes and organisation of the genes within 
the genome are also in use for subclassification. Sequence data has revealed that all 
herpesviruses are genetically related and viruses within a subfamily are more closely 
related to each other than to members of other subfamilies. Some of the herpesviruses 
have now been grouped into genera using DNA base and protein sequence homologies, 
similarities in gene and sequence arrangements and serologic relatedness of important 
glycoproteins of their virions.
1.1.4.1 Classification based on biological properties
The Herpesviridae have been divided into three subfamilies, namely, alpha-, beta- and 
gamma-herpesvirinae. The herpesviruses differ in their host range, cytopathology in cell 
culture, duration of replication cycle, sites of latency and the clinical conditions which 
they cause in their natural hosts (Roizman, 1982; Honess, 1984).
Alphaherpesvirinae
The alphaherpesviruses replicate in a variety of cells in vivo and in cell culture. They have 
a short growth cycle (18-20 h). In cell culture, these viruses spread rapidly, resulting in 
extensive cell destruction. Oncogenic transformation and generation of defective 
interfering particles have been observed in certain cell lines infected by some 
alphaherpesviruses (O'Callaghan et al., 1983). Alphaherpesviruses infect epithelial cells of 
the skin, eyes, oral cavity, respiratory and genital tracts of their natural hosts, causing mild 
primary lesions. They may persist in a latent state, primarily but not exclusively, in 
nervous tissues and may be reactivated causing recrudescence of lesions. Some may 
establish a latent state in peripheral blood leucocytes and lymphoid tissues (Welch et al., 
1992). The subfamily has been divided into two subgroups, a l  and a2  (Honess, 1984). 
Members of the a2  subgroup (e.g. VZV and simian varicella virus) differ from those of 
the a l  subgroup (HSV-1, HSV-2, BHV-1, EHV-1 and PRV) in that they replicate
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relatively slowly, have a narrow host range and are usually cell-associated. However, 
according to the new classification system based on DNA and protein sequence 
homologies, similarities in sequence arrangement, gene organisation and serologic 
relatedness of the important virion glycoproteins, HSV-1, HSV-2, simian herpesvirus or B 
virus are now grouped into the genus Simplex Virus, whereas VZV, PRV and EHV-1 are 
placed in the genus Varicellovirus.
Betaherpesvirinae
Betaherpesviruses, commonly known as cytomegaloviruses, have a narrow host range in 
vitro and in vivo and replicate slowly in cell culture. Cytomegalia, in which the cells 
become enlarged, is a characteristic feature of infection. Inclusion bodies can be observed 
both in the nucleus and cytoplasm. Two types of non-infectious particles comprised of 
virus tegument and envelope polypeptides, dense bodies and noninfectious enveloped 
particles, are frequently observed during replication (Gibson, 1981; Irmiere and Gibson, 
1983). Although betaherpesviruses cause inapparent and persistent infections in adults, 
they are capable of causing disease in neonates and immunocompromised hosts. In 
asymptomatic hosts these viruses can be isolated from the salivary glands, kidneys and 
lymphoreticular tissue which are the probable sites of persistence. Members of this 
subfamily include HCMV and Herpesvirus aotus (H. aotus-1 and H. aotus-3). The 
subfamily contains three genera, Cytomegalovirus (HCMV), Muromegalovirus (murine 
cytomegalovirus) and Roseolovirus (HHV-6). The genera Cytomegalovirus and 
Roseolovirus correspond to (31 and (32-herpesviruses.
Gammaherpesvirinae
The viruses in this subfamily have a narrow host range in vivo which is usually restricted 
to natural hosts within the same family or order. All members replicate in lymphoblastoid 
cells in vitro and some may cause lytic infection in some types of epithelial and 
fibroblastoid cells. The replication cycles of these viruses are variable in duration. They
immortalise either B lymphocytes (yl subgroup) or T lymphocytes (y2 subgroup) and 
some can cause lymphoproliferative disease in the host, e.g. EBV. In lymphocytes, 
replication of the virus is frequently arrested resulting in a state of latency. Infection may 
also be arrested at the lytic stage causing cell death without production of infectious 
virions. Productive infection also occurs, but in only a small proportion of lymphocytes. 
The yl sub-group of the gammaherpesvirinae is represented by EBV (human herpes virus- 
4) and related viruses of old world monkeys and apes. H. saimari, viruses of new world 
monkeys and lower vertebrates form subgroup y2 (Honess, 1984). The subfamily 
gammaherpesvirinae has two genera; Lymphocryptovirus (EBV) and Rhadanovirus (H. 
ateles and H. saimari). These genera correspond to yl and y2 subgroups.
1.1.4.2 Classification based on genome structure
Base composition, size of the genome and arrangement of repeat sequences within the 
genome can be used to classify herpesviruses. Base composition ranges from 32-75 G+C 
moles per cent. Genome base composition does show some correlation with the biological 
grouping of herpesviruses. For example, the 12 herpesviruses with a G+C content higher 
than 60% all belong to alphaherpesvirinae, the betaherpesviruses have a G+C content 
ranging from 50-60%, while some of the y2 herpesviruses have a G+C content of less than 
50% (Honess, 1984). Also, y2 herpesviruses are characterised by a low G+C content in 
their coding sequences and a high G+C content in their repeat sequences. Genome size 
cannot be used to place viruses into genera since it varies considerably, even among 
closely related members. The most useful characteristic for classification is the analysis of 
the arrangement of reiterated sequences 100 nucleotides or longer within the genome 
(Roizman, 1990). Based on this approach, herpesvirus genomes are categorised into six 
distinct groups designated A to F. However, there is no absolute correlation between the 
type of genome structure and grouping of viruses into subfamilies. A diagrammatic 
representation of each group in shown in Figure 1.2.
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Figure 1.2 Different types of herpesvirus genome structures (adapted from 
Roizman. 1990).
Group A
In the genomes of viruses comprising group A, a large sequence from one terminus is 
directly repeated at the other terminus. The group A genomes are exemplified by channel 
cat fish virus (Chousterman et al., 1979), HHV-6 (Martin et al., 1991), MCMV (Marks 
and Spector, 1988) and EHV-2 (Browning and Studdert, 1989; Colacino et al., 1989). The 
genome of EHV-2 is peculiar in that it exists in a single isomeric form. The genome 
contains 18 kb direct terminal repeats and a pair of unrelated short internal indirect repeats 
(Browning and Studdert, 1989a).
Group B
In group B genomes, the terminal sequence is shorter than that of group A genomes and is 
directly repeated a variable number of times at the genomic ends. Members of this group 
include H. saimiri (Bomkamm et al., 1976), H. ateles (Fleckenstein et al., 1978), bovine 
herpesvirus-4 (BHV-4) (Ehlers et al., 1985) and alcelaphine herpesvirus-1 (AHV-1) 
(Bridgen et al., 1989).
Group C
Group C genomes are characterised by multiple reiterations of one set of sequences in the 
same orientation at both termini, as well as by internal tandem reiterations of other sets of 
sequences (Raab-Traub et al., 1980). This group is represented by the EBV genome which 
is 172 kbp long, has a variable number of tandem direct repeats of 0.5 kbp at the genomic 
termini (Given et al., 1979) and a variable number of tandem internal direct repeats of 3 
kbp which divide the genome into short and long, largely unique, sequence domains (Ug 
and U l) (Given and Kieff, 1979). The largely unique sequence domains are also divided 
internally by directly repeated unrelated sequences. The genomes of other members of this 
group, Herpesvirus papio (Heller and Kieff, 1981) and Herpesvirus pan, (Heller et al.,
1982) have structures similar to EBV genome.
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Group D
Group D genomes are exemplified by VZV,  PRV, EHV-1, EHV-4 and BHV-1. Their 
genomes comprise two covalently linked segments, long (L) and small (S). L is a unique 
sequence (Ul) and S consists of a unique sequence (Ug) bounded by inverted repeats, an 
internal repeat (IRg) and a terminal repeat (TRg). The L segment is in fixed orientation 
whereas the S component can invert relative to L, thus giving rise to two isomeric forms of 
the genome. The VZV genome is composed of two regions, U l (approximately 100 kbp) 
and Ug (5.4 kbp). Ug is flanked by an inverted repeat sequence (6.8 kbp) (Dumas et al., 
1981). About 5% of VZV genomes contain an inversion of U l (Davison 1984). VZV 
virions thus contain four genome isomers, two major and two minor. The two orientations 
of Ug are present in equimolar concentrations, whereas one orientation of U l 
predominates. A similar disproportionate isomeric arrangement of the genome has also 
been observed for PRV (De Marchi et al., 1990). In EHV-1 U l is present in one 
orientation only (Yalamanchili et al., 1990).
Group E
In group E viral genomes, exemplified by those of HSV-1 and -2, sequences from both 
termini are repeated in an inverted orientation and juxtaposed internally, dividing the 
genomes into two components, L and S, each of which consists of unique sequences 
flanked by inverted repeats. Both components can invert relative to each other. Four 
equimolar populations, differing in the relative positions of their L and S components, can 
be demonstrated in DNA extracted from virions or infected cells (Roizman, 1979). The 
four linear isomers are designated as P (prototype), IL (inversion of L component), Ig 
(inversion of S component) and IgL (inversion of both S and L components). BHV-2 
(Buchman and Roizman, 1978 a,b), HCMV (Weststrate et al., 1980), MDV and HVT 
(Cebrian et al., 1982) are other members of this group.
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Group F
The group F genome is exemplified by tupaiid herpesvirus. The 200kbp genome consists 
of a unique long sequence flanked by non-identical terminal sequences which have no 
internal counterparts (Koch et al., 1985).
1 .1.4.3 Limitations of the current classification system
Most herpesviruses have been appropriately classified into subfamilies with both 
biological and genetic criteria. However, there have been exceptions including CCV, 
MDV and HVT, HHV-6 , EHV-2 and EHV-5 and BHV-4. CCV is classified as an 
alphaherpesvirus on the basis of biological properties, but it cannot be placed in any of the 
three subfamilies on the basis of genetic analysis. It has been suggested that it may be 
classified as the sole member of a new subfamily (Davison, 1992). Marek's disease virus - 
1 and -2 and HVT (meleagrid herpesvirus -1) were originally placed in the 
gammaherpesvirinae primarily on the basis of their tropism for T-lymphocytes. 
Comparative analysis of the amino acid sequences deduced from limited nucleotide 
sequence data and colinearity of their genomes with that of VZV suggests that they are 
more closely related to alphaherpesviruses (Buckmaster et al., 1988). HHV-6 , previously 
classified among the gammaherpesviruses on the basis of its tropism for T lymphocytes, is 
closely related to HCMV, a betaherpesvirus, by DNA hybridisation (Efstathiou et al., 
1988) and sequence analysis (Lawrence et al., 1990). Similarly EHV-2 and EHV-5 which 
were provisionally placed in betaherpesvirinae are now recognised as distinct members of 
gammaherpesvirinae on the basis of limited genetic analysis (Telford et al., 1993). 
Another betaherpesvirus, BHV-4 has now been placed among gammaherpesviruses on 
genetic basis (Bublot et al., 1992). Although the conservation and colinearity between the 
genes of two herpesviruses reflects genetic relatedness, the conserved genes may not 
necessarily represent the biological properties of these viruses, e.g. the domains of the 
MDV genome which are conserved with and colinear to the VZV genome are not those 
which are expressed during latency or in transformed cells (Sugaya et al., 1990). As the
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biological correlates of the genes in conserved and nonconserved regions of herpesviruses 
become known, a more useful classification system, based on both biological and genetic 
criteria, can be developed.
1.1.5 Replication of Herpesviruses
The replication of herpesviruses is well studied for HSV-1, an alphaherpesvirus. Although 
beta- and gammaherpesviruses probably have a similar mode of replication, their 
replication cycles are longer. In order to initiate infection, virus attaches through its 
envelope glycoproteins to receptors on the surface of the host cell, which in the case of 
HSV-1 and HSV-2, are heparan sulphate proteoglycans (WuDunn and Spear, 1989). 
Glycoprotein C (gC) has been shown to play a principal role in the adsorption of virus to 
cells and in infectivity (Herold et al. , 1991). The virus penetrates by fusion of the viral 
envelope with the plasma membrane of the cell. Glycoproteins gB, gD and gH of HSV-1 
are implicated in this process. Penetration by endocytosis has also been observed, but it 
results in nonproductive infection (Campadelli-Fiume et a l,  1988). Virions which attach 
but fail to fuse, are degraded in endocytic vesicles. Once the virus enters the cell the 
capsids are released into the cytoplasm and are transported to the nuclear pores where the 
DNA-protein complex is released from the nucleocapsid into the nucleus. Upon release, 
the linear viral genome circularises by ligation of the terminal sequences. Transcription 
and replication of viral DNA occurs in the nucleus. The lytic cycle of herpesviruses is 
schematically represented in Figure 1.3.
Three classes of messenger RNA, a, (3 and 7, are transcribed by the cellular DNA- 
dependent polymerase II in a co-ordinated, regulated and sequentially ordered cascade 
(Honess and Roizmann, 1974). a  messenger RNAs are translated to a  polypeptides which 
initiate transcription of (3 mRNA. The (3 polypeptides suppress further transcription of a  
mRNA. Five immediate early (IE) genes of HSV are the first to be expressed after 
infection. Their expression is induced by a virion tegument protein (Vmw65), also known
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Figure 1.3 Schematic representation of l)Tic cycle of herpesviruses (adapted 
from Fenner et a l , 1987).
as a  trans-inducing factor a-TIF. Vmw65 forms a complex with one or more host cellular 
factors, such as Oct 1, which interacts with a consensus element within the cis-acting 
sequences upstream of the immediate early (IE) gene (O'Hare et al., 1988; Preston et al., 
1988). The transcription complex then binds to the strongly acidic C-terminal amino acids 
of Vmw65 enhancing transcription (Cousens et al., 1989). The synthesis of a  
polypeptides reaches peak rates at approximately 2-4 h post-infection (p.i.) (Honess and 
Roizman, 1974). (31 genes are expressed earlier than (32 genes. These genes encode 
functions required for DNA replication. (31 and (32 polypeptides reach peak rates of 
synthesis at 5-7 h p.i. The expression of yj genes is minimally affected by inhibitors of 
DNA synthesis which suggests that these genes are expressed relatively early in infection. 
y2 genes are expressed late in infection and are not expressed in the presence of effective 
concentrations of inhibitors of viral DNA synthesis. More than 70 virus-encoded proteins 
are synthesised during the replication cycle.
Synthesis of viral DNA takes place in the nucleus and is signalled by (3 polypeptides, 
beginning at about 3 h p.i. and continuing for 9-12 h. Herpesviruses specifiy a number of 
enzymes and other factors involved in the DNA replication. The circular genome acts as a 
template utilising a rolling circle mechanism (Ben-Porat and Tokazewski, 1977). The 
newly synthesised head-to-tail-linked concatameric viral DNA molecules are cleaved by 
endonuclease activity. Those herpesviruses which contain large inversely orientated 
repeats also undergo genomic isomerisation.
Host cell DNA, RNA and protein synthesis declines concomitantly with viral biosynthesis 
and is shut off completely within 3-5 h. The host cell shut-off is brought about by 
preformed virion structural protein (s) known as virion host shut-off protein (s) (vhs) early 
in infection, but in the later stages other viral gene products may be involved in this 
process. In the lytic cycle, complete host cell shut-off eventually leads to death of the host 
cell.
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DNA is processed and packaged into immature capsids in the nucleus. The nucleocapsids 
acquire modified areas of inner lamellae of the nuclear membrane as envelope. Mature 
virions accumulate within vacuoles in the cytoplasm and egress by reverse phagocytosis or 
by cytolysis. It has also been proposed that the virions are secreted via the golgi apparatus 
(Johnson and Spear, 1982). Intranuclear inclusion bodies characteristic of herpesviruses 
are demonstrable in the infected cells. Non-infectious particles known as L particles, 
which lack capsids and viral DNA but contain five proteins including Vmwl75, an IE 
regulatory protein, have been demonstrated in cells infected with HSV-1 strain 17 
(Szilagyi and Cunningham, 1991). In addition HSV-1 strain F, EHV-1 and PRV also 
generate these particles in infected cells (McLauchlan and Rixon, 1992). In a recent study 
of the replication of a temperature-sensitive mutant of HSV-1 incapable of producing 
mature virions, it was demonstrated by electron microscopy that, although capsid assembly 
takes place in the nucleus, the DNA is not packaged; the immature capsids are retained in 
the nucleus and do not acquire a tegument or envelope (Rixon et al., 1992). Hence, the 
processes governing assembly of the tegument and envelope of L particles and mature 
virions are similar.
1.1.6 Latency
All herpesviruses are capable of establishing a state of latency in their natural hosts once 
the primary infection subsides. They can remain in this state probably for the lifetime of 
the host. The virus can periodically be recrudesced or reactivated, either spontaneously or 
after induction by a number of stimuli, resulting in recurrent shedding and lesions. The 
infected individual or animal may act as a source for the spread of virus to in-contacts. 
This attribute of herpesviruses is thus, important from the point of view of epidemiology 
and disease control. The neurotropic alphaherpesviruses primarily establish a latent state 
in nervous tissue though this may not be the exclusive site. HSV-1 remains latent in the 
neurons of sensory ganglia which serve the site of primary infection (Hill, 1985); VZV 
persists in the ganglionic cells (Mahalingham et al., 1990); Latent PRV DNA has been
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detected in ganglia and tonsillar tissue (Galeota Wheeler et al., 1991), peripheral blood 
leucocytes (PBLs) and bone marrow cells (Rziha et al., 1992); EHV-1 maintains latency in 
lymphoid tissue and PBLs (Welch et al., 1992). The probable sites of persistence in the 
case of betaherpesviruses are epithelial cells of various internal organs and lymphoreticular 
cells. The site of latency in the case of HCMV is the monocyte (Taylor-Wiedeman et al., 
1992). Gammaherpesviruses persist in lymphocytes.
Various useful animal models, including mice, rats, guinea pigs, rabbits and monkeys, 
have been developed to study HSV-1 latency in vivo (Roizman and Sears, 1987). Different 
sites such as peripheral (eye, ear, footpad or vagina), intracerebral or systemic 
(intraperitoneal or intravenous routes) are used for inoculation of the virus. The mouse is 
the most commonly used animal model. The development of sensitive techniques, such as 
in situ hybridisation and the polymerase chain reaction (PCR), has made it possible to 
investigate the molecular events that take place during the establishment and maintenance 
of latency and reactivation of the latent virus.
During the latent phase the virus is not present in infectious form in the infected cells, but 
can be reactivated spontaneously or by different stimuli. For example, the latent virus can 
be induced to replicate by cocultivation of latently infected tissue explants with permissive 
cells allowing the recovery of infectious virus. In latently infected cells the viral genome 
is present as a circular or linear concatameric molecule (Rock and Fraser, 1983, Efstathiou 
et al., 1986). Mellerick and Fraser (1987) demonstrated that latent HSV-1 viral DNA is 
present in the host cell in a non-integrated state as it can be separated from host 
chromosomal DNA by density gradient centrifugation.
During latency viral gene expression in the infected cells is repressed. Transcription of 
HSV-1 during latency is limited to a 10-kb region within the long repeat region of the 
genome in ganglia of animal models (Rock et al., 1987a,b; Dealty et al., 1988; Mitchell et
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al., 1990) and in human sensory ganglia (Croen et al., 1987) as revealed by in situ 
hybridisation. Transcription occurs from a region of the genome complementary to that 
encoding the IE mRNA and partially overlapping its 3' end (Rock et al., 1987b; Stevens et 
al., 1987). Three virus-specified transcripts, known as latency-associated transcripts 
(LATs), of 2.0, 1.5 and 1.45 kbp, have been detected by Northern blot analysis and 
localised within the region found positive by in situ hybridisation (Wagner et al., 1988). 
The LATs are predominantly nonpolyadenylated and are present in the nuclei of latently 
infected neurons. Using high resolution non isotopic hybridisation, Arthur et al. (1993) 
demonstrated that the major LAT species were distributed diffusely throughout the 
nucleoplasm, whereas minor LATs were localised to intranuclear foci of 1 to 3 pm in 
diameter in the sensory neurons of latently infected mice and humans. It has been 
proposed that latent phase transcription takes place from a single primary transcription 
unit of 8.3 kb which is processed to yield the major non-polyadenylated LATs (Devi-Rao 
et al., 1991). The 2.0 kb LAT transcript can down-regulate the IE gene product, infected 
cell polypeptide 0 (ICPO) (Farrell et al., 1991). Thus, this transcript may play some role in 
the establishment of latency.
The transcription of BHV-1 LATs in rabbit trigeminal ganglia is restricted to a 1.9 kb part 
of the viral genome within the long repeat region (0.734- 0.748 m.u.). The transcripts 
(LATs) are antiparallel and overlap to some degree the uncharacterized immediate early 
genes of the virus (Rock et al., 1987a). The LATs range in size from 0.77 to 1.16 kb in 
latently infected rabbit and cattle trigeminal ganglia (Kutish et al, 1990).
Similarly, transcription of PRV genome in latently infected neurons takes place from a 
region of the genome which overlaps IE gene region, 0.64-0.82 m.u. (Priola et al, 1990). 
Both polyadenylated (4.5 - 5.5 kb) and non polyadenylated (1.2 - 2.0 kb) LAT species 
have been detected (Cheung, 1989; Priola etal., 1990).
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In the case of VZV, five distinct regions of the viral genome have been shown to be 
transcriptionally active during latent-phase (Croen et al., 1988). Mahalingham et al. 
(1993) quantified latent VZV DNA in human trigeminal ganglia and detected 6 to 31 
copies of VZV genome per 105 ganglionic cells.
The LAT promoter, LAP, is located upstream of the 5' end of abundant LAT gene and 
contains neuron-specific promoter elements (Batchelor and O'Hare, 1990; Zwaagstra et al., 
1990). LAT promoter binding factor (LPBF), a nuclear factor present in neuronal and 
non-neuronal cells, binds to an eight nucleotide sequence, CCACGTGG, located at 
nucleotides -72 to -65 relative to the start of LAT transcription (Zwaagstra et al., 1991). 
Deletion of binding sequences greatly reduces LPBF binding activity and results in up to a 
30 fold reduction in LAT promoter activity. Thus, LPBF plays a major role in the 
regulation of LAT promoters. Devi-Rao et al. (1991) demonstrated that sequence elements 
between -258 to -161 were selectively required for LAP activity in murine neuroblastoma 
cell-line. The deletion of this sequence resulted in six-fold decrease in promoter activity in 
this cell-line. Batchelor and O'Hare (1992) identified a DNA-binding factor in human 
neuroblastoma cell-lines which binds to sequences -161 to 138 and is responsible for cell- 
type specific activity of LAP.
The role of LATs in establishment and maintenance of latency and in reactivation from the 
latent state has been investigated using defective or deletion mutants of HSV-1 in cell 
culture and in animal models. Studies on LAT deletion mutants of HSV-1 in rabbit or 
mouse models suggest that LATs are not required for the establishment or maintenance of 
latency (Javier et al., 1988; Ho and Mocarski, 1989; Leib et al., 1989; Steiner et al., 1989; 
Block et al., 1990). Studies on tk deletion mutants (Coen et al., 1989; Tenser et al., 1989), 
mutants with lesions in the Vmw 65 gene (Steiner et al., 1990; Valyi-nagy et al., 1991) 
and in the IE1 gene (Clements and Stow, 1989) have revealed that such mutants can 
establish latent state. The studies on the Vmw65 and IE mutants also indicate that
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immediate early gene expression and replication of viral DNA in ganglia are not pre­
requisites for establishment of HSV-1 latency.
LATs do not appear to establish or maintain latency through translation of RNA to protein, 
since mutations that formed stop signals were observed in the open reading frame 2 (ORF 
2) of LAT amplified by PCR using DNA from latently infected trigeminal and cervical 
ganglia of mice (Lynas et al., 1989). However, Doerig et al. (1991a) reported a 80 kDa 
LAT-encoded protein in cultured neurons latently infected with HSV-1.
Using PCR, Katz et al. (1990) quantified viral DNA in the trigeminal ganglia of mice 
inoculated intracomeally with a range of HSV-1 mutants and demonstrated that they 
could establish latency in mice.. These mutants included ribonucleotide reductase negative 
(RR-), thymidine kinase negative (tk"), ICP4 negative (ICP4") and other mutants which 
were severely impaired for viral DNA replication and gene expression. Tk* infected 
ganglia contained one copy of HSV-1 DNA per 100 cell equivalents, 50 fold less than the 
wild-type. RR deletion mutant-infected ganglia also contained one copy of HSV-1 DNA 
per 100 cell equivalents. Using ICP4" HSV-1 variant, Sedarati and coworkers (1993) 
demonstrated that latent infections can be established in the murine sensory neurons under 
conditions in which viral genetic expression and DNA replication are severely impaired.
Farrell et a l (1993) constructed a recombinant HSV-1 to alter the largest ORF in the 
latency-associated transcription unit. The recombinant virus had a wild-type reactivation 
phenotype which suggests that the HSV does not require a protein function from this ORF 
for efficient reactivation from latency.
The reports on reactivation kinetics of LAT' mutants are conflicting; while some LAT' 
mutants show similar reactivation kinetics to wild-type virus (Ho and Macaraski, 1989; 
Block et al., 1990), others are less efficient (Leib et al., 1989; Steiner et al., 1989). An
HSV-1 strain 17 variant 1716 which has a deletion encompassing a neurovirulence gene, 
on inoculation in footpads of mice is capable of peripheral replication but is not detectable 
in the dorsal root ganglia up to 10 d.p.i. (Robertson et al, 1992). This variant is thus, 
capable of establishing a latent infection but the kinetics of its replication are impaired 
compared to wild-type virus.
Following iontophoresis in a rabbit eye model, parental (17+) and rescuant (1704R) strains 
of HSV-1 reactivated from 76% and 64% of rabbits, respectively, while a LAT variant 
(1704) reactivated from only 1 out of 25 animals (4%) (Trousdale et al., 1991). Further, 
in studies on explant reactivation it was demonstrated that while 17+ and 1704R 
reactivated from 98% and 67% of trigeminal ganglia of rabbit, respectively, 1704 
reactivated from only 28% of trigeminal ganglia. The reactivation time for the parental 
strain and rescuant was 8-9 days, whereas the LAT variant took 17 days for reactivation in 
explant culture. These studies suggest the role of LATs in reactivation of the virus.
Latent infection with HSV-1 in neuronal culture is analogous to that observed in vivo. 
Following reactivation by nerve growth factor (NGF) deprivation, glycoprotein D mRNA 
was demonstrable in the latently infected neuronal cells (Doerig et al., 1991b). The gD 
mRNA is not normally detected in the latently infected neurons in culture and is 
characteristic of productive infection.
Speck and Simmons (1991) inoculated mice with wild-type HSV-1 in order to study the 
natural course of events following infection, as most earlier studies were conducted with 
replication defective mutants or in cell culture. Expression of viral antigens during 
productive infection was limited to fewer spinal ganglia innervating the site of inoculation 
(ninth thoracic spinal segment), than during the subsequent latent phase, in which neuronal 
expression of LAT and in vitro reactivation of virus from ganglionic explants was 
widespread. This suggests that the antigen positive (Ag+) cells observed during acute
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infection are not precursors of latently infected neurons. Using in situ hybridisation for 
detection of LATs and immunohistochemical staining for detection of viral proteins 
expressed during latency, Speck and Simons (1992) demonstrated that the Ag+ and latently 
infected neurons in mice appeared simultaneously in the spinal ganglia during the earliest 
stages of acute ganglionic infection. Both Ag+LAT" and Ag'LAT"1" neurons were 
demonstrable in spinal ganglia 3 days after inoculation in the flanks of mice. During the 
course of acute infection, all the three types of infected cells (Ag+ LAT", Ag+ LAT+, Ag" 
LAT+ increased in numbers. These studies suggest that the pathways leading to 
productive and latent infections diverge early in infection, supporting earlier studies with 
HSV-1 mutants.
A suitable in vivo model to study the molecular processes of HSV-1 reactivation has 
recently been developed, in which hyperthermia is used to induce reactivation of latent 
virus from the trigeminal and lumbosacral ganglia of mice (Sawtell and Thomson, 1992). 
Stress induced by the hyperthermia is indicated by the production of heat shock protein 
HSP70 in the trigeminal and lumbosacral ganglia. In this model, infectious HSV-1 virions 
were demonstrable in ganglia as early as 14 h post-treatment and the proportion of mice 
positive for the infectious virus was highest (60%) at 24 h suggesting a rapid switch from 
latent to active viral transcription following hyperthermic treatment. HSV-1 antigens were 
demonstrable by immunohistochemical staining in one to three neurons per ganglion 24 h 
post induction, but not in other types of cells within the ganglion. During reactivation, 
some antigen positive neurons showed degenerative changes. This is the first report of 
HSV-1 antigen detection in vivo following reactivation of the virus from the intact nervous 
system. These studies suggest that the neuron is the site of infectious virus during 
productive infection, as well as the site of reactivation of the virus.
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1.2 EQUID HERPESVIRUSES
Equine herpesviruses are antigenically distinct viruses infecting Equidae that cause a 
variety of clinical conditions, ranging from subclinical infections to fatal systemic 
diseases. Eight herpesviruses designated equid herpesvirus -1 to -8 have, so far, been 
isolated from equid species and at least partially characterized. EHV-2 and EHV-5 are 
antigenically and genomically heterogeneous slowly cytopathic viruses whose 
pathogenetic role is uncertain. These two viruses were provisionally included in 
betaherpesvirinae (Roizman, 1982; Browning and Studdert, 1987b) primarily on the basis 
of their biological properties but the genetic data suggests that they are distinct 
gammaherpesviruses (Telford et al., 1993). Among alphaherpesviruses, EHV-1 and EHV- 
4 are the most important pathogens that are implicated in various disease conditions, 
causing heavy losses to the horse industry. EHV-3, another alphaherpesvirus, causes a 
mild venereal condition, equine coital exanthema.
1.2.1 EHV-2
EHV-2, also known as equid cytomegalovirus, is among the most common viral agent of 
the horse. It has been isolated from the leucocytes of about 89% of apparently healthy 
horses (Roeder and Scot, 1975) and from the upper respiratory tract, tonsils, conjunctiva, 
genital tract, mammary gland, bone marrow and kidneys. The fact that infectious cell-free 
virus is not retrievable in cell culture from disrupted or non-viable leucocytes, but 
infectious centres can be demonstrated when leucocytes are cocultivated with equine foetal 
kidney monolayers (Dutta and Myrup, 1983; Gleeson and Coggins, 1985), suggests that 
EHV-2 persists in the leucocytes in a latent state. The virus has been isolated from young 
horses with upper respiratory tract disease (Palfi et al., 1978; Sugiura et al., 1983; Fu et 
al., 1986). Experimental infection of a mid-term foetus resulted in mild neonatal rhinitis 
and conjunctivitis but not abortion (Gleeson and Studdert, 1977). Multiple concurrent 
local infections with EHV-2 have been reported under field conditions; 5 isolates which
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differed in their restriction endonuclease patterns were recovered from a yearling 
(Browning and Studdert, 1987a).
Isolates of EHV-2 exhibit considerable antigenic heterogeneity in cross-neutralisation 
assays (Mumford and Thompson, 1978) and also differ considerably in the restriction 
endonuclease profiles of their genomes (Browning and Studdert, 1987b). No cross­
reactivity between EHV-2 and equine alphaherpesviruses has been observed by serum 
neutralisation (Homer et al., 1976). In DNA reassociation kinetic studies, 2.0-2.9% and 
1.0-2.0% homology has been demonstrated between EHV-1 and EHV-2, and EHV-2 and 
EHV-3, respectively (Staczek et al., 1983).
1.2.2 EHV-5
On analysis of 51 field isolates of EHV-2 for restriction profiles of their genomes , four 
had identical patterns that differed from others (Browning and Studdert, 1987b). These 
viruses had smaller genomes, grew very slowly in cell culture and exhibited reduced 
homology to representative isolates of EHV-2. These viruses were provisionally 
designated as EHV-5. Hybridisation studies have shown that the genome of EHV-5 strain 
5.2-141 differs from that of EHV-2; the genome is 179 kbp and does not contain large 
terminal sequences or internal repeats, although some very short repeat sequences are 
present in the genomic termini (Agius et al., 1992). This genome structure is unique 
among the equid herpesviruses.
1.2.3 EHV-7
A betaherpesvirus, asinine herpesvirus-2, isolated from the leucocytes of an apparently 
healthy donkey is now designated equid herpesvirus-7. EHV-7 shares few restriction 
fragments with EHV-2 and EHV-5 and exhibits a low level of DNA base sequence 
homology with them (Browning et al., 1988a).
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1.2.4 EHV-3
Equid herpesvirus-3 (EHV-3), an alphaherpesvirus, causes a venereal disease, equine 
coital exanthema (ECE), which is characterised by the formation of papules, vesicles and 
ulcers in the perineal region, on the vaginal and vestibular mucosa of mares and on the 
skin of the penis and prepuce of stallions (Bryans and Allen, 1973). Non-coital 
transmission of the virus has also been observed (Crandell and Davis, 1985). Lesions are 
occasionally seen on the teats, lips and respiratory mucosa. Cases of ECE are usually 
mild, unless complicated by bacteria (Evermann et al., 1983). Unlike EHV-1 and EHV-4, 
EHV-3 is not implicated in abortion. EHV-3 grows mainly in equine cells (Bryans and 
Allen, 1973) and its replication is restricted at 39°C to 39.5°C, the body temperature of its 
host (Bouchey et al., 1987). The temperature sensitive functions are related to the 
maturation of nucleocapsids into infectious virions (Jacob, 1986; Jacob and Steiner, 1988). 
On the basis of serum neutralisation, EHV-3 is antigenically distinct from other equine 
herpesviruses though some antigens are shared with EHV-1 as demonstrated by 
immunofluorescence and precipitation (Gutekunst et al., 1978). By reassociation kinetics 
and thermal analyses, homologous DNA sequences equivalent to 7.6-8 .2 megadaltons 
between EHV-1 and EHV-3 and 1.3-3.9 megadaltons between EHV-2 and EHV-3 have 
been demonstrated (Stackzek et al., 1983). The genomes of EHV-1 and EHV-3 are 
colinear and the immediate early RNA species of the two viruses have been shown to be 
homologous (Sullivan et al., 1990)
1.2.5 EHV-6
A herpesvirus, originally isolated from lesions resembling coital exanthema on the nares of 
a donkey foal and teats of its dam and referred to as donkey herpesvirus-1 (Burrows, 
1973), has recently been characterised (Jacob et al., 1988). The virus is serologically 
distinct from other equine herpesviruses, but has minor DNA base sequence homology 
with that of the EHV-3 genome. The virus differs in restriction enzyme digestion pattern, 
a characteristic feature being that its DNA is not digested with the restriction enzyme
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Xbal, and the DNA has a higher G + C content. This virus has now been designated equid 
herpesvirus-6 (EHV-6).
1.2.6 EHV-8
Another alphaherpesvirus, asinine herpesvirus-3 (AHV-3), was isolated from the nasal 
cavities of donkeys administered with high doses of corticosteroids. On the basis of DNA 
hybridisation studies, protein profiles of virions, serum neutralization and 
immunoprecipitation analyses, AHV-3 is more closely related to EHV-1 than to EHV-4 
(Browning et al., 1988a; Crabb and Studdert, 1990; Crabb et al., 1991). This virus is now 
designated equid herpesvirus-8 (EHV-8).
1.2.7 Equine rhinopneumonids virus (equine abortion virus)
Outbreaks of abortions in mares due to non-bacterial causes were reported at the 
University of Kentucky (USA) during 1922 to 1932. Dimock and Edwards (1932) induced 
abortions in pregnant mares by inoculation of foetal fluids and foetal tissue extracts. The 
induction of abortions by inoculation of bacteriologically sterile filtrates of foetal tissue 
extracts into pregnant mares (Dimock and Edwards, 1936) and demonstration of 
acidophilic, intranuclear inclusions in tissue sections from aborted foeti (Dimock, 1940) 
suggested viral etiology of the abortions. A respiratory syndrome was later associated 
with equine abortion virus (Doll et al., 1954, 1957). Based on the presence of main 
histological lesions in the respiratory tract of young horses and aborted foeti, the condition 
was named equine rhinopneumonitis and the virus equine rhinopneumonitis virus. The 
disease was later reported from many parts of the world (Matumoto et al., 1965; Bagust, 
1971). Mares inoculated with equine abortion virus developed myelitis following abortion 
(Manninger, 1949). Cases of EHV-l-associated neurological disease have been observed 
subsequently in nonpregnant mares, stallions, geldings and foals in the field. (Dinter and 
Klingebom, 1976; Crowhurst et al., 1981; Thein, 1981).
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1.2.7.1 Recognition of two subtypes
On the basis of cross neutralisation, an isolate of EHV-1 recovered from an aborted foetus 
in Japan, H-45, differed markedly from an American strain, Ky-D (Shimizu et al., 1959). 
Two major antigenic groups were later recognised (Kawakami et al., 1962; Burrows , 
1966). The antigenic subtypes were subsequently correlated with the sites of recovery of 
viral isolates; the majority of the foetal isolates belonged to subtype 1, while respiratory 
isolates were grouped into subtype 2 (Burrows and Goodridge, 1973). The two antigenic 
subtypes further differed in their biological properties such as in vitro host range, capacity 
to cause leucocyte-associated viraemia, abortigenicity, and in vivo and in vitro growth 
characteristics (Burrows and Goodridge, 1973; Studdert and Blackney, 1979). Besides 
differences in their antigenic and pathogenic characteristics, the two subtypes differed in 
the electrophoretic mobility of eight of their structural polypeptides (Turtinen et al., 1981). 
Restriction endonuclease analysis of the genomic DNAs of these subtypes revealed no 
common restriction sites (Sabine et al., 1981; Studdert et al., 1981; Turtinen et al., 1981). 
Based on these findings, Studdert et al. (1981) proposed that the two subtypes be 
recognised as distinct types, EHV-1 subtype 1 as EHV-1 and EHV-1 subtype 2 as EHV-4. 
This view was further strengthened by the finding that the two subtypes shared 17% of 
their genomic sequences as determined by DNA-DNA reassociation kinetic studies (Allen 
and Turtinen, 1982). However, the current sequence data suggests that their homology is 
remarkably higher (Section 1.3.7). It emerged from all these studies that the equine 
rhinopneumonitis virus (equine abortion virus, EHV-1) is not a single virus but 
biologically and genetically two distinct agents which are serologically related. The 
proposal of Studdert et al. (1981) to recognise the two subtypes as distinct viruses was 
ratified by the International Committee on Taxonomy of Viruses in 1987 and they are now 
known as EHV-1 and EHV-4.
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1.3 EHV-1 AND EHV-4
Though EHV-1 and EHV-4 are respiratory pathogens, EHV-1 is predominantly associated 
with abortion, neonatal foal mortality and neurological disease. Restriction endonuclease 
analyses of field isolates indicate that EHV-4 is a major cause of respiratory disease 
particularly in young horses and causes epizootics of respiratory disease in this group of 
animals (Allen et a l, 1983b; Studdert, 1983). Unlike EHV-1, this virus is rarely the cause 
of abortion, or neurological disease. The horse racing and stud industries suffer significant 
financial losses as a result of EHV-1 and EHV-4 infections due to poor racing 
performance, abortion or paralysis..
1.3.1 Pathogenesis and diagnosis of EHV-1 and EHV-4 infections
Different pathogenetic processes are involved in the development of the abortion, 
respiratory and neurological syndromes associated with EHV-1 and EHV-4. These 
processes are outlined in Figure 1.4. The determinants of pathogenicity of EHV-1 and 
EHV-4 in relation to the different manifestations of disease have not yet been fully 
characterised.
1.3.1.1 Respiratory infections
EHV-1 and EHV-4 are associated with upper respiratory tract disease in horses throughout 
the world. Horses acquire infection by inhalation of virus contained in aerosols or 
contaminated feed, water, bedding and other fomites and aborted foetal tissue. Following 
inhalation, the viruses replicate in the respiratory epithelium causing inflammation which 
may lead to necrosis and erosion of the mucosa. Both viruses have been detected in 
alveolar macrophages. In addition, EHV-1 replicates in vascular endothelial cells in the 
respiratory tract mucosa (Patel et al, 1982). After initial replication in the respiratory 
tract virus spreads via lymphatic vessels to the regional lymph nodes. EHV-1 respiratory 
tract infections are accompanied by leucocyte-associated viraemia, whereas EHV-4
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Figure 1.4
Pathogenesis of EHV-1 and EHV-4 infections
£<5
Figure 1.4 Clinical manifestations of EHV-1 and EHV-4 infections (adapted 
from Allen and Bryans, 1986).
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infections are usually confined to the respiratory tract and associated regional lymph 
nodes. Extensive necrosis of the respiratory mucosa renders it susceptible to bacterial 
invasion (Studdert, 1974).
In immunologically naive young horses, respiratory disease is generally seen in epidemic 
form after weaning and in the autumn and winter months of the first year of life. Acute 
infection with either virus is characterised by fever, which is often biphasic in the case of 
EHV-1, peak rectal temperatures as high as 105°F-106°F, serous nasal discharge which 
may later become mucoid or mucopurulent, anorexia, depression, occasional coughing and 
enlargement of submandibular and retropharyngeal lymph nodes (Allen and Bryans, 
1986). Clinical signs of acute disease are usually observed for 2-7 days. Young horses 
may develop bronchopneumonia or chronic bronchitis. Respiratory disease due to EHV-4 
is usually mild in comparison with EHV-1. Infected animals excrete virus and act as a 
source of infection for in-contact horses. Immunity to EHV-1 and EHV-4 infections is 
transient: horses are susceptible to reinfection within 3-6 months of previous exposure and 
may experience repeated infections throughout their lifetime. Upon reinfection, horses 
may not exhibit clinical signs of the disease but are viraemic for up to 5-7 days and 
excrete virus though for a shorter period of time than that following primary infection 
(Bryans, 1969).
Diagnosis
EHV-1 and EHV-4 respiratory infections can be diagnosed by isolation and identification 
of the aetiological virus from the nasopharynx. Virus isolation is more effective if 
nasopharyngeal swabs are taken during the febrile stage of the disease. Pharyngeal 
biopsies may be taken if endoscopic facilities are available. Virus can be recovered from 
heparinised blood if collected during the viraemic phase. The presence of EHV-1 in 
peripheral blood mononuclear cells can be detected by development of infectious centres 
on co-cultivation of these cells with permissive cultured equine cells (Dutta and Myrup,
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1983). Blood or pus may be collected with the help of fiber optic endoscope from the 
trachea of suspected cases which exhibit frothy discharge or haemorrhage from the 
nostrils, particularly following exercise.
Diagnosis of respiratory disease by serological methods is less definitive than virus 
isolation and requires paired serum samples. Correct timing in collection of serum 
samples from acute and convalescent animals is crucial for sero-diagnosis. When paired 
serum samples from a single animal are examined to diagnose infection several serological 
tests, including the serum neutralisation test, CF test and ELISA, may be necessary 
because rises in antibody titres sometimes may not be detected using a single test 
(Thomson et al., 1976). The CF test is generally the most sensitive; a four-fold decrease 
in CF antibody titre in a convalescent serum sample is indicative of infection in the 
previous 10 weeks. Both virus isolation and serological testing are relatively slow in 
providing results. Pools of EHV-1 or EHV-4 specific Mabs can be used in enzyme 
immunofiltration and indirect immunofluorescence assays for rapid screening of field 
isolates (Yeargan et al., 1985).
1.3.1.2 Abortigenic and neonatal foal disease
Infection of the reproductive tract by EHV-1 and EHV-4 is a potential sequelae to 
infection of the respiratory tract. In the case of EHV-1 a leucocyte-associated viraemia 
precedes infection of the uterus (Bryans, 1969). The virus is probably transported to the 
uterus by infected leucocytes. Recent studies suggest that the virus first establishes 
infection in endothelial cells of the endometrium and is then transferred across the placenta 
and establishes infection in the placental vasculature and foetus (Edington et al., 1991). 
The primary sites of infection in the foetus are endothelial cells of major blood vessels and 
in hepatic sinusoids. EHV-1-induced abortion can also occur due to endometrial damage 
alone without the establishment of foetal infection, as demonstrated by the abortion of 
virus-negative foeti (Smith et al., 1992).
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The first event in the process of abortion is the separation of the placenta from the 
endometrium causing suffocation of the foetus. The placental separation results from 
severe and widespread thrombosis in the uterine blood vessels which may occur prior to 
transfer of virus to the placenta (Smith et al., 1992). Focal necrosis due to thrombosis of 
uterine blood vessels may permit leakage of free virus or infected cells across the 
endometrial stroma (Edington, et al., 1991; Smith et al., 1993). EHV-1 replication in the 
endometrial vessels has been detected with immunoperoxidase staining as early as 6 days 
post-experimental inoculation of EHV-1 and is maximal at 9-11 days when 
thromboischaemic damage is widespread (Smith et al., 1993). Replication of EHV-1 
occurred at a number of different sites in the uterus (Smith et al., 1993). The foetus is 
expelled with intact placental membranes. At necropsy, the aborted foetus exhibits 
petechial haemorrhages of serosal surfaces, the respiratory mucosa and conjunctivae, 
oedematous lungs, pale foci in the liver and an enlarged spleen. The major histological 
lesions are necrotising bronchopneumonia and areas of focal necrosis in the liver and 
spleen. Typical herpes-type intranuclear inclusions may be observed in the affected cells. 
Foeti which acquire infection during the terminal stages of gestation may be stillborn or 
bom alive. The latter are highly susceptible to secondary bacterial infections and usually 
die during the first few hours or days of life (Dixon et a l, 1978; Hartley and Dixon, 1979).
Since EHV-1 and EHV-4 can remain in the latent or persistent form for long periods in the 
host, it is not clear whether abortion is caused by newly acquired infection, or by 
reactivation of the latent virus within infected leucocytes (Gleeson and Coggins, 1980). 
Analysis of DNA restriction patterns of the virus recovered from foetus and the challenge 
virus used to experimentally induce abortions in mares has been used to determine whether 
abortion is caused by the challenge virus. Following this approach Martens et al. (1989) 
found that challenge virus used to experimentally induce abortion in a mare had a DNA 
restriction pattern similar to that of the virus recovered from the aborted foetus, indicating 
that in this instance abortion was caused by the challenge virus.
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Mares which abort as a result of EHV-1 and EHV-4 infection usually show no 
premonitory signs of abortion. The incubation periods for abortion following EHV-1 
exposure is variable. Pregnant mares aborted 48-120 days after intranasal inoculation with 
EHV-1 (Doll and Bryans, 1962a). In recent experimental study on EHV-l-induced 
abortion in pregnant mares, about 44% (14 out of 32) aborted between 9 and 14 days post 
infection (Smith et al., 1992). Abortions due to EHV-1 often take place between 5-11 
months of pregnancy, 95% occuring during last four months of gestation (Doll and 
Bryans, 1963).
Abortions may be sporadic or occur in groups, often termed abortion storms. Although 
usually about 30% of exposed mares in a group abort, the magnitude of abortion can be as 
high as 87% (Carrigan et al., 1991). Abortion storms have been observed in premises 
where poor management practices, such as overcrowding and stress, prevail (Allen and 
Bryans, 1986; Carrigan et al., 1991) and in premises with unvaccinated animals 
(Chowdhury et al., 1986b). Widespread vaccination against EHV-1 over a prolonged 
period has reduced the abortion rate and abortion storms have rarely occurred in fully 
vaccinated populations (Allen and Bryans, 1986).
There are few reports of EHV-4-induced sporadic abortions (Shimizu et al., 1959; Sabine 
et al., 1981; Studdert et al., 1984; Allen and Bryans, 1986). EHV-4 viraemia is 
occasionally detected and the virus may be transported to the uterus via infected 
leucocytes, as is the case with EHV-1.
Although EHV-1 and EHV-4 are host-specific for equid species, isolates of herpesviruses 
from cattle and other ungulates have been shown to be similar to EHV-1 by DNA 
restriction endonuclease analysis and serum neutralisation assays. Based on DNA 
fingerprinting with restriction enzymes and neutralisation with EHV-l-specific antiserum, 
5 herpesviruses isolated from aborted bovine foeti, bovine tissues and nasal secretions
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have been characterised as EHV-1 (Crandell et al., 1988). The BamEl restriction pattern 
of one of the bovine isolates was identical to that of most of the EHV-1 strains involved in 
abortions in vaccinated horses. Chowdhury et al. (1988) compared three bovine foetal 
isolates and one antelope isolate with EHV-1, EHV-2 and EHV-4 reference strains and 
characterised them as EHV-1 on the basis of cross-neutralisation, DNA restriction profiles 
and Southern hybridisation. The antelope isolate with a different restriction profile 
exhibited significant DNA homology with EHV-1 and partial homology with EHV-4. The 
homologies with EHV-2 and HSV-1 DNAs were insignificant.
An epizootic of blindness and encephalitis in a herd of alpacas and llamas in the USA was 
associated with a herpesvirus serologically indistinguishable from EHV-1 (Rebhun et al.,
1988). A herpesvirus isolated from an onagar (Equus hemionus onagar) at the National 
Zoological Park in Washington, D.C. (Montali et al., 1985) had a unique DNA restriction 
profile when compared to more than 200 epizootically unrelated EHV-1 isolates from 
horses (Allen et al., 1983b).
Diagnosis
Abortions due to EHV-1 and EHV-4 can be diagnosed by isolation of the aetiologic virus 
from the aborted foetus and placenta. The virus can be isolated from a number of foetal 
tissues, such as lung, liver, thymus and spleen. If the mare is viraemic at the time of 
abortion, the virus may also be isolated from heparinised blood. A tentative diagnosis can 
often be made on the basis of histological lesions in foetal tissues and the presence of 
typical intranuclear inclusion bodies in the infected cells.
Serological tests such as serum neutralisation, complement fixation (CF) and enzyme- 
linked immunosorbent assay (ELISA), are less dependable in the diagnosis of EHV-1 and 
EHV-4 abortions. Immunofluorescence can be used to detect EHV-1 and EHV-4 antigens 
in frozen sections of foetal tissue and in cell smears collected from the nasopharynx.
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Immunoperoxidase staining has also been applied for detection of EHV-1 in tissue sections 
of aborted foeti (Gimeno et al., 1987; Jonsson et al., 1989). An indirect 
immunoperoxidase method has recently been described for demonstrating EHV-1 and 
EHV-4 antigens in paraffin-embedded and frozen sections, as well as on tissues fixed 
rapidly using a microwave oven (Whitwell et al., 1992).
DNA fingerprinting, together with blot hybridisation, has been used for rapid screening of 
large numbers of EHV-1 isolates from cases of abortion (Chowdhury et al., 1986a). The 
technique is sensitive but requires extraction of DNA from the field isolates for analysis.
EHV-1-specific DNA has been detected in aborted foetal tissues by Southern and dot blot 
hybridisation using cloned fragments of EHV-1 as probes (Morris and Field, 1988).
1.3.1.3 Neurological disease
Neurological disease is a potential consequence of infection due to EHV-1, EHV-4 is 
rarely a cause. It is most common in mares post-foaling, concurrent with outbreaks of 
abortion, or may follow outbreaks of respiratory disease (Greenwood and Simson, 1980; 
Chowdhury et al. 1986b). It also affects barren mares, geldings, stallions and foals (Thein, 
1981). Saxegaard (1966) isolated EHV-1 at necropsy from the nervous tissues of two 
mares and a stallion with paralysis. Each mare developed the disease about 4 weeks after 
aborting a foetus from which EHV-1 was isolated.
The affected horses acquire infection by inhalation of the virus, as for respiratory disease 
and abortion. The virus may reach the brain and spinal cord via infected leucocytes and 
localises in the endothelium and results in a serious neurological disorder due to vascular 
damage in the CNS (Edington et al., 1986). There is no evidence of primary neuronal 
infection.
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The clinical signs of the disease depend upon the extent and location of neurological 
lesions. Affected animals may exhibit ataxia, which is usually asymmetric, hind limb 
paralysis, in which a dog-sitting posture may be assumed, or they may be quadriplegic 
leading to recumbency and, in some cases, death. Other signs include urinary incontinence 
and subcutaneous oedema and loss of sensation in the pelvic limbs and perineal region 
(Bitsch and Dam, 1971; Jackson and Kendrick, 1971; Greenwood and Simson, 1980; 
Chowdhury et a l ,  1986b). Pyrexia and nasal discharge may be seen in the affected 
animals prior to the development of nervous signs and may also be seen in cohorts 
(Greenwood and Simpson, 1980; Crowhurst et al., 1981). Deaths result from pulmonary 
congestion, pneumonia, intussusception or rupture of the urinary bladder.
The gross lesions of the disease vary from none to small (2-6 mm) focal areas of 
haemorrhage distributed throughout the spinal cord and brain (Platt et al., 1980; Thein,
1981). Histological lesions range from mild to severe necrotising and haemorrhagic 
meningoencephalomyelitis or myeloencephalitis (Jackson and Kendrick, 1971; Charlton et 
al., 1976; Little and Thorsen, 1976; Jackson et al., 1977; Platt et al., 1980). The main 
histological lesion is vasculitis of small blood vessels in the CNS resulting in areas of 
malacia associated with affected arterioles. The vasculitis is characterised by perivascular 
cuffing with mononuclear cells and neutrophils, necrosis of the media of the vessel, 
endothelial proliferation and necrosis and occasionally thrombosis of blood vessels 
resulting in ischaemic anoxia (Charlton et al., 1976; Jackson et al., 1977; Edington et al., 
1986; Whitwell and Blunden, 1992).
Severe pulmonary changes such as consolidation of lungs, severe necrotising bronchitis 
and bronchiolitis, vasculitis and perivasculitis, often accompanied by thrombosis and focal 
haemorrhages, have been observed in foals in an outbreak of paresis in the U.K. (Whitwell 
and Blunden, 1992). Such lesions have not been reported previously in outbreaks of EHV- 
1-induced neurological disease in foals.
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Recently, EHV-4 was isolated from the brain of a horse with no history of respiratory 
disease (Meyer et al., 1987). Histopathological examination of the brain revealed status 
spongiosus of the rhombencephalon and cerebrum. EHV-1 and EHV-4 differ in their 
potential to cause neurological disease in mice. When 2-day-old mice were inoculated 
intracerebrally with EHV-4, paralysis did not occur and virus could not be recovered from 
any of the internal organs, nor could it be detected in tissues by indirect 
immunofluorescence (Patel and Edington, 1983). In contrast, mice inoculated 
intracerebrally with EHV-1 developed viraemia and the virus could be isolated and 
detected in neurons in the brain, in bronchial and renal epithelium and in lymphoid cells in 
the spleen.
Diagnosis
A tentative diagnosis may be made on the basis of the occurrence of neurological disease 
in one or more animals, a history of respiratory tract disease, particularly in young horses, 
and/or previous or concurrent abortion in the same or in-contact animals (Chowdhury et 
al., 1986b). The disease may be differentiated from other viral-induced and non-infectious 
causes by the demonstration of high levels of EHV-1 or EHV-4 neutralising or 
complement fixing antibody titres in the sera of the affected animals. The neutralising 
antibody to EHV-1 has been demonstrated in the cerebrospinal fluid (CSF) (Jackson and 
Kendrick, 1971) and its presence may support a diagnosis (Jackson et al., 1977; Keane et 
al.,1988). The unequivocal antemortem diagnostic test for this condition is isolation of the 
etiologic herpesvirus. EHV-1 can be recovered from the nasopharynx and blood 
leucocytes of affected horses before death, and from the brain, spinal cord, CSF, spleen, 
kidney, liver and pharyngeal mucosa of the affected horses at necropsy (Thorsen and 
Little, 1975; Mumford and Edington, 1980; Thein, 1981; Studdert et al., 1984; Caroll and 
Westbury, 1985; Chowdhury et al., 1986b; Whitwell and Blunden, 1992). Similarly EHV- 
4 may also be recovered from the nasopharynx and nervous tissues of the affected animals. 
A post-mortem diagnosis may be made by finding haemorrhages in the spinal cord grossly
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and necrotising vasculitis in the CNS histologically. Viral antigens can be detected in 
affected tissues by immunofluorescence (Platt et al., 1980) and immunoperoxidase 
methods (Whitwell et al., 1992). Recently, restriction endonuclease pattern analyses have 
been used to characterise isolates of EHV-1 or EHV-4 that are involved in the neurological 
disease condition (Chowdhury et al., 1986b; Meyer et al., 1987).
1.3.2 Virion Structure
EHV virions range in size from 150-170 mm. The capsid is 100 nm in diameter, as shown 
by electron microscopic studies, and is composed of 162 capsomers arranged to form an 
icosadeltahedron that exhibits 2-, 3- and 5-fold symmetry (O'Callaghan et al., 1978). Of 
these, 150 capsomeres are hexavalent (hexons) and 12 are pentavalent (pentons). The 
hexons are hexamers of a major capsid protein VP9 which is 148 kDa and accounts for 
about 65% of the total protein. The other capsid proteins are VP19, VP22, VP23, VP24 
and VP26 (Perdue et al., 1975; Newcomb et al., 1989). In EHV-1, three types of capsids 
have been separated by density gradient centrifugation. The slowest sedimenting particles, 
'light' capsids, contain no DNA (Perdue et al., 1975; Newcomb et al., 1989) and are non- 
maturable (Perdue et al., 1976). The particles which sediment at an intermediate position, 
'intermediates', are also devoid of DNA but contain an additional protein, VP22. The 
fastest sedimenting particles, 'heavies', contain packaged DNA. Three layers of density 
can be observed by cryoelectron microscopy and computer reconstruction techniques in 
light and intermediate capsids in the capsid shell (Baker et al., 1990). The outermost layer 
consists of protruding protions of both the hexons and penton capsomers and the middle 
layer consists of triplexes or trimers of VP23 or VP26. The innermost layer is of 
continuous density, except for the orifices of channels that traverse each capsomere. The 
core of EHV-1 virions has been shown to contain viral genome in a form that is 
significantly resistant to DNase (Perdue et al., 1976).
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1.3.3 EHV-1 and EHV-4 Genomes
1.3.3.1 EHV-1 genome
The EHV-1 genome is a linear double-stranded DNA molecule with a base composition of 
56 or 57% G + C (Darlington and Randall, 1963; Soehner et al., 1965). The DNA 
molecule is approximately 150 kbp in size and is comprised of two covalently linked 
components, Long (L) and Short (S), as revealed by restriction endonuclease analysis 
(Henry et al., 1981; Whalley et al., 1981) and electron microscopy (Ruyechan et al.,
1982). The L component consists of a unique sequence, U^, flanked by a small inverted 
repeat (IRl/TRl) (Chowdhury et al., 1990; Yalamanchili and O'Callaghan, 1990) and is 
present in a single orientation in EHV-1 virions. The S component is a unique sequence, 
Ug, flanked by a large inverted repeat (IRg/TRg) which enables the entire S region to 
invert and results in two orientations of Ug which are are present in equimolar amounts in 
the virion DNA. Two isomers of EHV-1 genome thus exist, characteristic of the group D 
genome. Restriction endonuclease cleavage maps of the genomes have been constructed 
with a number of enzymes for three EHV-1 strains; a low passage tissue culture-adapted 
Australian field isolate, HVS-25 (Whalley et al., 1981), a high tissue culture passaged 
mouse cell-adapted KyA (L-M) strain (Henry et al., 1981; Baumann et al., 1986a) and a 
Japanese strain HH1 (Kirisawa et al., 1993b). The restriction map of EHV-1 (HVS-25) is 
presented in Figure 1.5.
1.3.3.2 EHV-4 genome
The genomes of EHV-4 strains 1942 and 405/76 possess a structure similar to that of 
EHV-1 by electron microscopic studies and restriction endonuclease site mapping 
(Cullinane et al., 1988; Nagesha et al. ,1992). The genome is comprised of two covalently 
linked segments (1942 - L 109 kbp, S 35 kbp: 405/76 - L 112 kbp, S 33 kbp). The unique 
sequence (Us) in the S segment is flanked by inverted repeat (IRs/TRs). Although both the 
viruses EHV-1 and EHV-4 have similar structure of their genomes, they differ in the
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Figure 1.5 
Restriction maps of EHV-1 and EHV-4
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Fig. 1.5 Bam HI and EcoBl maps of EHV-1 strain HVS25 (Whalley et al.,
1981) and EHV-4 strain 1942 (Cullinane , 1988).
occurrence of EcoRI and BamHI restriction sites (Fig 1.5). Based on hybridization studies, 
the genome of EHV-4 is colinear with those of EHV-1 and HSV-1 (Cullinane et al. 1988).
1.3.3.3 Genetic variability in EHV-1 and EHV-4 genomes.
There is considerable homogeneity among the field isolates of EHV-1 passaged in equine 
cells. The multiple passages of EHV-1 in cell lines derived from non-equine species or in 
vivo passages in Syrian hamsters induce variation in the genome by loss or gain of 
restriction sites (Allen et al, 1983a; Studdert et al, 1986). Some live attenuated vaccine 
strains of EHV-1 possess a unique DNA restriction pattern as a result of a large number of 
passages of these strains in non equine cell lines (Allen et al., 1983b; Meyer et al., 1992). 
Variation in the EHV-1 genome may occur due to a variable number of copies of 
repetitive DNA sequences in the repeat regions of the genome that bracket the unique short 
region of the genome or to some variation in the length of U l (Allen et al., 1983b; 
Studdert et al., 1986, 1992). Restriction endonuclease DNA fingerprints provide a 
powerful tool to study the epidemiology of EHV-1 and EHV-4. Sixteen different DNA 
fingerprints or electropherotypes of field isolates recovered from 148 epizootics of 
abortion and from 24 different outbreaks that occurred among horses in Kentucky during 
22 year period have been identified (Allen et al., 1983b). Ninety percent of abortions 
were attributable to one of two dominant electropherotypes , IP and IB, which suggests 
less genomic diversity among different field isolates of EHV-1 in the U.S.A (Allen et al., 
1985). Differences among restriction patterns Austrian field isolates (Chowdhury et al. 
1986a) and Japanese isolates (Kirisawa et al.. 1993a) of EHV-1 have also been observed. 
On the other hand, EHV-4 isolates exhibit more extensive diversity in the DNA restriction 
patterns. Thirteen distinct electropherotypes among 21 epizootically unrelated isolates 
were identified and the most frequently recovered electropherotype involved in respiratory 
epizootics accounted only for 33% isolates of EHV-4 (Allen and Bryans, 1983b). In a 
similar study in Australia, the DNA fingerprints of 20 low-passage epidemiologically
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unrelated isolates of EHV-4 showed considerable heterogeneity in the repeat, unique short 
(Ug) regions of the EHV-4 genome (Studdert et al., 1986).
1.3.4 Virion Polypeptides of EHV1 and EHV-4
Structural polypeptides of EHV-1 have been identified by various groups (Abodeely et al., 
1971; Kemp et al., 1974; Perdue et al., 1974; Turtinen and Allen, 1982; Turtinen, 1983). 
EHV-4 virions reveal similar, but not identical, electrophoretic profiles (Turtinen et al., 
1981; Meredith et al., 1989; Crabb and Studdert, 1990; Crabb et al., 1991). Virions of 
both the viruses have glycoproteins of high molecular mass > 220 kDa. In cell culture, 
about 30 polypeptides are synthesised during EHV-1 or EHV-4 infection (Bridges et al.,
1988). The nucleocapsid is composed of six polypeptides (O'Callaghan et al., 1983). VP9 
is the most abundant nucleocapsid protein in the virions of EHV-1 (O'Callaghan and 
Randall, 1976). Other capsid proteins of EHV-1 are: VP19, VP22, VP23, VP24 and 
VP26. The tegument consists of six to eight polypeptides (Table 1.1). The envelope of 
EHV-1 and EHV-4 virions contains six high abundance glycoproteins that can be resolved 
by electrophoresis after metabolic labelling of virus-infected cells with radioactive 
glucosamine (Turtinen and Allen, 1982; Meredith et al., 1989; Crabb and Studdert, 1990). 
The major glycoproteins have been designated gp2, gplO, gpl3, gpl4, gp l8a, gp l8b, 
gp21/22a (Allen et al., 1992) and gp300, g p ll8 , gpl08, gp88 , gp76, gp60, gp58 and 
gp45 by Meredith et al. (1989). In addition, five glycosylated polypeptide bands of lower 
molar abundance, designated gp9b, gp l6 , gpl7, gp21 and gp25, were detected in 
polyacrylamide gels of EHV-1 virion proteins after prolonged exposures of the gel or by 
staining with glycoprotein-specific stains (Turtinen and Allen, 1982).
There is no commonly agreed system for nomenclature of EHV-1 glycoproteins and three 
systems are in use at present. The first is the one described by Turtinen and Allen (1982), 
in which the glycoproteins are identified by their mobility in sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE), e.g. gpl/2, gpl3,14. The second system
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Table 1.1
Structural proteins of EHV-1 and EHV-4
EHV-1 Virion proteins EHV-4 virion proteins
Protein Size
(kDa)
Nature Location Protein Size
(kDa)
Nature Location
1 250 G E 1 250 G E
2** 190-240 G(M) E 2** 190-240 G(M) E
9 140 - NC 9 140 - NC
9a 140 G E
10a 128 G E
10 124 G(M) E 10 124 G(M) E
11 117 - T 11 117 - T
12 110 - T
13* 96 G(M) E 13* 110 G(M) E
13a 98 - T
14a 94 ? ?
14 90 G(M) E 14b* 87 G(M) E
14c 84 ? ?
15 82 - T 15 82 - T
16 74 G E 16 74 G E
17a 70 - T
17 68 G E 17 68 G E
18a 64 - T
18 63 G(M) E 18* 61 G(M) E
19 60 - T 19 60 - T
20 54 - NC 20 54 - NC
21 45 G E 21 45 G E
22a 41 G(M) E 22a 41 G(M) E
22b 39 - NC 22b 39 - NC
23 36 - T 23 36 - T
23a 33 - T 23a 33 G E
24a 31 - NC 24a 32 - NC
24b 27 - NC 24b 27 - NC
25* 24 G E 25* 25 G E
26a* 18 - T 26a* 19 - T
26b* 17 - NC 26b* 18 - NC
27 16 - T 27 16 - T
Table 1.1 Profiles of structural polypeptides of EHV-1 and EHV-4 (Allen and Bryans, 1986) 
G, glycoprotein; G(M), major glycoprotein; E, envelope; T, tegument; NC, nucleocapsid; (-), n 
determined; (*), exhibts intertypic electrophoretic mobility differences; (**), exhibits intratypic 
electrophoretic mobility differences.
is based on the apparent size of the glycoproteins, e.g. gp300, gpl08 (Meredith et al.,
1989). This system presents difficulties because the apparent sizes of proteins can vary 
under different gel running conditions and may lead to misidentification of proteins when 
analysed by different groups. The third system, which is in more common use, is the 
nomenclature based on homology to HSV glycoproteins, e.g. gB, gC etc. The current 
status of EHV-1 glycoproteins using all the three systems of nomenclature is summarised 
in Table 1.2.
Some of the glycoproteins of EHV-1 and EHV-4 have been characterised. Glycoprotein 
gp2 or gp300 of EHV-1 has extensive O-linked carbohydrates (Whittaker et al., 1990)and 
is cross-reactive with its counterpart in EHV-4. It has been implicated in cell-to-cell 
spread (Edington et al., 1987). Glycoprotein gpl8/gp60 of EHV-1 is a homologue of the 
HSV-1 gD (Whittaker et al., 1992). The Mab raised against it neutralised virus infectivity 
and prevented penetration of EHV-1 into the cell.
The gB glycoproteins (gpl4, gp88) of EHV-1 and EHV-4 consist of a dimer of two 
polypeptides specified by the gB gene, both of which react with gB polyclonal antisera. 
As precursor molecules, the gBs of EHV-1 and EHV-4 migrate with apparent molecular 
masses of 108 kDa and 112 kDa respectively but are cleaved to give glycoproteins of 76 
kDa and 58 kDa (EHV-1 gB) and 74 kDa and 61 kDa (EHV-4 gB). The smaller 
polypeptides are held together by disulphide bonds in the active dimeric form, but 
separated by electrophoresis under reducing conditions (Meredith et al., 1989; Sullivan et 
al., 1989).
Some glycoproteins consist of a mixture of two comigrating glycoproteins. For example, 
g p l8 represents the EHV-1 homologue of HSV gD and a small subunit (58 kDa) of the 
EHV-1 gB heterodimer complex. The gplO consists of a poorly resolved mixture of three 
different EHV-1 glycoproteins: (1) gpl3/14 homologue of HSV-1 i.e. gplO which is a
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Table 1.2
M ajor envelope glycoproteins of EHV-1 and EHV-4
EHV-1 HSV
Homologue
EHV-4
Aa Bb C A B C
gp2 gp300 250k Unknown gp2
(190-240k)
gp300 gp260 
SP220
gp270k
gplO region
(a) 120k gpH 8 110k gH(?) gplO
(124k)
(b) 115k VP14 gpl38 113k
(c) 110k gpl08* 127k gB g p l l2* 127k
gpl3 (96k) gp88 87k gc gpl3
(110k)
gp92 67k
gpl4 (90k) gp76* 78k gB gpl4 (b) 
(87k)
gp74* 77k
gp l8a
(58-60k)
gp60 58k gD gp l8a
(61k)
gp59 56k
gp l8b
(58-60k)
gp58* 60k gB - gp61* 62k
gp21/22a
(41-45k)
gp45 49k Unknown gp21/22a gp45 ND
ND ND ND gl ND ND ND
ND ND ND gE ND ND ND
ND ND ND gG ND ND 63k
Table 1.2 Comparative analysis of envelope glycoproteins of EHV-1 and EHV-4 for 
American, British and Australian isolates as identified by (A) Allen et a l  (1992); (B) 
Meredith et a l (1989) and (C) Crabb and Studdert, 1990; Crabb et al., 1991 and 1992.
The nomenclatures: (Aa) Turtinen et a l (1992) and (Bb) Meredith et al (1989) are used 
to describe the glycoproteins. The (*) represents the component of the disulphide- 
linked complex. The molecular weights in respect of glycoproteins identified by group 
(C) are presented as such, k represents kilodaltons (kDa). The gplO region of EHV-4 
has not been characterized by group A as for EHV-1; (-) indicates that the dimeric form 
of EHV-4 gB is not known. The (?) represents hypothesised homologue.
tegument glycoprotein of EHV-1 (Whittaker et al., 1991), (2) the uncleaved form of gB 
(110 kDa) (Meredith et al., 1989) and (3) the homologue of HSV-1 gH which is 120 kDa 
protein in EHV-1 virion.
Crabb et al. (1991) demonstrated the existence of EHV-4 glycoproteins antigenically 
related to those of EHV-1 using Mabs against each of the six major glycoprotein antigens 
of EHV-1 raised by Allen and Yeargan (1987). In addition, an envelope glycoprotein of 
EHV-4 with a molecular mass of 63 kDa, designated glycoprotein G (gG), has been 
identified and shown to be type-specific (Crabb et al., 1992). Although virions of both 
EHV-1 and EHV-4 have apparently comparable glycoproteins, significant and constant 
differences in the electrophoretic mobility of eight of the viral proteins were observed 
when strains of these viruses were compared (Turtinen et al., 1981). Virion polypeptides 
13, 16, 17, 18, 23, 25 and 26a of EHV-4 isolates had high molecular weights in 
comparison to the hamster adapted Kentucky A and Army-183 strains of EHV-1. The 
virion polypeptide 8a was not present in EHV-4 isolates. In addition, a major non­
envelope protein (VP19) with molecular mass of 58 kDa was present in reduced amounts 
in EHV-4 strains. The direct comparison of the protein profiles of EHV-1 and EHV-4 
virions, determined by various research groups for different isolates, cannot conclusively 
be made from the mobilities of the proteins in gels, because the mobility not only depends 
on the polyacrylamide gel systems and their running conditions, but also on the virus 
strains used in their studies and the cell lines in which those strains were propagated. The 
protein profiles of EHV-1 and EHV-4 are shown in Table 1.2.
1.3.5 Antigens
Following infection or vaccination, the humoral responses of the horse are directed against 
the surface glycoproteins of EHV-1 and EHV-4 (Papp-Vid and Derbyshire, 1979). The 
envelope glycoproteins, as well as some membrane proteins, also act as targets for cell 
mediated-responses. The responses, in terms of lymphocyte transformation, are directed
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against glycoproteins gp9a, gplO, gplOa, gpl3, gpl4 and gp21 of EHV-1 and gplO, gpl3, 
gpl4, g p l8 and gp21 of EHV-4 (Bridges et al., 1988).
In immunoblot assays, convalescent sera from horses recovered from experimental EHV-1 
infection reacted with 5 of the 6 major glycoproteins, gp2, 10, 13, 14 and 22a, in addition 
to the major capsid protein, VP9 (Allen and Bryans, 1986). Serum collected from a horse 
infected with EHV-1 was similarly reactive with glycoproteins gp2, 10, 13 and 14 of 
EHV-4. In a similar study, serum from horses which had experienced primary infection 
with EHV-1 reacted against each of the six glycoproteins, gp2, gplO, gp21/22a, gB and gC 
(Ostlund et al., 1992). Immunoreactivity with hyper-immune rabbit sera revealed that 
gp2, 10, 13 and 14 contained cross-reactive antigenic determinants, whereas the type- 
specific determinants were located on gpl8 and 22a (Turtinen, 1983). Glycoproteins gp2, 
10, 13 and 14 were the most immunogenic viral antigens both in horses and rabbits, while 
gp2 and 14 were the most typically cross-reactive of the viral antigens of EHV-1 and 
EHV-4. Following experimental infections with EHV-1 or EHV-4, the major capsid 
protein, VP9 and glycoprotein B (gp 14) were the most antigenic in ponies (Ahmed et al., 
1993).
The glycoproteins gp2, 13, 14 and 18, as well as a 120 kDa glycoprotein of EHV-1, 
presumed to be EHV-1 gH, and a 116 kDa glycoprotein of EHV-4, believed to be EHV-4 
gH, have been shown to be important immunogens in both naturally infected mares post- 
EHV-1-induced abortion and in experimentally infected specific-pathogen-free (SPF) foal 
as demonstrated in immunoprecipitation assays using 14C-glucosamine-labelled EHV-1 
and EHV-4 antigens (Crabb et al., 1991). Glycoproteins gp2, gH and, to a lesser extent, 
gpl3 and 18, were shown to be significantly type-specific. Recently, EHV-4 gG, whose 
counterpart in EHV-1 has not yet been characterised, has been shown to be type specific, 
as demonstrated by its reactivity with monospecific sera raised in SPF foals (Crabb et al., 
1992).
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Using a panel of mouse Mabs, four categories of epitopes on the envelope glycoproteins of 
EHV-1 or EHV-4 have been characterised (Allen and Bryans, 1986): (1) type-specific, i.e. 
determinants specific to all isolates of EHV-1 or EHV-4; (2) type-specific but may be 
present on some isolates and not on others; (3) epitopes shared by some isolates of both 
EHV-1 and EHV-4 and (4) epitopes common to all isolates of both virus types.
The glycoproteins gB and gC have been shown to afford some protection against EHV-1 
and EHV-4 infection, at least in animal models. Mabs directed against EHV-1 
glycoproteins gpl3 (gC) and gpl4 (gB) passively protected hamsters against EHV-1 
challenge (Stokes et al., 1989). Hamsters inoculated with recombinant vaccinia virus 
containing gC were protected against potentially lethal EHV-1 challenge (Guo et al.,
1989). A similar construct expressing both gC and gB of EHV-1 was even more effective 
in stimulating a protective response in immunised hamsters (Guo et al., 1990). Mice 
vaccinated with recombinant vaccinia virus containing EHV-1 gB produced antibodies that 
recognised precursor and product proteins of EHV-1 gB on Western blot, but lacked in 
vitro neutralising capacity (Bell etal., 1990).
Using affinity-purified EHV-1 glycoproteins in immunoblot assays to quantify antibodies 
against individual glycoproteins in sera from convalescent horses, anti-gB antibodies were 
highest in most, followed by anti-gC antibodies (Ostlund et al. 1992).
Onions et al. (1992) studied the immunogenicity of peptides with predicted antigenic sites 
derived from gB, gC and gH protein sequences of EHV-4 and demonstrated that, although 
the peptides were capable of inducing anti-peptide antibody and, in most cases, antiviral 
antibody, none of the peptides induced neutralising antibody or protected hamsters against 
EHV-1 challenge.
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Sinclair et al. (1989) characterised neutralising and non-neutralising Mabs against EHV-1, 
three of which neutralised EHV-1 strain Army-183 but not EHV-4 strain MD in the 
presence of complement. These three Mabs immunoprecipitated the 83 kDa glycoprotein, 
gpl3. In immunoblot assays using purified EHV-1 virions, the target antigens of four 
non-neutralising Mabs were identified as two polypeptides of >205 kDa (VP1-2), a 
polypeptide of 97 kDa and an unidentified polypeptide of 13 kDa. The 97 kDa protein 
was EHV-4 specific whereas others were cross-reactive.
Allen and coworkers (1988, 1992) mapped five antigenic domains, designated I to V, to 
EHV-1 gC and six, I to VI, to EHV-1 gB using panels of MAbs in competition binding 
assays . A neutralising epitope was mapped to domain IV of gC and on domain V of gB. 
Two domains of gB, domains I and II, were localised on the large subunit of gB, whereas 
domains III and IV were located on the small subunit (gpl8) of the dimer. The fifth gB 
domain was recognised by a single virus-neutralising Mab. Linear B cell epitopes were 
identifed on gB and gC by Pepscan analysis (Allen et al. 1992). Antibodies bound to 
linear epitopes on domains I and VI of gB and domains I and V of gC. The minimum 
essential amino acid sequence comprising the linear epitope of gB domain I was 
determined as ETPDLR (amino acids 116-122) and for domain I of gC as KKSRRG 
(amino acids 147-152). The studies on B-cell epitope mapping of gC have shown that, 
apart from antigenic site I comprising amino acid residues 147-152, the epitopes are not 
arranged linearly, but scattered over the glycoprotein surface in a discontinuous manner 
(Coogle et al., 1992). The antigenic domain IV of gC, which contains a neutralising 
epitope, was immunodominant among sera from convalescent horses in a competitive 
ELISA and the responses to domains I and III of gB in the form of competitive ELISA 
titres were greater than responses to any other domains of gB and gC (Ostlund et al., 
1992).
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An epitope common to EHV-1 and EHV-4 was located on gp2 using Mabs raised against 
the vaccine strain Rac-H of EHV-1 (Meyer and Hubert, 1988). Two epitopes (amino acid 
residues 4-22 and 267-285) were identified on glycoprotein D (Flowers and O'Callaghan, 
1992). The former is a continuous neutralising epitope.
1.3.5.1 Antigenic variation among the isolates of EHV-1 and EHV-4 
Apart from studies on immunoreactivity of EHV-1 and EHV-4 isolates with monoclonal 
antibodies (Mabs), there is so far no conclusive evidence for antigenic variation among 
field strains. With a panel of seven Mabs, 12 epizootiologically unrelated and genetically 
diverse EHV-1 field isolates were grouped into nine antigenically different serotypes 
(Yeargan et al., 1985). In a similar study with a panel of 42 Mabs raised against the 
glycoprotein C (gC) of a vaccine strain of EHV-1, it was demonstrated that of the 72 
isolates examined some reacted with all of them, while a majority differed from the 
vaccine strain in one or more epitopes (Allen et al., 1988). Seven percent of these Mabs 
reacted with the gC of EHV-4 isolates, seven percent reacted with some, but not all, and 
85% did not react with any of the EHV-4 isolates. However, using five anti-EHV-1 gC 
Mabs, no antigenic differences were observed among four epizootiologically distantly 
related Australian isolates of EHV-1 (Studdert et al., 1992). Although EHV-1 and EHV-4 
isolates show intratypic variations among their restriction endonuclease patterns (Allen et 
al., 1983b, Chowdhury et al., 1986a; Studdert et al., 1986, 1992; Kirisawa et al., 1993a), 
it is not clear whether such variations are of any significance in representing the 
differences in their antigenicity and other biological properties. Further, eight EHV-1 and 
seven EHV-4 isolates did not exhibit significant intratypic variations in the electrophoretic 
profiles of their structural proteins (Turtinen, 1983).
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1.3.6 Host Immunity and Immune Mechanisms
The immunity to natural infection and vaccination against EHV-1 and EHV-4 is short­
lived. Horses can be reinfected without apparent disease at 3-6 month intervals (Bryans, 
1969). Since the equine foetus receives no maternal antibody transplacentally, colostrum 
is the sole source of passive immunity (Kendrick and Stevenson, 1979). The duration of 
the immunity conferred by ingestion of colostrum depends upon the colostral antibody 
titre and the amount of colostrum ingested within 24 h of birth. Serum antibody titres in 
foals are correlated with those in the serum of their dams (Higgins et al., 1987). Foals 
exposed to EHV-1 or EHV-4 rarely develop high levels of circulating antibodies against 
these agents (Dutta and Shipley, 1975; Gerber et al., 1977; Coignoul et al., 1984a). 
However, they may develop a cell-mediated immune (CMI) response, which is important 
in protection against EHV-1 (Gerber et al., 1977; Wilks and Coggins, 1977; Frymus, 
1980). Following infection with EHV-4, the motility of neutrophils and their antibody- 
dependent cell-mediated function in foals were low in comparison with mares, which may 
partially explain the increased susceptibility of foals to EHV-4 and other viral and 
secondary bacterial infections (Coignoul et al., 1984b). Bumgardner et al. (1982) studied 
the mitogenic responses of T lymphocytes from ponies experimentally infected with EHV- 
1. These responses peaked at three times the base line value by 4-5 days p.i. and declined 
to base line by day 7
Fitzpatrick and Studdert (1984) studied the immune responses to EHV-1 and EHV-4 in 
colostrum-deprived SPF foals which were vaccinated with inactivated EHV-1 or EHV-4 
and later challenged intranasally with EHV-1 then EHV-4 or EHV-4 then EHV-1. The 
foals exhibited both cellular and humoral responses to inactivated antigens, which were 
enhanced by exposure to the challenge viruses. Serum neutralising antibodies were type- 
specific for foals vaccinated with inactivated EHV-1 and were cross-reactive after these 
foals were challenged with EHV-4. Cellular immune responses, as judged by in vitro 
lymphocyte blastogenesis, were cross-reactive after foals were challenged with either
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EHV-1 or EHV-4. Based on these observations, the use of a bivalent vaccine to control 
EHV-1 and EHV-4 infections, has been suggested.
Mumford and Bates (1984) vaccinated ponies with two or three doses of inactivated 
Pneumabort-K vaccine, which contains antigen of EHV-1 strain Army-183, and 
challenged them with EHV-4. Those ponies which received three doses of the vaccine 
resisted the challenge. In another study using the same vaccine, yearlings and in-foal pony 
mares failed to resist EHV-1 challenge, despite the presence of EHV-1 neutralising 
antibodies (Burrows et al., 1984). In order to investigate protective mechanisms other 
than neutralisation by antibody, serum samples from the vaccine trial conducted by 
Burrows et al. (1984) and from non-vaccinees challenged with virulent EHV-1 were 
examined for antibody-dependent cellular cytotoxicity (ADCC) and complement 
dependent lysis (CDL) (Stokes and Wardley, 1988). ADCC is mediated by peripheral 
blood mononuclear cells and neutrophils which, when armed with antibody, are capable of 
killing virus-infected cells. CDL is a consequence of activation of complement following 
the attachment of virus-specific antibody to target antigens on the surface of infected cells, 
resulting in lysis of these cells. The sera from both groups, vaccinees and non-vaccinees, 
were capable of mediating both ADCC and CDL to both EHV-1 and EHV-4. Antibodies 
capable of lysing infected target cells in vitro in the presence of complement were 
demonstrable by 10 days p.i. This was the first in vitro demonstration of these immune 
mechanisms operating after EHV-1 infection. It is believed that these mechanisms are 
important in assisting recovery from infection rather than offering a means of protection 
following vaccination.
Bridges and Edington (1987) established autologous monolayers by cocultivating skin 
biopsies with monocytes in order to develop a CTL assay. These cultures served as targets 
for further passage and for infection with these viruses. Using this system, genetically
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restricted cytolysis in ponies was demonstrable at days 7 and 21 following a second 
exposure to EHV-4 (Edington et al., 1988).
Bridges et al. (1988) studied transformation responses of lymphocytes from ponies 
experimentally infected with EHV-4 to virus-infected cell polypeptides (ICPs). The 
cellular responses were directed against virion polypeptides, VP10, VP13, VP14, VP18 
and VP21/22, and a capsid protein 9 of EHV-4. The cells also responded to the 
corresponding EHV-1 proteins, except to VP18. Hyperimmune serum from horses 
exposed to both EHV-1 and EHV-4 recognised as many as 10 polypeptides, to some of 
which a cellular response was also observed, e.g. VP21/22. It was further demonstrated 
that major virion proteins VPs 1-2, 9, 10 and 21/22 are present on the infected cell surface 
and could act as recognition units for cytotoxicity (Bridges et al., 1988).
Stokes et al. (1989) developed a hamster model suitable for studying immune responses to 
EHV-1. After intraperitoneal (i.p.) or intranasal (i.n.) inoculation of hamsters with EHV-1, 
virus-specific cytotoxic cells were demonstrable in the spleens by day 6 . This cytotoxic 
effect, demonstrable by lysis of autologous cells, ie. hamster embryo fibroblasts and BHK- 
21 infected with EHV-1, was mediated by T cells. This was demonstrable by specific 
inhibition of cytotoxic T cells by a monoclonal antibody directed against T lymphocytes. 
Also, antibodies capable of lysing EHV-1-infected target cells in vitro in the presence of 
complement were demonstrable by day 4 p.i. The passive transfer of serum from 
recovered hamsters to naive recipients 24 h before challenge protected 80% of animals, 
whereas transfer of serum 24 h after challenge reduced the titre of virus recovered from 
target organs. The complement-mediated antibody lysis of infected cells may be one 
mechanism for antibody-mediated immune protection. Further, administration of a pool of 
Mabs directed against six major glycoproteins provided 100% protection of i.n. challenged 
hamsters and 80% of i.p. challenged hamsters (Stokes et al., 1989). The Mab to gpl3 
alone protected 75% of i.n. challenged animals and 80% of i.p. challenged animals. Mab
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to gpl4 protected 100% of i.p. challenged animals but only 20% of i.n. challenged 
animals. The exact mechanism by which these antibodies induce protection is not clear as 
they failed to neutralise EHV-1 strain KyD in vitro and did not mediate antibody- 
dependent cell-mediated cytotoxicity (ADCC) of virus-infected target cells in the presence 
of murine peritoneal macrophages unless all six Mabs were used together.
The sera from hamsters immunised with affinity-purified gpl3 of EHV-1 had antibodies 
which showed virus neutralising activity and complement-mediated antibody lysis of 
EHV-1 infected target cells (Stokes et al., 1991b). The hamsters immunised with this 
glycoprotein were protected against EHV-1 challenge. Two of the murine anti-gpl3 Mabs 
showed high levels of neutralisation of virus, complement-mediated lysis of virus infected 
cells and passive protection of the hamsters. Glycoprotein gpl3 contains a neutralising 
epitope which is recognised by EHV-1 immune horse serum (Stokes et al., 1991b).
Studies on cellular immune responses were slowed for lack of availability of markers to 
differentiate lymphocyte subsets. Mabs specific for equine lymphocytes, thymocytes and 
major histocompatibility complex (MHC) class I and class II have been analysed by the 
First International workshop on equine leucocyte antigens (Kydd and Antczak, 1991) and 
are now available to pursue such studies.
Mab CVS8 , which interacts with equine CD8 , has been shown to block allogeneic 
restricted cytotoxicity in the equine mixed lymphocyte reaction (O'Brien et al., 1991). In 
SPF foals re-exposed to EHV-1, in which infection did not establish, there was a decline in 
CD8+ cells, indicating that this subset of T lymphocytes plays a key role in prevention of 
reinfection (Lunn et al., 1991).
A non-specific EHV-1 immunosuppression in horses has been observed on second 
exposure to EHV-1 which is not related to transient leucopaenia and neutropaenia
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generally seen during EHV-1 infection (Hannant et al., 1991). The non-specific 
lymphocyte function was shown to be compromised after infection in that the polyclonal T 
cell activation was depressed for at least 40 days. The mechanism for this non-specific 
immunosuppression is not yet known.
Besides the specific immune mechanism, non specific mechanisms have been shown to 
operate in EHV-1 infection. EHV-1 induces C3b receptors on bovine fibroblasts and 
bovine pulmonary artery endothelial cells (Ohman and Babiuk, 1988). Binding of 
complement leads to direct activation of complement and lysis of EHV-1 infected cells. In 
addition, polymorphonuclear (PMN) cells form rosettes with EHV-1 infected cells. 
Complement is also bound to these PMNs and is activated by infected cell proteases, 
leading to complement-dependent neutrophil-mediated cytotoxicity (CDNC). EHV-1 
infected cells also bind complement directly which leads to direct activation of the 
complement and lysis of the infected cells.
1.3.7 Mapping and Sequencing Data
The complete DNA sequence of EHV-1 strain Ab4 has been determined (Telford et al., 
1992). The genome, which is 150,223 bp in size, contains 80 open reading frames 
(ORFs), with potential to encode proteins. Four of the opening reading frames are 
duplicated in the major inverted repeat, two are probably expressed as spliced mRNA and 
one may contain an internal transcriptional promoter. The genome is therefore, considered 
to contain 76 distinct genes. The genes are arranged colinearily with those in the genomes 
of VZV and HSV-1.
Allen and Yeargan (1987) were first to locate the positions of glycoprotein genes on EHV- 
1 genome. They constructed a Xgtll library of EHV-1. Recombinant bacteriophages 
expressing epitopes of six major glycoproteins were identified with EHV-1-specific MAbs. 
Genes for five of the six glycoproteins, gp2, gplO, gpl3, gpl4 and gp21/22a, were mapped
to the L component of the genome and the sixth (gpl7/18, now known as gp l8) was 
localised in the Us region of the genome. Three potential glycoprotein genes, gD, gl and 
gE were later mapped in the Us region (Audonet et al., 1990; Elton et al., 1991a, b). The 
gp l8 is encoded by the gD gene homologue of HSV-1 (Flowers et al., 1991; Elton et al., 
1992). A glycoprotein gene which encodes a homologue of HSV-2 glycoprotein gG and 
another glycoprotein gene which is unique to EHV-1 have been mapped in the Us (Colie et 
al., 1992). A gene homologue of the HSV-1 gK gene has been mapped at the left 
terminus of U l (Zhao et a l,  1992). HSV gH homologue in EHV-1 has recently been 
identified and the gene encoding this glycoprotein maps within U l (Robertson et al.,
1991). The physical map of the EHV-1 genome showing the locations of genes encoding 
important glycoproteins is presented in Figure 1.6. Some of the mapping and sequencing 
data is presented below.
1.3.7.1 EHV-1 gpl4 or EHV-1 gB
The gene was localised in a 4.3 kbp EHV-1 Pstl-Clal fragment (0.40-0.43 map units) and 
identified as HSV-1 gB homologue (Whalley et al., 1989). This fragment contains an 
ORF that can potentially encode for a polypeptide of 980 amino acids. The EHV-1 gB 
glycoprotein has 50-60% identity over a 617 amino acid conserved region with the gB 
gene products of HSV-1, HSV-2, PRV and VZV, and 20-30% with those of HCMV and 
EBV. The amino acid residues 137-172 are the best conserved regions among the gB 
glycoproteins of the EHV-1, PRV, BHV, VZV, HSV-1, HCMV and EBV (Guo, 1990). A
3.4 kbp transcript that encodes EHV-1 gB has been mapped to co-ordinates 0.40 and 0.43 
(Bell etal., 1990).
1.3.7.2 EHV-4 gB
Riggio et al. (1989) located the EHV-4 gene within a 2.95 kbp BamWl-EcoKl subfragment 
of BamWl-C of EHV-4 restriction fragment and the right hand end of the adjacent BamYil 
M fragment. The gene encodes a 975 amino acid protein. The EHV-4 gB has amino acid
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sequence homologies of 47% with HSV-1 gB, 54% with PRV gpVI, 51% with VZV gpll, 
29% with HCMV, 30% with EBV gB and 88% with EHV-1 gB/gpl4.
1.3.7.3 EHV-1 gpl3 or EHV-1 gC
The gene encoding EHV-1 gpl3 was localised within a 1.8 kbp Accl-EcoVl restriction 
fragment (m.u. 0.136-0.148) in the U l region of the genome. (Allen and Coogle, 1988). 
The transcriptional unit has an ORF (1,404 bp) that encodes a 468 amino acid primary 
translation product. Regions of significant sequence homologies have been demonstrated 
between the amino acids of the carboxy half of EHV-1 gpl3 and those of the same region 
of homologous glycoproteins of HSV (gC-1 and gC-2), PRV (gP III) and VZV (gP66). 
The sequences of the N-terminal region are much less conserved.
1.3.7.4 EHV-4 gC
Nicolson and Onions (1990) localised the EHV-4 gC gene within a 2 kbp Bglll-EcoRl 
fragment mapping between 0.15 and 0.17 m.u within Uj .^ An ORF of 1,455 bp which 
encodes a 485 amino acid protein, gC was identified in this region. EHV-4 gC shares an 
amino acid homology of 22-29% with HSV (gC-1 and gC-2), VZV gpV, PRV gill, BHV- 
1 gill and A antigen of MDV and 79% with EHV-1 gpl3 (gC).
1.3.7.5 EHV-1 gD, gl, gE
Audonnet et al. (1990) determined the nucleotide sequence of a 6.4 kbp portion of the 10.6 
kbp BamRl D fragment contained in the Us region of the EHV-1 genome. Analysis of 
nucleotide sequence revealed five ORFs, four complete and one incomplete. Comparisons 
of the homologous genes of other alphaherpesviruses at the amino acid level demonstrated 
regions of significant sequence similarity between the three complete ORFs 2, 3 and 4 of 
EHV-1 and HSV 1 gD encoded by the US6 gene, HSV-1 gl encoded by the US7 gene and 
HSV-1 gE encoded by the US8 gene respectively. The interrupted ORF 5 exhibited partial 
homology with the HSV-1 US9 encoded protein. The three colinear EHV-1 ORFs
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encoding putative glycoproteins with homology to the HSV-1 glycoproteins were 
designated as EHV-1 gD, gl and gE respectively. Similarities between EHV-1 gD and 
PRV gp50, between EHV-1 gl and PRV gp63, and VZV gpIV, and between EHV-1 gE 
and PRV gl and VZV gpl have also been observed by these researchers.
1.3.7.6 EHV-4 gD, gl and gE
The genes encoding glycoproteins gD, gl and gE have been mapped within Us (Cullinane 
et al., 1988, 1993). The gD gene encodes a peptide of 402 amino acids which has 83% 
identity with its counterpart in EHV-1.
1.3.7.7 EHV-1 gG
This glycoprotein is encoded by an ORF designated as EUS4 within the Ug (Colle et a l,
1992). This ORF corresponds to gene 70 (Telford et al., 1992). The predicted protein has 
383 amino acids and is a homologue of gX of PRV.
1.3.7.8 EHV-4 gG
The gene encoding EHV-4 gG was mapped in the Ug region of the EHV-4 genome 
towards the internal repeat region (Crabb et al., 1992). Four ORFs were identified in this 
region, of which ORF 4 showed 52% similarity to the gene product of PRV (gX), which is 
a homologue of HSV-2 gG. ORF 4 coded for a primary translation product of 405 amino 
acids which shared 28% identity with PRV gX and 16% identity with HSV-2 gG. This 
ORF has been designated EHV-4 gG.
1.3.7.9 EHV-1 gH
Robertson et al. (1991) located EHV-1 gH gene in a 5.3 kbp BamUl-Clal fragment at 
0.47-0.49 map units which contains an ORF capable of encoding a polypeptide of 848 
amino acids. The gH gene is conserved, particularly towards the C terminus among 
herpesviruses. The overall identities for the EHV-1 gH polypeptide, excluding signal
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sequences, have been shown to be 32% and 23% with VZV and HSV-1, respectively, and 
23% between HSV and VZV.
1.3.7.10 EHV-4 gH
Nicolson et al. (1990a) located the EHV-4 gene homologue of HSV-1 gH immediately 
downstream of the thymidine kinase (TK) gene at approximately 0.49-0.51 map units 
within the BamHl C fragment of the genome. The primary translation product of this gene 
has been predicted to be an 855 amino acid long polypeptide.
1.3.7.11 EHV-1 gK
An ORF designated UL4 encoding a protein of 381 kDa has been mapped at the left hand 
terminus of U l within Xbal G fragment (m.u. 0.010 to 0.046) (Zhao et al., 1992). This 
ORF is a homologue of UL53 of HSV-1. The predicted protein, gK, has 26% identity 
with HSV-1 gK.
1.3.7.12 EHV-1 TK
Robertson and Whalley (1988) located EHV-1 TK gene within a 3.15 kb BamHl-Pstl 
fragment at around 0.47 map units on EHV-1 genome.
1.3.7.13 EHV-4 TK
Nicolson et al. (1990b) mapped the EHV-4 TK gene at approximately 0.48 map units 
within the U l  region of the genome. The gene was shown to be flanked by genes 
encoding HSV-1 UL24 homologue. The predicted protein consisted of 352 amino acids 
and exhibited 36% identity to the predicted TK of HSV-1.
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1.3.8 Lytic Infection Cycle of EHV-1
The lytic cycle of EHV-1 has been studied in young Syrian hamsters and in cell culture. 
Following inoculation of 108 LD50 of EHV-1 per hamster, there is marked viremia 
resulting in death of all infected hamsters at 12 ± 0.5 h and more than 95% of their hepatic 
parenchymal cells show typical intranuclear inclusions (Bracken and Randall, 1957; 
O'Callaghan et al., 1972). The virus replicates in mouse L-M cells in a similar manner, 
but the infectious cycle is longer (18-24 h) (Perdue et al., 1974). In organ cultures of 
equine foetal tracheal epithelium infected with EHV-1, viral nucleocapsids were observed 
by transmission electron microscopy in nuclei of infected cells at day 1 p.i. (O'Neill et al., 
1984).
1.3.8.1 Initial stages of infection
Virus attaches to the host cell receptors by its surface glycoproteins and penetrates the cell 
rapidly; by 15 minutes after attachment, virions are demonstrable in cytoplasmic vacuoles 
by electron microscopy. The observation of enveloped virions in cytoplasmic vacuoles 
indicates that the virus gains entry by viropexis (Abodeely et al., 1970). This is not in 
agreement with the general mode of entry of herpesviruses which occurs by fusion of the 
envelope with the plasma membrane. The de-enveloped capsids are probably transported 
to the nucleus as for other herpesviruses.
1.3.8.2 Transcription and Protein Synthesis
Using competitive hybridisation, Huang et al. (1971) first demonstrated that the synthesis 
of specific viral transcripts varied during productive EHV-1 infection of L-M cells, 
indicating that the expression of EHV-1 genes takes place in a regulated manner. Cohen et 
al. (1975) reported the presence of two classes of EHV-1 RNAs that were distinguishable 
by their relative molar concentrations within the infected cells. The synthesis and relative 
molar concentration of these two classes of viral RNA was altered by 5' fluro-2 
deoxyuridine, a DNA inhibitor indicating that EHV-1 transcriptional regulation was linked
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to the onset of viral DNA replication (Cohen et al., 1977a). Caughman et al. (1985) 
demonstrated that the synthesis of EHV-1 polypeptides is co-ordinately regulated into 
immediate early (IE), early and late phases in productively infected rabbit kidney and 
hamster embryo cells. As many as 34 infected cell-specific polypeptides (ICPs) ranging in 
molecular weights from 16.5 kDa to 213 kDa were detected. Twenty two of these ICPs 
comigrated with virion structural proteins. Four ICPs (mol. wt. 203 kDa, 176 kDa, 151 
kDa, 129 kDa) were designated as EHV-1 immediate early (a) ICPs. Eighteen ICPs were 
classified as early ((3) ICPs. A 31.5 kDa which is a non-structural protein, and another 74 
kDa protein were the most abundant early ICPs. Twelve ICPs were classified as late (7) 
polypeptides, as their synthesis was reduced in cultures in which viral DNA replication 
was inhibited by phosphonoacetic acid. All but one of these late ICPs, of 40 kDa, 
corresponded to virion structural proteins. Later, Gray et al. (1987a, b) mapped the 
immediate early viral RNA within the inverted repeat DNA sequences (m.u 0.78-0.83 and 
0.95-1.0). Using a 32P-labeled DNA probe from this region, they identified a single early 
viral transcript of approximately 6 kb and further demonstrated that the transcription of 
early and late genes was not restricted to any specific region on the viral genome, since the 
labeled early and late RNA hybridised to EHV-1 restriction endonuclease fragments from 
both long and short components of EHV-1 DNA. The gene expression was shown to be 
temporally regulated in a, |3 and 7 fashion.
Caughman et al. (1988) characterised the immediate early polypeptides designated IE1, 
IE2, IE3 and IE4. Of these, IE1, a phosphorylated species, was the most abundant IEP. 
The four IEPs are antigenically related as demonstrated by immunoblotting assays using 
monospecific rabbit antisera.
In vitro translation experiments on EHV-1 IE mRNA (Robertson et al., 1988) 
demonstrated that all the four IEPs are produced in vitro from a 6 kb mRNA and that these 
IEPs correspond in overall size and antigenicity to those synthesised in the infected cells.
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In time-course pulse-chase experiments, these workers showed that three of the major 
IEPs, IE1 (193 kDa), IE3 (166 kDa) and IE4 (130 kDa), were produced concomitantly, 
while synthesis of two other species, IE11 (145 kDa) and IE2b' (120 kDa) was delayed. 
They further demonstrated that production of these IEPs is not dependent upon the 
accumulation of IE mRNA which occurs during the cyclohexamide-blocked infection, 
since the mRNA species isolated during early or late stages of the infection cycle could be 
translated to yield all of the four IE proteins (Robertson et al., 1988). The 6 kb IE mRNA 
is spliced at the 5' terminus and the alternative splicing of this transcript may function in 
regulating translation of IE mRNA species (Harty et al., 1989).
1.3.8.3 DNA synthesis
In L-M cells infected with EHV-1, the synthesis of viral DNA begins at 4-6 h p.i., 
increases rapidly and reaches a peak at 12 h p.i., after which DNA synthesis declines 
rapidly (O'Callaghan et al., 1968a, b). In EHV-1-infected Syrian hamsters, synthesis of 
viral DNA begins at 3-4 h p.i., increases until 8 h p.i. and then declines; animals die at 12- 
14 h p.i (O'Callaghan et al., 1972). Such kinetics of DNA synthesis were studied by 
labeling of L-M cells or hamsters with (3H) deoxythymidine at different time intervals 
during the course of infection. The amount of radioactivity incorporated in the viral DNA 
was quantified and its identity established by hybridisation to purified viral DNA. The 
replication of DNA occurs via a rolling-circular mechanism, as postulated for other 
herpesviruses, in which the circular genome formed after ligation of the genomic termini 
acts as a template (Roizman, 1979). The replicative intermediates are cleaved to give unit 
length virions, which are subsequently packaged into capsids in the nucleus.
1.3.8.4 Effect of EHV-1 infection on host macromolecular synthesis
Inhibition of cellular DNA synthesis begins at about 6 h p.i. and continues throughout the 
lytic cycle in EHV-1-infected L-M cells (O'Callaghan et al., 1968a, b). About 95% of 
DNA synthesis is inhibited at 12 h p.i. in these cells. In contrast, cellular DNA synthesis
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in hepatocytes is apparently unaltered during EHV-1 strain Ky-ha infection of hamsters 
(O'Callaghan et al., 1972). Inhibition of cellular RNA synthesis begins at 2 h p.i. and more 
than 95% of cellular RNA synthesis is inhibited by 12 h p.i. in infected cells. (Lawrence, 
1971).
1.3.8.5 Capsid assembly and envelopment.
The assembly of nucleocapsids of EHV-1 takes place in the nucleus of the infected cell 
and envelopment of the capsid occurs by budding through the nuclear membrane, as for 
other herpesviruses (O'Callaghan et al., 1978). Having acquired their envelopes at the 
inner nuclear membrane, the enveloped virus particles can be seen in the perinuclear 
cistemae and traversing the membranous channel connecting the perinuclear cistema with 
the mucosal surface in the organ culture using transmission electron microscopy (O'Neill 
et al., 1984).
1.3.9 Defective Interfering Particles
The serial propagation of animal viruses at high multiplicities of infection results in the 
generation of defective interfering particles (DEPs) (O'Callaghan et al., 1983). These 
particles inhibit the replication of standard (STD) virus but they require helper replicative 
functions of the STD virus for their own multiplication. Several herpesviruses, such as 
HSV-1, HSV-2, PRV and HCMV generate DI particles upon high multiplicity passage.
EHV-1 DI particles are produced both in vivo in LSH hamsters (Campbell et al., 1976) 
and in vitro in suspension cultures of mouse fibroblasts, L-M cells (Henry et al., 1979, 
1980). These particles mediate the co-establishment of oncogenic transformation and 
persistent infection in permissive hamster embyro fibroblasts (Robinson et al., 1980a, b; 
Dauenhauer et al., 1982). DIP-enriched EHV-1 preparations can establish persistent 
infection in RK cell lines (Gray et al., 1989). The underlying mechanisms of such 
functions are not understood at present. Several persistently infected cell lines (DI cells)
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have been established (O'Callaghan et al., 1983). In such cell lines, only a minor 
population of producer cells release infectious virus and most of the cells are transformed. 
DI cells can cause metastatic tumours when inoculated into adult syngeneic mice.
The EHV-1 DIP genome has a molecular weight similar to that of the STD EHV-1 
genome (94 MDa) and contains multiple repeat and sequences of low complexity 
(Baumann et al., 1986b, 1987). In DIP-enriched preparations, transcription is temporally 
regulated in immediate early, early and late stages as in STD lytic infection (Gray et al., 
1989). Those domains which are conserved in DIP genomes are predominantly expressed 
in RK cells during first 8 h of infection. In STD virus, by contrast, 58-98% of the EHV-1 
genome is transcriptionally active during 1.5-2 h post-infection (Gray et al., 1987a). 
Many of the major mRNA species synthesised in infections with standard virus are not 
detectable in the first 12 h with DIP-enriched preparation. The majority of viral transcripts 
that are synthesised in the DIP-enriched infections correspond to those expressed in STD 
infections (Gray et al., 1989).
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1.4 EHV-1 AND EHV-4 LATENCY
The preliminary evidence to indicate that EHV-1 can establish a latent relationship with its 
equine host were based on field observations by Burrows and Goodridge (1978a). These 
investigators observed spontaneous shedding of EHV-1 in eight ponies following stress in 
a herd of Welsh mountain ponies kept in isolation for years. Seven of these ponies 
developed four-fold or more increases in neutralising antibodies in their sera. These 
studies indicated either reactivation of latent EHV-1 or circulation of the virus on the 
premises. The retrospective serological analysis within the closed herd revealed periodic 
increases in serum-neutralising antibody levels to EHV-1 up to three-fold in 21 different 
ponies suggesting reactivation of latent EHV-1. Attempts to induce reactivation of latent 
virus with corticosteroids or the recovery of virus from tissue explants were however, 
unsuccessful (Burrows and Goodridge, 1984).
It is now well established that EHV-1 can be recovered from the leucocytes following 
respiratory infection with the virus (Bryans, 1969; Burrows and Goodridge, 1972; Glesson 
and Coggins, 1980; Bumgardner et al., 1982; Dutta and Myrup, 1983). Because infectious 
EHV-1 can be isolated only after cocultivation of intact peripheral blood mononuclear 
cells with permissive equine cells in culture and not from non-viable or disrupted 
leucocytes, it has been suggested that the cell-associated viraemia by EHV-1 represents a 
latent infection of equine leucocytes (Scott et al., 1983).
Definitive evidence for the establishment of latent state by EHV-1 in ponies following 
experimental infection with the virus has been provided by Edington et al. (1985) who 
successfully induced reactivation of the virus by administering immunosuppressive 
corticosteroids in these ponies. The ponies infected by intranasal instillation of 2 x 105*5 
TCID50 of paresis isolate of EHV-1 exhibited clinical signs typical of EHV-l-induced 
respiratory disease, leucocyte-associated viraemia up to five days p.i., and nasal shedding
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of the virus for up to 12 days p.i.. Rises in CF antibody levels in the sera of ponies were 
demonstrable at three weeks p.i. These ponies kept in isolation for three months exhibited 
a four-fold decrease in their complement fixing antibodies. Following immunosuppression 
two weeks later with corticosteroids, prednisolone and dexamethasone in doses higher than 
therapeutic levels, EHV-1 was recovered from six of the eight ponies within 14 days, five 
of which were viraemic and three of them shed virus in their nasal secretions. Significant 
rises in the complement fixing and neutralising antibodies were demonstrable in the sera of 
four and two animals respectively. It was concluded from these studies that EHV-1 
establishes a latent infection and the virus can be induced to reactivate by 
immunosupressive effect of corticosteroids. Further in their studies, using therapeutic 
doses of corticosteroids, the virus was recovered from nasal swabs of five of the ten ponies 
on single days between five and 12 days post treatment (Edington, 1988). Viraemia was 
demonstrable in only one pony and there were no significant increases in CF and serum 
neutralising antibodies. On similar lines, Browning et al. (1988b) successfully reactivated 
EHV-4 from horses infected with this virus under natural conditions.
The most definitive and direct evidence of EHV-1 latency has emerged from recent studies 
on experimentally infected ponies (Welch et al., 1992). The latent virus was detected ten 
weeks after primary infection by PCR and recovered by co-cultivation of explanted tissues 
predominantly from the lymphoid tissues draining the upper respiratory tract of ponies. 
Latent EHV-1 was also demonstrable in the peripheral blood leucocytes (PBLs). Latent 
EHV-4 was also detected in some tissues including PBLs from all animals, the origin of 
which these investigators presume from preceding natural infection. In a survey of 40 
abattoir horses, EHV-1 and/or EHV-4 DNA in tissues of 87.5% of horses was detected by 
PCR (Edington et al., 1993). Both the viruses were simultaneously present in some tissues. 
Bronchial lymph node was the predominant site harbouring the latent virus. Other lymph 
nodes draining the upper respiratory tract, mandibular and retropharyngeal were also
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latently infected. The virus was recovered from tissues of 60% of the horses by co­
cultivation.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 Viruses
EHV-1 Strain Abl
EHV-4 Strain 1942 
EHV-1 Strain Ab4
EHV-4 Strain MD
2.1.2 Cell lines
Rabbit kidney (RK-13)
Equine cell (AGO 8422)
2.1.3 DNA markers
Lambda-M/tt/III, <j>X YlAHaelW
EHV-1 DNA library in pBR322 
EHV-4 DNA library in pUC9
Provided by Institute of Virology 
Glasgow, UK.
Provided by Dr. A. Cullinane 
Institute of Virology, Glasgow 
Provided by the Department of 
Clinical Vet. Medicine, 
University of Cambridge 
Provided by Dr. R. Killington, 
University of Leeds
American Type Culture 
Collection (ATCC), Rockville, 
Maryland, USA 
Aging cell repository, Coriell 
Institute for Medical Research, 
Cambden, New Jersey, USA
Betheseda Research Laboratories 
(BRL), Paisley, UK 
Provided by Dr M. Whalley, 
Macquarie University, Sydney. 
Provided by Dr A. Cullinane, 
Institute of Virology, Glasgow
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2.1.4 Enzymes and Kits
Restriction endonucleases 
Kit for end-labelling
2.1.5 PCR Reagents
Tspll and reaction buffer 
PCR core reagents and Ampli Taq 
DNA polymerase
dNTPs
Oligonucleotide primers
2.1.6 Tissue culture reagents
Hank's Balanced Salt Sol. (HBSS) 
with and without calcium and magnesium, 
RPMI, DMEM, M-199, L-glutamine, 
foetal calf serum, gentamicin, penicillin/ 
streptomycin, HEPES buffer, trypsin-EDTA
2.1.7 Reagents for bacteriological media
Tryptone, yeast extract, 
bacteriological agar 
Bacto-peptone
BRL
BRL
Cambio, Cambridge, UK 
ILS Ltd., London, UK 
Perkin Elmer Cetus, 
Beaconsfield, UK 
Pharmacia, Milton Keynes, UK 
Alta Bioscience, University of 
Birmingham, UK
Gibco/BRL.
Oxoid Ltd, Basingstoke, UK 
Difco, East Molesey, UK
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2.1.8 Chemicals
Tris-equilibriated phenol
Ampicillin
Agarose, acrylamide, TEMED, 
methylene bis-acrylamide,
Ammonium persulphate
Sephadex G-50 (medium),
bromophenol blue, xylene cyanol
Glycerol, 30% ammonia (Aristar), boric acid,
EDTA, ethanol, isopropanol, chloroform,
glacial acetic acid, HC1, trisodium citrate,
high vacuum silicon grease, tris, SDS
Ficoll-Paque
Quikhyb solution
Salmon sperm DNA (Type ID) sod. salt, lysozyme 
Ficoll, polyvinylpyrolidine, DMSO,
Bovine serum albumin (Pentax fraction - V)
Triton X-100, ethidium bromide, mineral oil 
Spermidine
Formamide
Sea Plaque agarose
Rathbum Chemicals Ltd,
Walkerbum, UK
BCL, Lewes, East Sussex, UK
BRL
Pharmacia LKB-Technology, UK
BDH Ltd., Poole, UK 
Pharmacia
Stratagene Ltd., Cambridge, UK
Sigma Chemical Co. Ltd., Poole, 
Dorset, UK
Fluka Chemicals Ltd., Glossop, 
UK
ICN Biomedicals Ltd., UK
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2.1.9 Radioisotopes
(y32p )_ATp ICN
2.1.10 Miscellaneous items
Polaroid type 55,57 and 667 film
X-ray film Hyperfilm
Whatman 3mm paper
Gel blotting paper
Hybond-N 
Nick columns
Autoclavable plastic bag rolls
Disposable gowns, overall suits 
Positive displacement pipettes 
and pipette tips
Polaroid U.K. Ltd, St.
Albans, Heartfordshire, U.K. 
Amersham International 
Pic., Amersham, UK.
Whatman International Ltd, 
Maidstone, U.K.
Anderman and Co., Kingston 
upon Thames, UK.
Amersham International Pic. 
Pharmacia
DRG Hospital Supplies, 
Brislington, Bristol, UK 
Fast Aid Products Ltd, Glasgow 
Scotlabs, Bellshill, UK
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2.2 METHODS
2.2.1 Preparation of virus stocks
2 .2 .1.1 Cells
EHV-1 grows in a variety of cell lines, whereas EHV-4 isolates are usually restricted to 
cells of equine origin. In the present study, rabbit kidney cell line, RK-13 was used for the 
propagation of EHV-1 and equine cells (AGO 8422) for growing EHV-4. Cell aliquots of 
AGO 8422 at passage level of 6 and RK13, passage 85, stored in liquid nitrogen were 
thawed quickly. Cells were transferred to centrifuge tubes and 5 ml medium added very 
slowly in order to remove DMSO from the cells. Cells were centrifuged at 1500 rpm for 
10 min in a Beckman GPR centrifuge, the supernatant discarded and the cell pellet 
resuspended in 5 ml of HBSS, centrifuged at 1000 rpm for 7 minutes. Three such 
washings were given with HBSS. Cells were finally resuspended in growth medium. The 
cells were maintained as monolayers in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% foetal calf serum (FCS), 400 units/ml of penicillin and 400 pg/ml 
of streptomycin, 2mM L-glutamine in an environment containing CO2 in a 37°C 
incubator.
2.2.1.2. Infection
RK-13 cells at confluence in a large flask, 125 cm2, were infected at a multiplicity of 
infection (m.o.i.) of 0.001 pfu/ml of EHV-1 Abl which had an original titre of 108 pfu/ml. 
Similarly, equine cells were infected with EHV-4 strain 1942, 104 pfu/ml, at an m.o.i. of 
0 .01.
2.2.1.3. Growth of the stock virus
Virus was adsorbed onto the appropriate cells at 37°C for 1 h in a volume of medium just 
sufficient to cover the cell sheet. Additional medium was then added to increase the 
volume to 15 ml in a 75 cm2 flask and 25ml in a 125 cm2 flask. The cells were incubated
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for 2-4 days at 37°C and examined daily for the development of cytopathic effects (CPE) 
produced by the virus. The virus was harvested as soon as the whole sheet had undergone 
complete CPE. Cells and medium were spun at 3000 rpm for 30 min in a Beckman 
general purpose table top centrifuge to pellet the cell debris. The supernatant was 
aliquoted into Bijoux bottles and stored at -80°C until required.
2.2.2 Titration of the virus by plaque assay
EHV-1 and EHV-4 were titrated in appropriate cells by plaque assay. Cells were grown in 
medium flasks to confluence, trypsinised and counted. Petri plates (25 cm2) were seeded 
with 2 x 106 cells in 5 ml medium and incubated at 37°C till the cells had reached 80% 
confluence. The virus aliquot was thawed rapidly and placed on ice. Serial 10-fold 
dilutions of the virus were prepared (10*1 to 10'6) using eppendorf pipette tips. The 
medium was removed from the plates and 1 ml medium was added to the negative control. 
Then, starting at the highest dilution, 1 ml of diluted virus was added to duplicate test 
plates. The pipette tips were changed between each transfer. The plates were returned to 
the incubator and the virus allowed to adsorb for 1 h. A 2% Sea Plaque agarose solution 
was prepared in tissue culture grade water and sterilised by autoclaving. The molten 
agarose was added to an equal volume of 2 x medium, M-199 containing 10% FCS and 
antibiotics at 40°C and the mixture maintained at 40°C until required. Starting with the 
negative control followed by highest dilution, 5 ml of the overlay was pipetted slowly 
down the side of the plate to avoid introduction of air bubbles. After 10-15 min at room 
temperature to facilitate solidification of the agarose, the plates were returned to the 
incubator. The plates were examined for plaques from the second day onwards. Each 
plate was fixed and stained with 3 ml working solution of crystal violet stain (Table 2.1). 
The plates were left on the bench overnight, after which the agar overlay was washed out, 
the plates allowed to air dry and examined for plaques.
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2.2.3 Growth and storage of plasmids and preparation of recombinant plasmid 
DNAs
The K coli Strain JM 101 carrying the appropriate plasmid was inoculated into 5 ml of L 
broth containing ampicillin at the standard working concentration (Table 2.1). Bacterial 
cultures were grown by overnight incubation at 37°C in an orbital shaker. One ml of this 
culture was used to prepare glycerol stocks by adding an equal volume of 80% v/v 
glycerol/2% w/v bactopeptone and the stock was stored at -20°C . Of the remaining 
culture, 1 ml was inoculated into 500 ml of L broth containing ampicillin and incubated in 
an orbital shaker for 16-20 h at 37°C. Bacterial cells were pelleted by centrifugation at 
7000 rpm for 10 min at 4°C in a Beckman JS 7.5 rotor.
2.2.3.1. Small scale preparation of plasmid DNA
Small scale isolation of recombinant plasmid DNA was carried out using the boiling 
method (Holmes and Quigley, 1981). Seven to ten bacterial colonies were picked from 
agar plates with sterile toothpicks and seeded separately into 3 ml broth containing 100 p. 
g/ml ampicillin in screw-cap tubes. The cultures were incubated overnight at 37°C in an 
orbital shaker. One ml of each culture in eppendorf tube was pelleted by centrifugation at 
12000 rpm for 30 sec in a microcentrifuge. The medium was removed by aspiration 
leaving the bacterial pellet as dry as possible. The bacterial cell pellet was resuspended in 
140 pi of STET buffer (Table 2.1). Ten microlitres of freshly prepared lysozyme (10 
mg/ml in STET buffer) were then added and the contents vortexed briefly, followed by 
boiling in a water bath for 40 sec. The bacterial lysate was centrifuged at 12000 rpm for 
10 min at room temperature in a microcentrifuge. The DNA from the supernatant was 
extracted with phenol:chloroform (1:1). The upper aqueous layer was transferred to 
another tube and the precipitation of DNA carried out at -70°C for 1 h with 2 vol. of 
ethanol and 1/10th vol. of 5 M NaCl. The pellet of DNA was recovered by centrifugation 
at 12000 rpm for 10 min, freeze-dried and resuspended in 30 i^l of 1 x TE buffer.
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To analyse the DNA by cleavage with appropriate restriction endonuclease enzymes, 1 pg 
of DNA was digested with the restriction enzyme in appropriate reaction buffer containing 
spermidine (Table 2.1) at 37°C for 2 h in a water bath. The digested DNA in gel loading 
buffer was loaded onto 0.8% agarose gel and electrophoresed at a constant voltage (70 V 
for 1 h) in a minigel apparatus using 0.5 x TBE buffer.
2.2.3.2. Large scale preparation of plasmid DNA
The bacterial cells were harvested from a 500 ml culture by centrifugation at 7000 rpm for 
10 min in a Beckman J-21 rotor. The pellet was resuspended in 40 ml of ice-cold solution 
I (Table 2.1). Ten ml of freshly prepared lysozyme (20 mg/ml in Solution I) was then 
added and allowed to act for 30 min. on ice. 80ml of Solution II (Table 2.1) was added to 
the lysate with gentle mixing for 10 min on ice. 40 ml of Solution III (Table 2.1) was then 
added with gentle mixing and the lysate incubated for a further 15 min. The contents were 
spun at 7,000 rpm for 15 min at 4°C in a Beckman JS 7.5 rotor. The supernatant was 
filtered through a sterile cotton gauge in order to remove cellular debris. The plasmid 
DNA was precipitated with 100 ml of isopropanol at -20°C for 30 min followed by 
centrifugation at 7,000 rpm for 20 min in a Beckman JS 7.5 rotor. The pellet was 
suspended in 17 ml of 1 x TE buffer (Table 2.1) and 18 g of caesium chloride and 1.8 ml 
of 3 mg/ml ethidium bromide added. The refractive index of the solution, ideally 1.388- 
1.390, was adjusted if required. The contents were transferred to 12 ml Beckman Quick 
Seal centrifuge tubes, the tubes heat-sealed and samples centrifuged in a Beckman fixed 
angle 50Ti rotor at 45,000 rpm at 18°C for 36 to 48 h. Generally, two bands were 
observed within the gradient and an RNA pellet at the bottom of the tube and a protein 
pellet at the top. The larger, lower band which consisted of closed circular plasmid DNA, 
was withdrawn into a 2 ml syringe using a 19-gauge needle. The DNA was extracted with 
isopropanol. An equal volume of isopropanol was added to the DNA and vigorously 
mixed to partition the ethidium bromide into the upper solvent phase. The aqueous phase 
was retained and extractions repeated four times, 0.2 ml of distilled water was added to the
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aqueous phase between extractions so as to maintain the volume until all traces of 
ethidium bromide were removed from aqueous phase. The DNA was finally dialysed 
extensively against 1 x TE buffer overnight so as to remove caesium chloride, precipitated 
with two vol. of ethanol and l/10th vol. of sodium chloride for 1 h at -70°C or overnight at 
-20°C. It was then pelleted by centrifugation in a benchtop microcentrifuge at 13,000 rpm 
for 10 min, washed with 70% ethanol briefly and freeze dried. The DNA was resuspended 
in glass distilled water and the optical density at 260 nm determined before storing 
at -20°C.
2.2.4 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) is a method by which a nucleic acid sequence can be 
exponentially amplified in vitro (Saiki et al., 1985; Mullis and Faloona, 1987; Saiki et al., 
1988). The amplification process requires two oligonucleotide primers that flank the DNA 
segment to be amplified, equimolar concentrations of four deoxynucleoside triphosphates, 
dNTPs (dATP, dCTP, dGTP, d'lT'P), thermostable DNA polymerase and an appropriate 
reaction buffer. The primers are small stretches of chemically synthesised polynucleotides 
usually 16 to 30 bases long, and are designed from selected sequences on the two strands 
of duplex DNA that flank the target sequence. Each primer can hybridise to the 
complementary sequences on the corresponding strand. The amplification process involves 
repeated thermal cycling which is carried out in a reaction tube containing the required 
reagents using automated thermal cycling device. Each thermal cycle consists of three 
defined steps: denaturation of duplex target DNA to produce single DNA strands, 
generally at a temperature above 90°C, annealing of each primer to the complementary 
sequences on the corresponding strand, usually at 40°C-55°C and finally the extension of 
annealed primers at their 3' hydroxyl ends on the template DNA strands. The extension of 
primers is directed towards each other such that the DNA segment flanked by the two 
primers is amplified. The extension step is usually carried out at 72°C and is catalysed by a 
heat-stable DNA polymerase and generally, 25-40 cycles are performed in a PCR assay.
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During the first few reaction-cycles, extension of each oligonucleotide primer on the 
original DNA template will generate one single-stranded DNA molecule of indefinite 
length in each cycle. These molecules act as templates for subsequent cycles in which 
strands of specific length whose ends are defined by the 5’ ends of the two primers, are 
produced. Since the extension products are also complementary to and capable of binding 
primers, the amount of DNA in each cycle is doubled. The whole process results in the 
exponential accumulation of a specific target fragment until a plateau is reached. The 
various steps in the amplification process are depicted in Figure 2.1.
With this technique, DNA fragments upto 10 kb can be amplified (Jeffery et al., 1988). 
Not only DNA but RNA can also be amplified with PCR following the production of 
complementary DNA (cDNA) from RNA, with catalytic action of the enzyme reverse 
transcriptase. The cDNA synthesised in this manner can act as template for amplification.
2.2.5 Analysis of PCR Products
2.2.5.1 Polyacrylamide gel electrophoresis
The PCR amplified product was electrophoresed through a non-denaturing polyacrylamide 
gel using a vertical gel electrophoresis apparatus (BRL). Glass plates were washed with 
warm detergent solution, rinsed with water, followed by a rinse with 70% ethanol. 50 ml 
of 6% polyacrylamide solution from the 30% stock solution (Table 2.1) was prepared as 
follows: 10 ml of stock solution was added to 35 ml of water to which 5 ml of 10 x TBE, 
420 ml of 10% APS and 42 ml of TEMED were added. The solution was mixed by 
swirling and poured quickly between glass plates filling the space almost to the top. The 
plates were laid against a support and a 20-teeth comb was inserted immediately very 
carefully such that air bubbles were not trapped under the teeth. The polyacrylamide was 
then allowed to polymerise for 30-45 min at room temperature. The gel plates were then 
attached to the electrophoresis assembly. The comb was then removed carefully and the 
wells flushed with water using a syringe and needle. The reservoirs of the electrophoresis
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tank were filled with 1 x TBE. The air bubbles trapped at the bottom of the gel were 
removed with a bent syringe needle.
The DNA sample was mixed with an appropriate amount of 6 x gel loading buffer (Table 
2.1) and loaded onto the well carefully under the electrophoresis buffer. The gel was 
electrophoresed at a constant current of 30-35 mA until the marker dyes had migrated the 
desired distance. The gel was then removed and gently submerged in staining solution 
(0.5 mg/ml of ethidium bromide in 1 x TBE), stained for 15 min at room temperature and 
destained in deionised water for 20-30 min. The gel was placed on an ultraviolet 
transilluminator and photographed using Polaroid film type 55, 57 or 667 as required. The 
gel below the desired bands was excised with a scalpel blade.
2.2.5.2. Electroblotting
The DNA was transferred onto nylon membrane, Hybond-N, under an electric field. 
Precisely, the gel was soaked in denaturation buffer, (pH 12-14) (Table 2.1 ) for 35 min 
followed by neutralisation for 35 min in neutralisation buffer, pH 8.0 (Table 2.1). The gel 
was finally immersed in 1 x TAE buffer for 15 min and placed on the Hybond N- 
membrane presoaked in 1 x TAE between gel blotting papers pre-soacked in water such 
that DNA from the gel under electric influence migrated towards anode. The DNA was 
electroblotted onto the membrane at a constant voltage of 15 V overnight in an electroblot 
apparatus (Bio-rad) containing 1 x TAE buffer which was constantly mixed using a 
magnetic stirrer. The membrane was washed in 1 x TAE, dried between filter pads and 
immobilised by baking in an oven at 80°C for 2 h.
2.2.5.3 Preparation of oligonucleotide probes
EHV-1 or EHV-4-specific oligonucleotide probes were synthesised in an Applied 
Biosystems automated DNA Synthesiser at 0.2 pmole scale. Each probe was retrieved 
from the column by passing 2 ml of 35% ammonium solution through it over a two h
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period. The solution was transferred to two screw-cap tubes and incubated at 55°C for a 
minimum of 5 h. The oligonucleotide was precipitated with 2 vol. of ethanol and 1/1 Oth 
vol. of 5 M NaCl at -70°C for 1 h, spun at 12,000 rpm for 10-15 min in a microcentrifuge 
and washed with 70% ethanol. The pellet was freeze-dried and the oligo resuspended in 
400 pi ultrapure water. The OD260 was determined and the concentration calculated before 
storing the oligonucleotide at -20°C.
2.2.5.4 Labeling of oligonucleotide probes
Oligonucleotide probes were end-labelled to high specific activity with crude [y32P]-ATP 
(ICN) using T4 polynucleotide kinase. The enzyme T4 polynucleotide kinase specifically 
transfers the 32P label from ATP to a 5'-OH group of DNA or RNA. Therefore, this 
reaction can be used to end label synthetic oligonucleotide probes which possess a 5'-OH 
group. The following procedures were carried out in a designated area for the handling of 
radiolabelled chemicals. Behind a plexi glass shield, 250 pCi of [y32P]-ATP and 15 units 
of T4 polynucleotide kinase were added to 1 pg of oligonucleotide in 1 x forward reaction 
buffer/kinase buffer (Gibco/BRL). The contents were mixed by spinning for 5 sec in a 
microcentrifuge and incubated in a water bath at 37°C for 45 min. The labelled DNA was 
recovered by size separation on a Nick column (Pharmacia) where the oligonucleotide 
probes were 20 bases or longer or on a Sephadex column in case of shorter oligos. 
Sephadex G-50 columns were prepared by pouring G-50 Sephadex into the column slowly 
so as to avoid trapping of air bubbles. The column was allowed to settle so as to form a 
single uniform column, and then washed with 1 x TE buffer (Table 2.1 ) before loading 
the DNA sample. The radioactive peak was collected into 3 screw cap tubes as it eluted 
from the column. Five ml of scintillation fluid and 10 pi of a 1:20 dilution of the eluate 
were mixed in a scintillation vial and counted in a Beckman scintillation counter. In the 
case of Nick columns, 400 pi of the sample was eluted according to the instructions of the 
manufacturer and a scintillation count was conducted.
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2.2.5.5 Hybridisation
The hybridisations were carried out as described by Anderson and Young (1985) with 
suitable modifications. Baked membranes were placed in polythene bags and 10-20ml of 
the pre-hybridisation buffer depending upon the size of the membrane, added in order to 
pre-coat sites on the membrane which would otherwise bind the probe non-specifically. 
Salmon or herring sperm DNA was denatured in a boiling water bath for 7 min, chilled 
quickly on ice and added to pre-hybridisation buffer at a final concentration of 100 p-g/ml. 
All the air bubbles were removed, the bag double sealed after checking for leakage, and 
finally placed in a plastic box containing water and incubated for 12 h or longer in a 
shaking water bath at 37°C. Alternatively, prehybridisation was carried out in Quikhyb 
buffer in a volume just sufficient to cover the membrane, a minimum of 5 ml, in glass 
tubes in a Hybaid mini hybridisation oven at 58°C and 42°C for EHV-1 and EHV-4 
specific gH probes respectively for 30 min.
An appropriate amount of probe in 1-2 ml of fresh pre-hybridisation buffer (plus salmon 
sperm or herring sperm DNA at 100 pg/ml) was added to the pre-hybridisation buffer in 
the bag/tube. The final concentration of probe was 1 x 106 cpm per ml pre-hybridisation 
buffer or Quikhyb. Air bubbles were carefully removed and bags re-sealed after ensuring 
that there was no leakage. Bags, in a plastic box, were placed in a shaking water bath at 
37°C and hybridisation allowed to occur for 16 h or longer. Hybridisation tubes were 
returned to the oven and hybridisation carried out at specified temperatures for a 
minimum of 2 h.
2.2.5.6 Washing
One comer of the bag was cut and the hybridisation solution drained into a designated 
sink. The bag was then cut open completely and the membrane immersed in 6 x SSC 
followed by three quick washes with 6 x SSC, 0.1% SDS. The membranes were washed 
thrice at 30 min intervals in 400 ml of 6 x SSC, 0.1% SDS at 5-10°C below the melting
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temperature (Tm). The final washing was performed at Tm for 2 min in 2 x SSC, 
0.1% SDS. Mismatched hybrids would therefore dissociate rapidly at this temperature. 
The membrane was finally rinsed in 6 x SSC and air dried to dampness sealed in polythene 
bags. The washing conditions are described in the methods of individual result chapters.
2.2.5.7 Autoradiography
The membranes were exposed to Amersham MP film at -70°C in the presence of 
intensifying screen in a light-proof cassette. The film was developed in a Kodak X- 
OMAT film processor.
The optimisation of reaction conditions for PCR and its application to the detection of 
EHV-1 and EHV-4 specific sequences in equine nasal secretions and peripheral blood 
mononuclear cells (PBMCs) is detailed in subsequent chapters of this thesis.
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Table 2.1
General Stock Solutions and Buffers
L-broth medium
Tryptone 10 g
Yeast extract 5 g
NaCl 10 g
dH2 0  to 1 litre
Sterilised by autoclaving.
L-agar
L-broth 200ml
Agar 3 g
Sterilised by autoclaving.
Ampicillin
Sodium salt of ampicillin was dissolved in CIH2O at a concentration of 100 mg/ml, filter 
sterilised and stored at -20°C . Used at final concentration of 100 pg/ml.
Lysozyme
The stock solution of lysozyme was prepared by disolving lysozyme in solution I at a 
concentration of 20 mg/ml. The composition of solution I is given on the following page. 
Stored at -20°C. Each aliquot was discarded after use.
10% SDS
SDS
dH20
100 g
to 1 litre
STET buffer
5% Triton X-100 
50 mM EDTA (pH 8.0)
50 mM Tris (pH 8.0)
8% sucrose
Solution I
1 M Tris 
1 M Glucose 
0.2 M EDTA 
dH20
Solution II
10% SDS 
5 M NaOH 
dH20
Solution III
3 M Potassium acetate (pH 5.0)
1 M Tris
Tris base 
dH20
pH adjusted with concentrated HC1, 
volume made to 1 litre with dH20  
sterilised by autoclaving.
12.5 ml 
25 ml 
25 ml 
438 ml
50 ml 
20 ml 
430 ml
121.1 g 
800 ml
0.5 M EDTA (pH 8.0)
EDTA 186.1 g
dH20  800 ml
pH adjusted to 8.0 with NaOH, 
volume adjusted to 1 litre with dH20  
and solution sterilised by autoclaving.
5 M NaOH
NaOH 200 g
dHoO to 1 litre
Sterilised by filtration.
5 M NaCl
NaCl 292.2 g
dH20 to 1 litre
Sterilised by autoclaving.
10 x TBE
Tris base 108 g
Boric acid 55 g
0.2 M EDTA (pH 8.0) 50 ml
dH20  to 1 litre
Ethidium  brom ide (10 mg/ml)
Ethidium bromide 1 g
dH20 to 1 litre
Stored in dark.
Gel loading buffer (6x)
Bromophenol blue 0.25 g
Xylene cyanol FF 0.25 g
Glycerol 30 ml
CIH2O to 100 ml
Stored at 4°C.
100 x T E
Tris base 121 g
EDTA 37 g
dH20 to 1 litre
10% Ammonium persulphate
Ammonium persulphate 1 g
H20 to 10 ml
30% Acrylamide
Acrylamide 29 g
N-N'methylene bis-acrylamide 1 g
H20 to 100 ml
D enaturation buffer (pH 12-14)
NaOH 20 g
NaCl 87.66 g
dH20 to 1 litre
Neutralisation buffer (pH 8.0)
Tris base 60.7 g
NaCl 175.32 g
HC1 33 ml
dH20 to 1 litre
50 x TAE
Tris base 242 g
Glacial acetic acid 57.1 ml
0.5 M EDTA (pH 8.0) 100 ml
dH20 to 1 litre
Denatured, fragmented, salmon sperm DNA/Herring sperm DNA
Salmon sperm DNA (Sigma Type III sod. salt) or herring sperm DNA was dissolved in 
water at a concentration of 10 mg/ml, stirred on a magnetic stirrer until the DNA was 
completely dissolved, boiled for 10 min, sheared by passing through a 23-25 gauge 
hypodermic needle several times, aliquoted and stored at -20°C until used. The solution 
was heated in boiling water bath for 7 min. and chilled quickly in ice water.
D enhardt's solution (50x)
Ficoll 5 g
Polyvinylpyrolidone 5 g
Bovine serum albumin (Fraction V) 5 g
dH20 to 500 ml.
Filtered through a disposable Nalgene filter. 
Stored at -20°C.
Prehybridisation buffer
Denhardt's 10 x
Tris pH 7.4 50 mM
SSC 6 x
EDTA 10 mM
SDS 0.1%
Formamide to lower hybridisation temperature
Denatured salmon sperm DNA 250 pg/ml
20 x  SSC
NaCl 175.3 g
Sodium citrate 88.2 g
dH20 800 ml
pH adjusted to 7.0 with 10N NaOH and volume made to 1 litre.
Sterilised by autoclaving.
Formamide (deionised)
Formamide 50 ml
Ion exchange resin 5 g
(Bio-rad AG 501-X8, 20-50 mesh)
Stirred for 30 min at room temperature then filtered twice through Whatman No. 1 filter 
paper. Dispensed into aliquots and stored at -20°C
NIB (PCR buffer with non ionic detergents)
50 mM KC1 
10 mM Tris (pH 8.3)
100 g/ml gelatine
1.5 mM MgCl2 
0.45% NP40 
0.45% Tween20
Spermidine
Stock solution (3.5 M) of spermidine was prepared by dissolving spermidine base in 
water, sterilised by filtration and used at a final concentration of 1 mM.
Crystal violet stain
Stock solution (5%) was prepared in methanol and was used at a working dilution of 
1:10.
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Figure 2.1 An outline of the underlying principle of PCR.
CHAPTER 3
OPTIMISATION OF REACTION CONDITIONS FOR PCR
3.1 INTRODUCTION
The polymerase chain reaction (PCR) is a technique by which DNA sequences can be 
amplified in vitro (Mullis and Faloona, 1987). The amplification process involves the 
binding of two oligonucleotide primers to complementary DNA strands and extension of 
the annealed primers by incorporation of deoxynucleoside triphosphates catalysed by a 
heat stable DNA polymerase, as described in Chapter 2. By repeated cycles of heat 
denaturation of DNA, primer annealing and extension of the annealed primers, copies of a 
target DNA sequence can be amplified a million fold within a few hours with this 
technique (Saiki et al., 1988). The sequence should be at least partially known, such that 
suitable primers flanking the region to be amplified can be designed. The large amounts 
of DNA amplified by PCR can subsequently be used for various analyses. DNA 
sequences from the human (3-globin gene were the first sequences to be amplified by PCR 
(Saiki et al., 1985; Mullis and Faloona, 1987). For its sensitivity, rapidity, simplicity and 
ability to utilise minute amounts of DNA in crude samples or crude DNA preparations as 
targets for amplification, the PCR technique has now become a popular and invaluable 
research tool in various fields, e.g. molecular biology, population genetics, medical and 
veterinary diagnostics, forensic and anthropological analyses. With this technique, DNA 
can be amplified from hair roots (Higuchi et al., 1988), mouth washings (Lench et al., 
1988), paraffin-embedded tissue samples (Shibata et al., 1989), sperm lysates (Li et al.,
1988) and several body fluids.
3.1.1 Some applications of PCR
3.1.1.1 Detection of human and animal pathogens
PCR has been employed in medical and veterinary diagnostics to detect bacterial, fungal, 
viral and other parasitic pathogens. The amplification of the target nucleic acid sequences 
not only results in an exponential increase in the number of copies of DNA, but also 
facilitates probing of the amplified sequence by reducing the complexity of the nucleic
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acid. PCR has several advantages over the conventional procedure of propagating 
pathogens in vitro in suitable media or cell lines. Pathogens that are difficult to propagate 
in vitro e.g. mycobacteria (Brisson-Noel et al., 1989) or those organisms which grow 
slowly in culture e.g. mycoplasmas can now be readily detected by PCR. The technique is 
very rapid for the detection of pathogens compared to isolation procedures, the latter may 
sometimes take weeks to achieve a diagnosis. Another advantage of PCR over isolation 
procedures is that a crude clinical sample may be used for amplifying the target DNA 
sequence (Bugawan et al., 1988), whereas contamination by other micro-organisms makes 
samples unsuitable for the isolation of pathogens in culture. PCR is a highly sensitive 
technique compared to conventional methods and can detect up to one molecule of target 
DNA in a sample.
Being more sensitive, PCR is now used for the detection of important human pathogens, 
e.g. human immunodeficiency virus-1 (HIV-1) (Ou et al., 1988), human T lymphotropic 
virus-I (HTLV-I) (Kwok and Higuchi, 1989), HTLV-II (Lee et al., 1989) and hepatitis B 
virus (Larzul et al., 1988). papillomaviruses (Shibata etal., 1989, Johnson et al., 1990).
PCR has also been used in detection of various viral pathogens of animals such as bovine 
viral diarrhoea virus (Hooft van Iddekinge et al., 1992, Belak and Ballagi-Pordany, 1991), 
foot and mouth disease virus (Laor et al., 1992), bluetongue virus (McColl and Gould,
1991), pseudorabies virus (Schebra et al., 1992), African swine fever virus (Steiger et al.,
1992), infectious laryngotracheitis virus (Williams et al., 1992), chicken anaemia virus 
(Todd etal., 1992), rabies virus (Sacramento et al., 1991), bovine leukaemia virus (Naif et 
al., 1992) and feline immunodeficiency virus (Hohdatsu et a l,  1992) and many more. 
PCR has also been used to detect other animal pathogens such as bacteria and blood 
parasites.
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3.1.1.2 Detection of genetic disorders
PCR has been used for characterisation of gene defects, prenatal diagnosis of genetic 
diseases, neonatal screening and carrier testing and typing of HLA and disease 
susceptibility genes. A large number of genetic diseases have been studied with PCR, 
including sickle cell anaemia (Embury et al., 1987). (3-thalassaemia (Wong et al., 1987), 
haemophilia A (Inaba et al., 1989) and haemophilia B (Winship et al., 1989). Embryos 
developed by in vitro fertilisation can be analysed for genetic defects by examining a 
single cell biopsy taken at the six to eight cell stage and sexing it by amplification of the Y 
chromosome-specific repeat sequence, before implantation into the uterus (Handyside et 
al., 1990). Hair roots and buccal washings can also be analysed by PCR for screening of 
carriers of genetic diseases. Lo et al., (1989) demonstrated Y chromosome-specific DNA 
sequences in the circulation of pregnant women with male foeti.
PCR combined with direct sequencing of HLA loci can be used for HLA haplotyping and 
determination of disease susceptibility genes (Gyllensten and Erlich, 1988). Recently, 
mutations in the angiotensin converting enzyme that appear to predispose to myocardial 
infarction (Cambien et al., 1992) and mutations in the angiotensin genes that predispose to 
hypertension (Jeunemaitre et al., 1992) have been identified by PCR.
3.1.1.3 Detection of cancer
Single base mutations in oncogenes, e.g. the ras oncogene, can be detected by PCR by 
hybridisation of the allele-specific probe with the amplified product (Rodenhuis et al., 
1987). PCR can be employed to detect translocations in leukaemias and lymphomas, e.g. 
B cell lymphoma (de-Jong et al., 1989), follicular lymphoma (Lee et al., 1987) and 
chronic myeloid leukaemia (Dobrovic etal., 1988).
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3.1.1.4 Anthropology
Thirteen thousand year old DNA from extinct animals has been amplified by PCR (Paabo,
1989). DNA from human bones between 300-5500 years of age has successfully been 
extracted and amplified (Hagelberg et al. , 1989). PCR has also been used to study 
polymorphisms in mitochondrial DNA (Wrischnick et al., 1987). DNA from 125-135 
million years old fossilized insect weevil, has been successfully extracted and amplified 
(Cano e t a l ,  1993).
3.1.1.5 Forensic Use
PCR has advantages over conventional methods of analysis of biological evidence in 
forensic cases. It utilizes very minute amounts of DNA which can be amplified from 
traces of blood spots on clothing and also from single hair. Human DNA contains 
hypervariable regions knows as mini-satellites which can give an individual fingerprint 
(Rollo et al., 1987). The DNA from evidence samples is generally moderately degraded. 
Partially degraded samples can be amplified by PCR (Paabo et al., 1988).
3.1.1.6 Other Applications
PCR has several applications in basic research, some of which are mentioned below.
The DNA amplified by PCR can be cloned and sequenced (Scharf et al., 1986) or 
sequenced directly (Wrischnick et a l,  1987). PCR can also be used during actual 
sequencing reaction using different dye-labelled primers, a system know as 'cycle 
sequencing'.
PCR is valuable in physical mapping of genomes e.g. the genome of Drosophila 
melanogaster (Garza et al., 1989) and the human genome.
Restriction enzyme recognition sequences can be added to the 5' end of primers which are 
incorporated into the amplified product (Embury et al., 1987). The restriction sites
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facilitate cloning of the amplified product. Similarly, certain regulatory sequences can 
also be added (Mullis and Faloona, 1987).
Specific radioactively or non-radioactively labelled probes can be generated by PCR for 
use in analysis of clinical samples. This is accomplished either by the use of PCR primers 
that are end-labelled at their 5* ends or by the incorporation of labelled dNTP analogues in 
the reaction mixture during amplification.
New or uncharacterized sequences related to a known family of genes can be identified by 
use of degenerate primers in the PCR e.g. feline herpesvirus thymidine kinase genes has 
been identified by using degenerate primers selected after alignment of the moderately 
conserved regions of TK genes of other alphaherpesviruses (Nunberg et a l ,  1989). This 
approach is being adopted for detection of new viruses which are yet unidentified 
members of existing viral families.
3.1.2 Some adaptations and modifications of PCR
With advancement in PCR technology, several modifications in the PCR technique have 
been made according to the research needs. Some of the important modifications are 
described below.
3.1.2.1 Nested PCR
This type of PCR involves two rounds of amplification, each consisting of 20 to 25 cycles 
of amplification, to improve the efficiency of amplification. In the first round of 
amplification, an external pair of primers is utlized producing a larger fragment which acts 
as a template for the second set of primers which are internal to the initial set. This 
process provides an additional specificity to the reaction and greatly enhances the 
efficiency of amplification.
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3.1.2.2 Hot Start
This procedure increases the sensitivity of PCR, particularly when amplification of low 
copy number targets is required. The process utilizes the addition of formulated wax, PCR 
Gem (Perkin-Elmer) to a reaction tube containing subset of the reaction components. The 
tube is heated to 75°C or above for 5-10 minutes and then cooled to room temperature, 
allowing the formation of solid wax over the aqueous layer. The left out reagent and the 
sample containing target-sequences are then added and thermal cycling carried out. The 
hot start procedure prevents annealing of the primers to non-target sites and primer 
oligomerisation which may occur prior to the amplification. This procedure thus improves 
the specificity and sensitivity of PCR.
3.1.2.3 In Situ PCR
It is a type of PCR by which DNA in morphologically intact cell or tissues can be 
amplified. The fixed cells or tissue specimens mounted on the microscope slides serve as 
a source of target DNA. The PCR reagents are then added, which diffuse into the cellular 
milieu and amplification allowed as for conventional PCR. The amplified product can be 
labelled during the process of amplification by incorporation of digoxigenin or biotin 
labelled dUTP which may be visualised with enzyme-antibody conjugates (Nuovo et a l , 
1991a,b). The amplified product can also be detected by non-isotopic in situ hybidisation. 
With in situ PCR, it is possible to correlate PCR results with specific cell in a tissue which 
otherwise is not possible with standard PCR. Another advantage is that there are no 
chances for contamination by carryover products. In situ RNA-PCR assays have also been 
developed.
3.1.2.4 Inverse PCR
This is a method of PCR by which an unknown DNA segment flanking a known sequence 
can be amplified (Triglia et al, 1988). The primers are derived from the known sequence 
which direct the synthesis from the known sequence away from each other. The DNA is
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first digested with a restriction enzyme that cuts outside the known sequence on either 
side. The cut fragment can be circularised by ligation. The primers are then added and 
amplification allowed to occur. The amplified product is cut with another restriction 
enzyme within the known sequence and the amplified DNA can be sequenced.
3.1.2.5 Assymetric PCR
This is a method in which one primer in excess of the other, usually one hundred fold, is 
used in amplification process in order to bias the production of one DNA strand of the 
target duplex DNA and hence, termed asymmetric (Gyllensten and Erlich, 1988). This 
method is generally employed to produce probes or single-stranded DNA template.
3.1.2.6 Anchored PCR
Anchored PCR is used to clone and sequence 5’ or 3' flanking regions of a known fragment 
of single stranded DNA e.g. cDNA generated from mRNA (Loh et al., 1989). A poly-G 
tail is added to the 3' end of the cDNA with the catalytic action of terminal 
deoxynucleotidyl transferase. A polyC nucleotide can then be used as a primer for the 
synthesis of DNA in one direction, whereas the other primer derived from the known 
sequence of the cDNA segment directs the synthesis in the other direction.
3.1.2.7 Immuno-PCR
This type of PCR assay has been developed to detect antigens very efficiently with specific 
antibody-DNA conjugate. A linker molecule which has bispecific binding affinity for 
DNA and antibody is used to attach a DNA molecule. The latter acts as a marker molecule 
and forms a specific antigen-antibody-DNA conjugate. With suitable primers, the attached 
marker can be amplified. The presence of specific PCR products demonstrates that the 
marker DNA molecules are attached specifically to antigen-antibody complexes. Sano et 
al. (1992) employed this procedure to detect varying amounts of bovine serum albumin 
(BSA) immoblized to micro-titre plate wells using Streptavidin-protein A chimera as a
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linker. The linker had two separate specific binding affinities for biotin, derived from the 
streptavidin moiety and the other to the Fc portion of IgG molecule. The detection 
procedure followed by these workers was similar to standard ELISA, in which a 
biotinylated linear plasmid DNA (pUC 19) conjugated to the streptavidin-protein A 
chimera was used instead of secondary antibody directed against the primary antibody. 
The comparison with the standard ELISA using chimera-alkaline phosphatase conjugate 
revealed that the immuno-PCR assay was about 105 times more sensitive.
3.1.2.8 Multiplex PCR
It is a method of amplification by which several PCR products can be obtained in a single 
reaction using more than one primers pair, allowing thereby multiple analysis of a single 
sample (Chamberlain et al. , 1988)
3.1.3 Optimisation of reaction conditions for PCR
Although the underlying principle of a polymerase chain reaction appears very simple and 
straighforward, the reaction, in fact, involves complex kinetic interactions during the 
process of amplification between the template, the primers, the deoxynucleotide 
triphosphates, the reaction products and the thermostable DNA polymerase. Several 
problems may arise while attempting to amplify certain targets: complete failure of 
amplification, too low yield of the desired reaction product and non-specific amplification. 
The latter may result either from the annealing of primers to non-target sites (mis-priming) 
and their extension (mis-extension). The formation of primer-dimers may be seen in some 
reactions, particularly when the 3' ends of the two primers used in the reaction are 
complementary to each other and may be observed as predominant products in some 
assays. A primer-dimer is a double-stranded DNA fragment and is formed when one 
primer is extended over the other by DNA polymerase.
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The specificity and yield of the reaction products in a PCR assay can be improved by 
determining the optimal concentrations of the reaction components and by working out 
optimal thermal cycling conditions.
3.1.3.1 Reaction components 
PCR buffer and MgCl2
The specificity and yield of reaction products is greatly influenced by the concentration of 
MgCl2 in the PCR buffer. Mg++ are required for the activity of Taq polymerase. Since 
these ions can bind to deoxynucleotide triphosphates, primers and DNA template, an 
optimal concentration of free Mg++ in the reaction buffer is necessary for optimal activity 
of the enzyme. The optimum level of MgCl2 varies with primer pair used in the 
amplification process and the target sequence being amplified. In general, an excess of 
Mg++ results in the production of non-specific reaction products, whereas a low 
concentration of Mg++ may reduced the yield of PCR product, particularly when chelators 
of Mg++, such as EDTA, are present in the primer stocks or the sample containing the 
target DNA.
Deoxynucleotide triphosphates (dNTPs)
Deoxynucleotide triphosphates are generally used in the concentration of 50-200 pM of 
each dNTP in PCR assays. Higher concentrations of dNTPs may lead to their 
misincorporation by the DNA polymerase in the PCR product (Petruska et a l , 1988). Use 
of equimolar concentration of all the four dNTPs (dATP, dGTP, dCTP, d'lT'P) minimises 
the misincorporation errors. Low dNTP concentrations minimise binding of the primers to 
non-target sites on the template DNA and reduces the chances of extending mis- 
incorporated nucleotides (Innis et a l,  1988). Deoxynucleotide triphosphates containing 
alternative bases such as deoxyuridine (dUTP) or modified bases such as deaza-dGTP and
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biotin-dUTP can be used (Huang et a l ,  1990). These bases are commonly used to 
introduce deliberate errors or labelled moieties into PCR products which may then serve as 
probes during hybridisations.
Primer concentration
The optimal concentration of primers in a PCR assay depends upon a number of factors 
such as primer sequence, target sequence, sequence complexity of the sample DNA and 
amount of target DNA initially present in the sample. Primer concentrations of 0.1-1.0 p. 
M are usually used for amplification. In a conventional PCR, both the primers are used at 
equimolar concentrations. Excessive levels of primers result in loss of specificity and 
increase the chances of primer-dimer formation.
Enzyme concentration
Taq DNA polymerase is generally used in the range of 1-2.5 units per 100 pi reaction 
under other optimised conditions. Too high concentration of the enzyme in the reaction 
mixtures results in formation of non-specific PCR products and a low amount of enzyme 
may lead to reduced yield of the desired DNA fragment (Saiki et al. , 1988). The amount 
of enzyme required in a PCR assay depends on the nature of target DNA and the primers.
3.1.3.2 Thermal Cycling
The cycling parameters are critical in the reaction and need optimisation while developing 
a PCR assay. The denaturation, annealing and extension temperatures and duration of each 
step during thermal cycling require optimisation.
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Denaturation time and temperature
Most of the amplification failures result from incomplete denaturation of the target DNA. 
The incompletely denatured strands snap back, resulting in reduced yield of the PCR 
product. The double stranded DNA can be denatured by heating the sample briefly 
at 90°-95°C. The target sequences with high G+C content and secondary structures may 
require high denaturation temperature and time, particularly during initial denaturation of 
the DNA strands in the sample. Denaturation at too high temperature and for prolonged 
period leads to unnecessary loss of enzymic activity. The Taq DNA polymerase is 
inactivated gradually with a half life of 130 min, 40 min and 5-6 min at 92.5°C, 95°C and 
97.5°C respectively (Gelfand and White, 1990). The lowering of denaturation time after 
the initial few cycles results in a better yield of the reaction products, particularly in cases 
where the target sequence being amplified is short (Yap and McGee, 1991).
Primer annealing temperature and time
The annealing temperature and time are the most critical parameters in determining the 
specificity and yield of the reaction product, and depend upon factors such as base 
composition, length and concentration of the primers. Prolonged incubation at the 
annealing temperature leads to formation of non-specfic products. The annealing of 
primers takes place instantaneously in the presence of large molar excess of each primer in 
the reaction mixture. Annealing temperatures too high or too low than the melting 
termperature (Tm) of the primers result in the formation of undetectable or reduced yield 
of the desired product as well as reduced specificity.
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Primer extension temperature and time
Extension of the annealed primers is generally carried out at 72°C. This temperature is 
very close to the maximum activity of Taq DNA polymerase. The extension time 
at 72°C depends upon the length of DNA fragment to be amplified. In general, 1 minute 
time is considered sufficient when a target sequence of 1 kb is being amplified. Prolonged 
extension results in the production of non-specific reaction products (Saiki et al. , 1988). If 
short sequences 150 bases or less are to be amplified, the primer extension step can be 
avoided. In some situations, annealing of primers may take place at 72°C and the 
amplification process may be limited to a two step cycle.
3.2 MATERIALS AND METHODS
3.2.1 Aliquoting of EHV-1 and EHV-4
The stocks of EHV-1 and EHV-4 were prepared and their titres determined as described in 
Chapter 2. Different dilutions of each virus were prepared in DMEM. Several 10 and 20 
pi aliquots with a definite number of plaque-forming units were dispensed using positive 
displacement pipettes starting from the highest dilution of each virus. The virus was 
dispensed into sterile 1.5 ml eppendorf tubes. The aliquots were stored at -70°C till their 
use in PCR assays. The aliquoting of the two viruses was done on separate occasions in 
order to avoid cross contamination.
3.2.2 Preparation of plasmid DNAs
Recombinant plasmid DNAs, pUC 9: EHV-4 BamYU G, pUC  9: EHV-4 BamYU C, pBR  
322: EHV-1 BamYU H and pBR  322: EHV-1 BamYU B were prepared as described in 
Chapter 2. The BamYU library of EHV-1 strain HVS-25 in pBR  322 was kindly provided 
by Dr J.M. Whalley of the Macquarie University, Australia and the EHV-4 strain 1942 
BamYU. library in pUC 9 by Dr Ann Cullinane, Institute of Virology, University of 
Glasgow. One microgram of each recombinant plasmid DNA was digested with 
restriction enzymes BamYU and EcoRI in appropriate buffer containing spermidine and 
eletrophoresed in 0.8% agarose gel at 70V for 1 h in order to ascertain that the fragment 
sizes were correct. The recombinant DNAs were used as controls in PCR assays. 
Different dilutions of each plasmid DNA were prepared and dispensed as 10 pi aliquots 
for use in titration experiments, overlaid with 75 pi of mineral oil using pastettes and 
stored at -70°C until used.
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3.2.3 PCR primers and probes
3.2.3.1 Primers used in PCR assays
Primers were derived from the conserved regions of gene homologues of HSV-1 genes 
encoding TK, gH and gC such that the same primer pair could amplify both EHV-1 and 
EHV-4 specific sequences. The products amplified from EHV-1 and EHV-4 targets could 
be distinguished by their hybridisation to type-specific oligonucleotide probes derived 
from less conserved or divergent regions within the amplified segments.
Inner gH  Primers
The leftward and rightward primers were derived from nucleotide sequences 190-207 and 
343-362 of EHV-4 strain 1942 gene gH (the sequence data and the numbering is according 
to Nicolson et al., 1990a). The leftward primer was derived from the C-terminal coding 
region of TK gene (upper strand) and the rightward primer the gH gene (lower strand) 
The nucleotide sequences of the primers are: 5’-ACA ACC GTA TCT AAA AAT-3' for 
the leftward primer and 5'-TTA TCC TGT CAT ACC TGG TT-3' for the rightward 
primer. The corresponding sequences on EHV-1 gH are located between nucleotides 
2384-2401 for leftward primer and 2516-2535 for rightward primer (sequence data and 
numbering is according to Robertson and Whalley, 1988). There is a single base mismatch 
in each primer sequence between EHV-1 and EHV-4 gH. The position of the gH primers 
on EHV-1 and EHV-4 gH genes is presented in Figure 3.1.
Nested set o f primers
The external/outer pair of primers in the nested set was derived from TK and gH genes of 
EHV-4 (Fig. 3.2). The leftward and rightward primers were derived from nucleotide 
sequences 1987-2004 and 662-678 (sequence data and numbering is according to Nicolson 
et a l,  1990a,b). The nucleotide sequences of the primers are 5'-AAC GCG GAG ATG 
GGC GTC-3' (leftward) and 5’-GAC CGC TCA AAC GTC TA-3’ respectively. The 
corresponding sequences on EHV-1 are located at positions 2135-2152 and 2835-2851
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(sequence data and numbering is according to Robertson and Whalley, 1988). Whereas 
rightward primer sequence is fully conserved between EHV-1 and EHV-4, there is one 
mismatch in the primer sequence of the leftward primer. Although one of the outer 
primers of the nested set is derived from the TK gene, this set of primers will be referred 
to as outer gH primers throughout. The inner pair of the nested primers consisted of gH 
primers as described above. The nested set of primers and probes on the EHV-1 and EHV- 
4 TK and gH genes are schematically presented in Figure 3.2.
gC  Primers
The leftward gC primer derived from EHV-4 gC corresponds to nucleotide sequence 790- 
809 and has the sequence 5'-AAC CAG CGC ACC CCA TTT TC-3', whereas the 
rightward primer derived from nucleotide sequence 1083-1103 has the sequence 5'-ACG 
GTA ACG CTG GTA CTG TTA-3' (sequence data and numbering is according to 
Nicolson and Onions, 1990). Both the primer sequences were fully conserved in the gC 
sequences of EHV-4 and EHV-1. These sequences correspond to nucleotide sequences 
453-473 and 744-764 in EHV-1 gC (sequence data and numbering is according to Allen 
and Coogle, 1988). The positions of the primers on genes encoding EHV-1 and EHV-4 
gC are shown in Figure 3.3.
Primer design and their synthesis
The primers were examined for complementarity with a computer programme. They were 
synthesized at 0.2 pmol by Alta Bioscience, University of Birmingham.
3.2.3.2 Probes
The probes used to detect EHV-1 or EHV-4 specific sequences in the PCR amplified- 
products were internal to the primers. Their positions on the corresponding genes of 
EHV-1 and EHV-4 are shown in Figures 3.1, 3.2 and 3.3. The probes were synthesized in
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the Department of Veterinary Pathology, University of Glasgow at 0.2 pmol level using an 
automated DNA synthesizer, Applied Bio-Systems.
3.2.4 Development of PCR assay for detection of EHV-1 and EHV-4 specific DNAs
The methods of Mullis and Faloona (1987) and Saiki et a l (1988) were followed with 
suitable modifications. Specific regions of EHV-1 and EHV-4 gene homologues of HSV- 
1 gene encoding thymidine kinase (TK) and glycoproteins gH and gC were attempted for 
amplification. EHV-1 and EHV-4 targets and the recombinant plasmid DNAs were used 
as targets for amplification.
In PCR assays conducted for initial amplification and for optimisation of reaction 
conditions lOpil containing a specific number of p.f.u. of EHV-1 or EHV-4 or plasmid 
DNA served as targets. The virus samples were overlaid with 75 pi of mineral oil using 
pastettes, steamed for 10 min. in order to disrupt cell membranes, denature virion proteins 
and separate DNA strands. In case of plasmid DNA, this objective was accomplished by 
heating target at 94°C for 5 min. on the thermal heating block after addition of reaction 
components.
The standard reaction mix consisted of 200pM dNTPs, 50pmol of appropriate primer 
pairs, 1 x reaction buffer, 1.5mM MgCl2 and 2.5 units Amplitaq in a 50pl reaction 
volume. Where a different MgCl2 or primer concentration, or enzyme was used this is 
specified in the text.
After initial denaturation of the viral target the reaction mixture was added and the bottom 
of the eppendorf tube smeared with silicone grease to ensure good contact in the block. 
Eppendorfs were placed in a Hybaid Intelligent Heating Block and thermal cycling 
performed as described in the Results section.
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3.2.5 Optimisation of reaction conditions for PCR
The conditions for PCR assays that were optimised included: titration of MgCl2 in the 
reaction buffer, titration of primer concentration and optimisation of annealing 
temperatures using inner gH, outer gH and nested sets of gH primers for amplifying EHV- 
1 or EHV-4 targets. Procedures are described in the Results section.
3.2.6 Analysis of PCR reaction products
Reaction products were electrophoresed, blotted and probed as described in Chapter 2. 
Specific washing conditions for the probes used in this chapter are outlined below.
Washing of membranes
The membranes were washed thrice with 6 x SCC at room temperature followed by three 
quick washes with 6 x SSC, 0.1% SDS. Three 30 min. washes were performed at 50°C and 
45°C for EHV-4 and EHV-1 specific gC probes and at 55°C and 42°C for EHV-1 and 
EHV-4 specific gH probes. The final washing was carried out at melting temperature of 
the respective probes in 2 x SSC, 0.1% SDS for two min. The membranes were finally 
rinsed with 2 x SSC, dried to dampness, sealed and autoradiographed.
3.2.7. Contamination-avoidance procedures
As a consequence of the sensitivity of the PCR technique, the contamination of the 
samples or reaction mixes with previously amplified DNA or carry over products can 
result in false positives. We adopted strict protocols to avoid contamination. Synthesis 
and purification of the oligonucleotide primers and preparation of DNA-free reaction 
mixes (master mixes) were performed outside the University. Within the department 
separate laboratories were designated for the following activities - (1) storage of reagents 
and other material for PCR, (2) aliquoting of reaction mixes, (3) preparation of samples 
and addition of reaction mixes to the steamed samples, (4) preparation of second round 
amplification reactions in case of nested set of primers and (5) addition of positive control
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virus and DNA to reaction mixes and analysis of PCR amplified products. Dedicated 
positive displacement pipettes were used for different activities wherever possible and 
gloves changed between samples. In each PCR experiment, appropriate negative controls 
and a DNA-free control or reagent control were always included. Plasmid DNA 
containing the target sequence was substantially diluted whenever it was used as positive 
control in PCR assays.
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3.3 RESULTS
3.3.1 Restriction endonuclease analysis of recombinant plasmid DNAs
The results of the restriction analysis of the recombinant plasmid DNAs, pBR322:EYYV-l 
BamYil B,/7#/?322:EHV-l BamYil H; pUC9:EYlV-4 BamYil C and /?f/C9:EHV-4 BamYil 
G are presented in Figure 3.4. Bands of expected sizes were observed which were 
consistent with those already published (Cullinane et al., 1988; Whalley et al., 1981).
3.3.2 Amplification of EHV-1 and EHV-4 targets using inner gH primers and 
establishment of the specificity of PCR products with type-specific 
oligonucleotide probes
EHV-1 (102 pfu) and EHV-4 (10 pfu) served as targets using inner gH primers and 
standard reaction components (3.2.4). Thermal cycling was carried out under conditions: 
denaturation at 94°C for 10 sec, annealing of primers at 50°C for 10 sec and extension of 
the annealed primers at 72°C for 30 sec. Thirty five cycles were performed using a 
Hybaid Intelligent heating block.
EHV-1- and EHV-4-specific gH sequences were successfully amplified from EHV-1- and 
EHV-4 targets. A band of the expected size of 173 bp was observed in DNA amplified 
from the EHV-4 target and a band of the expected size of 152 bp was observed in the 
reaction products of the EHV-1 target on ethidium bromide-stained polyacrylamide gels 
(Fig. 3.5a). A band of higher molecular weight, to which probe hybridised was also 
observed in the latter (Fig. 3.5c). A probe derived from the EHV-4 sequence hybridised 
only to EHV-4 amplified DNA (Fig. 3.5b), whereas a probe derived from the EHV-1 
sequence hybridised only to EHV-1 amplified DNA (Fig. 3.5c).
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3.3.3 Optimisation of MgCl2 concentration in the PCR assay
PCR buffer II (Perkin-Elmer Cetus) containing 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5 and 4.0 
mM of MgCl2 (PCR-core reagents) was used to determine the optimum concentration of 
MgCl2 using 50pmol inner and outer gH primer pairs, 200 pM of each dNTP, 2.5 units of 
Amplitaq and 10 pil of EHV-1 or EHV-4 as target for amplification. Reaction conditions 
were selected arbitrarily as denaturation at 94°C for 10 sec, annealing of primers at 45°C 
for 10 sec and extension of the annealed primers at 72°C for 30 sec for inner gH and 45 
sec for outer gH primers. Thirty five cycles of amplification were performed. Using EHV- 
4 as a target for amplification with inner gH primers, amplification was observed on 
ethidium bromide stained gels in reactions which contained 1 mM to 4.0 mM MgCl2 in the 
reaction mixtures. A band of the expected size was not seen in reactions in which MgCl2 
was not added or had 0.5 mM MgCl2 (Figure 3.6). A concentration of 1.5 mM MgCl2 was 
considered optimal.
For optimisation of MgCl2 using gC primers, the PCR reaction mix contained the 
appropriate target, 3.0 units of TspII enzyme, 200 pM of each dNTP (Pharmacia) and 50 
pmol of each primer in the appropriate reaction buffer containing 0.5, 1.0, 1.5, 2.0, 2.5, 
3.0 and 3.5 mM final concentration of MgCl2 reaction mix. After initial denaturation of 
the target at 94°C for 10 min., thermal cycling was carried out using conditions: 
denaturation at 94°C for 10 sec, annealing of primers at 50°C for 10 sec and extension of 
the annealed primers at 72°C for 1 min. The optimum concentrations of MgCl2 in PCR 
assays that utilised gC primers or outer gH of the nested set of primers were determined to 
be 1.5 mM and 2.5 mM MgC^, respectively.
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3.3.4 Determination of the optimum concentration of inner gH primers for 
amplification using plasmid DNA as target
Plasmid targets (10-6  to 10-9 pg) were tested using varying amounts of inner gH primers, 
200, 100, 50, 25 and 12.5 pmol in a standard reaction mix (3.2.4). Thermal cycling was 
carried as detailed in 3.3.2.
Amplification was observed in reactions containing 10-6, 10-7  and 10~8 pg of plasmid 
DNA (pBR322:EHV-l BarriRl B) using 200,100, 50 and 25 pmol of each primer (Figure 
3.7a). However, a band of the expected size was not observed using all specified 
concentrations of primers from 10-9  pg of the target plasmid. On probing with an EHV-1- 
specific probe, positive signals were observed with reaction products resulting from 
amplification from all concentrations of plasmid DNA, although a very weak signal was 
seen with products amplified from 10-9  pg of the target using 100 pmol of each primer in 
the reaction (Figure 3.7b). Positive signals were also seen when 12.5 pmol of each primer 
was used in the reaction from all concentrations of plasmid DNA, except for 10-9  pg of 
the target (Figure 3.7c). However, a faint signal was produced from the latter on 
prolonged exposure.
3.3.5 Titration of EHV-1 plasmid target using inner gH primers and annealing 
temperatures of 40°C, 45°C and 50°C
EHV-1 (10“4 to 10_1° pg) and EHV-4 (10“5 to 10-12 pg) plasmid target DNAs were 
titrated using inner gH primers. Temperatures of 50°C, 45°C and 40°C were used for 
annealing in order to determine the optimal annealing temperature. The 10-12 pg of EHV- 
4 target was not analysed using an annealing temperature of 40°C.
At annealing temperatures of 40°C, 45°C and 50°C, using inner gH primers, amplification 
was achieved from 10-4  to 10-8 pg of recombinant plasmid target (pBR322:EHV-l
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BamYil B) in all cases (Figure 3.8 a, b and c). However, a faint signal was also observed 
using 10-9  pg of the target on longer exposure at 40°C and 45°C (Figure 3.8 d).
3.3.6 Titration of EHV-4 plasmid target using inner gH prim ers and annealing 
tem peratures of 40°C, 45°C and 50°C 
Using 10-5  to 10-11 pg of recombinant plasmid (pUC9:EHV-4 BamYil C) as targets for 
amplification with inner gH primers employing annealing temperatures of 40°C, 45°C and 
50°C, positive signals were observed with 10-5  to 10-9  pg of the target (Figure 3.9 a, b 
and c). Amplification was not achieved from 10-10 to 10“ 12 pg of the target (Figure 3.9 a 
and c) and 10-10 to 10-11 pg (Figure 3.9 b). In the latter case, 10-12 pg of target was not 
included in the assay.
3.3.7. Titration of EHV-1 using inner gH primers
EHV-1 (1()3 pfu to 10-4  pfu) was titrated using inner gH primers. The reaction conditions 
were essentially similar to those used in 3.3.2. EHV-1 DNA could be amplified from as 
few as 0.1 pfu of the target (Figure 3.10).
3.3.8 Titration of EHV-1 plasmid target using outer gH prim ers of the nested set
Amplification was achieved with greater than or equal to 10-8  pg of target using the outer 
set of gH primers (Fig. 3.11) using cycling conditions as described in 3.3.3.
3.3.9 Titration of EHV-1 plasmid target using the nested set of gH primers
Amplification using the nested set of gH primers was observed in greater than or equal to 
10~10 pg of the target plasmid (pBR322:EHV-l BamYil B) (Fig. 3.12).
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3.3.10 Comparative analysis of sensitivity of inner gH and the nested set of primers
Amplification using outer gH  primers
EHV-1 plasmid target (10-6  pfu to 10-14 pg) was titrated using outer gH primers. The 
reaction mixture contained components as described in other plasmid titration experiments. 
The thermal cycling conditions were also similar, except that the extension was allowed at 
50°C for 45 sec.
Amplification using inner and nested set o f primers
Using inner gH primers, amplification was achieved from as few as 10" 2 pfu of EHV-4 
target (Fig. 3.13 a). Twenty cycles of thermal cycling were allowed during the first round 
of the amplification using outer gH primers. The PCR products were diluted 1:10 in 
sterile water and 10 pi of the diluted products were used for amplification in the second 
round using inner gH primers. Twenty five cycles were performed in the latter round. 
With the nested set of primers, amplification could be achieved from as few as 10-3  pfu of 
the EHV-4 target (Fig. 3.13 b).
3.3.11 Amplification of EHV-1 and EHV-4 targets using gC primers and specificity 
of the EHV-1 and EHV-4 probes
Using gC primers, amplification from recombinant plasmid DNA ^?^R322:EHV-1 BamYil 
H; pUC9:EHV-4 BamYU G) and EHV-1 and EHV-4 virus targets was attempted using 
standard buffer (3.2.4) and 3 units of Tspn enzyme in a 50 pi reaction. Cycling 
conditions were essentially the same as utilized in PCR assays using inner gH primer pair 
(Section 3.3.2.).
This experiment confirmed that the primers were functional in amplification of gC-specific 
sequences and that the probes were specific to EHV-1 or EHV-4 (data not shown: see Fig. 
4.4a,b)
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3.3.12 Titration of EHV-1 and EHV-4 using gC primers for amplification
Using gC primers, amplification of EHV-1 and EHV-4 virus target using identical 
reaction mix and cycling conditions to those described in 3.3.11 was attempted. DNA 
could be amplified from greater than or equal to 0.1 pfu of the EHV-1 target (Fig. 3.14) 
and 10~4 pfu of the EHV-4 target (Fig. 3.15).
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Figure 3.1
Position of primers and probes derived from the gH gene
Primer 1 —»
EH V-4 ATGTCACAACCGTATCTAAAAATAGCTATCTTAGTGGC
E H V -1 ATGTTACAACCGTATCGAAAAATGCTGATCTTTGCAGT
s t a r t  o f  gH
EH V-4 CGCTACTATTGTGTCTGCGATTCCCGTTTGGACAACAC
E H V -1 TGTTACTGTTGCCTTTGCGATGGCTGTCTGGTCAACGC
Probe
EHV- 4 CGGTTTCAACTTCACCACCCCAACAAACAAAATTGCAC
EHV-1 CCGTCCCA GCCACTCCGTC___________ T GGC
EH V-4 TATGTGGGAAATGGTACCTGGGTACACAACAATACATT
EHV-1 £TGGGTAACGCTACTTGGG CA ACCAATAGCTT
<r- Primer 2
EH V-4 CAACGTAACCAGGTATGACAGGATAACCATGGAA
E H V -1 CAACATAACCAGGTATGACAAGATAACCATGGGA
Fig. 3.1 Diagram showing the position of the primers and probes derived 
from gH gene. Both the primers were derived from EHV-4 gH gene and were used 
to amplify both EHV-1 and EHV-4 gH sequences. The sequence of primer 2 is 
complementary to that indicated above. The amplifed products were distinguished 
by type-specific probes. Sequence data from Nicolson et a l , (1990a) and Robertson 
and Whalley (1988).
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Figure 3.3
Nucleotide sequence of primers and probes derived 
from gC genes of EHV-1 and EHV-4.
EHV-4
EH V-1
EHV-4
EH V-1
EH V-4
EH V-1
EHV-4
EH V-1
EHV-4
EHV-1
EHV-4
EH V-1
EHV-4
EH V-1
Primer 1 -»
GAAATTC AC CTAAAC CAGCGC AC C C C ATTTTC AGAC ACGCCTC C TGGTG A 
GAGATTTACTTGAACCAGCGCACCCCATTTTCGGGTACGCCCCCCGGCGA 
C C AAGAAAAC TATGTTAAC C AC AAC GC T AC C AAAG AC C AAAC CCTGCTGT 
C GAAGAAAAC T AC ATC AAC C AT AAC GC C AC C AAGGATC AG AC T C TGC TAT 
EHV-4 Probe
TATTTTCAACCGCACATTCTAGCGCGAAATCTCGAAGGGTTGGCCAGCTG
AAATC TC GAAGGGGTGGC CAGC C CTATTCTCAACGGCAGAGAGGAAA 
EHV-1 Probe
GGCGTTATTCCAGACAGGCTACCTAAGCGTCAACTGTTCAACCTCCCGGC
I I  M i l l  l l l l l l l l l l l l l l  M i l l  I I  M i l l  M i l l  I I
GGAGTTATCCCAGACAGGCTACCAAAGCGCCAGCTGTTTAACCTTCCCCT 
C C AC AC GAACGGTGGTACAAATTTTC CAC TAAAC ATAAAATC TATAGAC T
I I I I I I I  I I I I I I I I I I  I I I I I I I I I I I I I I  I I I I I I 1 1 1 1  I
C C AC ACGGAAGGTGGTACAAAGTTTC CACTGAC CATC AAATC TGTAGATT 
GGCGTAC C GC GGGAGTTTATGTGTGGTAC TTGTTTGC C AAAAACGGC TC A 
GGC GGAC AGC CGGC ATTTACGTGTGGTC C TTGTATGC C AAAAATGGC AC G 
Primer 2
C TC ATTAAC AGTAC C AGCGTTAC CGTGTTAAC GTAC AAC 
C TC GTTAACAGTAC CAGC GTTAC C GT C TCAAC C TACAAC
Fig. 3.3 The locations of gC primers and probes on gC genes of EHV-1 and 
EHV-4 are shown. Both the primers were derived from EHV-4 gC gene sequence 
which could amplify both EHV-1 and EHV-4 gC gene segments. The amplified 
products were distinguished by type specific probes. Sequence data taken from 
Nicolson and Onions (1990) (EHV-4 gC) and Allen and Coogle (1988) (EHV-1 gC).
Fig. 3.5 (a) PAGE analysis of PCR products of amplification from EHV-1 and 
EHV-4 virus control targets. A band of expected size, 173bp, is evident in lanes 
containing DNA amplified from EHV-4 target (lanes 4,5,11,12). A band of 152bp 
was amplified from EHV-1 target (lanes 1,2,8,9) as well as a band of higher 
molecular weight. (]>X174 HaeTR DNA marker was loaded in lane 6 .
Fig. 3.5 (b) The left side of the gel, lanes 1 to 6, was blotted and probed with an 
oligonucleotide probe derived from EHV-4 gH sequence. A positive signal was 
evident in lanes 1 and 2 only : the probe is specific for DNA amplified from EHV-4.
Fig. 3.5 (c) The right side of gel, lanes 7 to 12, was blotted and probed with an 
oligonucleotide probe derived from EHV-1 gH sequence. A positive signal was 
evident in lanes 11 and 12 only : the probe is specific for DNA amplified from 
EHV-1.
Figure 3.5
Amplification of EHV-1 and EHV-4 targets using inner gH prim ers : specificity
of probes
(a) 1 2 3 4 5 6 7 8 9 10 11 12
173bp- -152bp
(b) 1 2 3 4 5 6 (c) 7 8 9 10 11 12
r
Figure 3.6
Optimisation of MgCH concentration in PCR assay using inner gH primers
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Fig. 3.6 PAGE analysis of PCR products from EHV-4 virus target using inner 
gH primer pair. MgCl2 was added to reaction mixes at a final concentration of OmM 
(lane 1) , 0.5mM (lane 3), l.OmM (lane 5), 1.5mM (lane 7), 2.0mM (lane 7), 2.0mM 
(lane 9), 2.5mM (lane 11), 3.OmM (lane 13), 3.5mM (lane 15) and 4.0mM (lane 17). 
Primer control with 1.5mM MgCl2 is in lane 19 and (j)X174 Haelll marker in lane 
20 .
Fig. 3.7 (a) PAGE analysis of reaction products from amplification using plasmid 
pBR322:EHV-l BamYil B as target. Amplification from 10'6,10'7,10'8 and 10‘9 ug 
plasmid was performed using 200pmol (lanes 1-4), lOOpmol (lanes 6-9), 50pmol 
(lanesll-14) and 25pmol (lanes 16-19) primer pair. Primer control is in lane 10 and 
<j)X174 HaeIII marker in lane 20.
Fig. 3.7 (b) Blot 3.7 (a) was probed with an EHV-1-specific gH probe. Positive 
signals were evident in all cases although the combination of 10'9ug plasmid and 
lOOpmol primer produced a very weak signal.
Fig. 3.7 (c) Reaction products of 10~6,10~7,10‘8, 10'9ug plasmid (lanes 1-4) 
amplified in the presence of 12.5pmol primer were probed with the EHV-1-specific 
gH primer. Signal was extremely weak in the case of the 10'9ug plasmid sample but 
was evident on longer exposure (not shown).
Titration of inner gH primers using plasmid DNA as target
(a) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
-152bp
(b) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
I
Figure 3.8
Titration of EHV-1 plasmid target using inner gH primers and annealing 
temperatures of 40°C, 45°C and 50°C.
1 2 3 4 5 6 7 8 9  (b) 1 2  3 4 5 6 7  8
1 2 3 4 5 6 7 8 9  (d) 3 4 5 6 7
Fig. 3.8 Autoradiographs of blots probed with EHV-1-specific gH probe. A 
range of amounts of pBR322:EHV-l BamWl B, 10'4, 10‘5, 10‘6, 10'7> 10-8’ 10'9 and 
10*10ug (lanes 1-7), served as target for amplification with inner gH primers at 
annealing temperatures of 40°C (a), 45°C (b) and 50°C (c). Positive signal was 
obtained for 10*4 to 10’8ug target at all annealing temperatures. Additionally a faint 
signal was observed in 10*9ug target amplified at annealing temperatures of 40°C 
and at 45°C on longer exposure (d). Primer controls in lanes 9 (a and c) and 8 (b) 
were negative.
Figure 3.9
Titration of EHV-4 plasmid target using inner gH primers and annealing 
temperatures of 40°C, 45°C and 50°C.
(a)
(c) 1 2 3 4 5 6 7 8 9 10
m
Fig. 3.9 Autoradiographs of blots probed with EHV-4-specific gH probe. A 
range of amounts of pUC9:EHV-4 BamUl C , 10-5,10-6,10-7,10-8,10-9, lO’10, 10'11 
and 10~12ug (a and c only) (lanes 1-8 (a) and (c): lanes 1-7 (b)), served as target for 
amplification with inner gH primers at annealing temperatures of 40°C, 45°C and 
50°C. Positive signal was obtained foL 10*5 to 10'9 ug target. Primer controls were 
in lane 9 (a and b) or 10 (c).
Figure 3.10
Titration of EHV-1 using inner gH primers
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Iff:
Fig. 3.10 PCR products from a range of target EHV-1 amounts, 103 pfu to 10~4 
pfu, were probed with EHV-1-specific gH oligonucleotide. Positive signal was seen 
in 103 (lane 1), 102 (lane 3), 10 (lane 5), 1 (lane 7) and 0.1 (lane 9) pfu targets. 
Lower amounts of EHV-1 target, 10'2, 10-3 and 10'4 (lanes 11, 13 and 15), were 
negative as was primer control in lane 16..
Figure 3.11
Titration of EHV-1 piasmid target using outer gH primers
5 6 7 8 9 10 11 12 13 14 15 16 17
Fig. 3.11 A range of pBR322:EHV-l BamY{\ B amounts, 10'6 to 10‘14 ug, 
served as target for amplification using the outer set of gH primers. Reaction 
products were probed with EHV-1-specific gH oligonucleotide. Positive signal was 
seen for 10*6 (lane 1), 10'7 (lane 3) and 10‘8 ug target (lane 5). 10'9 to 10’14 ug 
target (lanes 7 , 9 ,  11, 13, 15 and 17) proved negative.
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Fig. 3.13 EHV-4 served as a target for amplification using inner gH (a) and 
nested gH (b) primer sets. Reaction products were probed with EHV-4-specific 
gH probe. Positive signal was observed from targets greater than or equal to 10"^ 
pfu using inner gH primers (10 pfu to 10'- pfu in lanes 1 to 4 (a)). Signal was not 
observed in targets of 10"^ to 10"~ pfu (lanes 5-9) and negative DNA control 
(BamHI N of EHV-4 : lane 11). Using the nested set of primers amplification of 
gH sequence was observed from targets of 10 pfu to 10'^ pfu (lanes 1 to 5 (b)). 
Samples from 10~  ^ to 10'^ (lanes 6-11), negative DNA control (lane 13) and 
primer control (lane 14) were negative.
Figure 3.13
Com parative analysis of sensitivity of inner gH and nested set of primers using
EHV-4 as target
a) 1 2 3 4 5 6 7 8 9 10 11
b) 1 2 3 4 5 6 7 8 9 10 11 12 13 14
« • -  *
Figure 3.14
Titration of EHV-1 using gC primers
10 11 12 13
4 4 #  #
Fig. 3.14 Probing of reaction products from serial ten fold dilutions of EHV-1 
amplified in a PCR assay using gC primers with EHV-1-specific gC probe. Positive 
signal was observed in 104, 102, 102, 10 and 0.1 pfu of EHV-1 in lanes 1, 3, 5, 7, 9 
and 11. No amplification occurred from negative control DNA (pUC9: EHV-4 
BamWl N in lane 13).
Figure 3.15
Titration of EHV-4 using gC primers
1 2 3 4 5 6 7 8 9 10 11 12 13
m
Fig. 3.15 Probing of reaction products from serial ten fold dilutions of EHV-1 
(102 to 10*8 pfu) amplified using gC primers with EHV-4-specific gC probe. Signal 
was observed from 102 pfu to 10*4 pfu (lanes 1-7). Products from 10'5 pfu and lower 
(lanes 8-11) , negative DNA control (pUC9:EHV-4 BamHl N in lane 12) and primer 
control (lane 13) were negative.
3.4 DISCUSSION
The primers derived from the conserved regions of the HSV homologues of genes 
encoding gC, gH and TK of EHV-1 and EHV-4 used in the present study successfully 
amplified specific segments of these genes in the EHV-1 and EHV-4 targets. These 
segments were bounded by the primers. The primer pairs derived from gC, gH and TK 
sequences of EHV-4 strain 1942 were used to amplify both EHV-1 and EHV-4 targets. 
The specificity of the amplified products was established by their hybridisation to either y 
22P-labelled EHV-1- or EHV-4-specific probes. The probes were derived from the more 
divergent regions within the target sequences and could clearly distinguish between EHV- 
1- and EHV-4-specific sequences. Besides specific bands of the expected size, additional 
bands of higher molecular weights were also demonstrable when PCR products from 
EHV-1 and EHV-4 targets amplified using gH primers in the assay were analysed. Such 
bands might correspond to single-stranded DNA, early cycle PCR products or secondary 
structures in the amplified sequence. Whatever the case, the sequences were specific, as 
they were recognised by the respective probe. Using gC primers, single bands of the 
expected sizes were observed in ethidium bromide-stained polyacrylamide gels from the 
electrophoresed EHV-1 and EHV-4 reaction products.
Amplification using gH primers was achieved from EHV-4 virus targets in reactions that 
contained 1.0 mM to 4.0 mM of MgC^. A concentration of 1.5 mM of MgCl2 was 
considered optimal. In general, lower MgCl2 salt concentrations enhance specific 
amplification. The reactions that contained no MgCl2 or had 0.5 mM MgCl2, did not yield 
visible bands.
In the primer titration experiment, the amplification could be achieved from equal to or 
greater than 10' 9 pg of the recombinant plasmid target, pBR 322: EHV-1 Bam HI B in 
PCR assays that utilised different concentrations of inner gH primers (12.5 p. moles, 25,
50, 100 and 200 p. moles). A concentration of 50 p. moles of inner gH, outer gH in the 
nested PCR and gC primers was used in all PCR assays in subsequent studies. The outer 
set primers in the nested PCR could be used at lower concentration so as to minimise or 
prevent amplification in the second round by the residual primers. Alternatively, the 
reaction products from the first round can be diluted before proceeding to next round in 
which they serve as targets for further amplification using inner set of primers.
EHV-1 and EHV-4 targets from infected cell culture supernatants were subjected to 
boiling for 10 min. in order to disrupt the virion proteins and to denature the virion DNA. 
Similarly, the initial denaturation of the plasmids containing EHV-1 or EHV-4 targets was 
carried out at 94° C for 5 min. These treatments were adequate for initial denaturation of 
the duplex DNA containing the target sequence. Using inner gH primers, amplification 
from as low as 10‘9 pg of the recombinant plasmid target ipUC 9: EHV-4 Bam HI C) was 
achieved employing annealing temperatures of 40°C, 45°C, 50°C and annealing time of 10 
sec. Sensitivity one order of magnitude higher was observed at lower annealing 
temperatures (40°C, 45°C) when recombinant plasmid ipBR 322: EHV-1 Bam HE B) 
served as target. At these temperatures, amplification was achieved from equal to or 
greater than 10*9 pg of the plasmid target. The specificity and sensitivity of a PCR assay 
largely depends upon the annealing temperature of the primer used and the annealing time 
allowed during thermal cycling (Section 3.1.3.1). The primer extension times of 30 sec. 
for inner gH and gC primers and 45 sec. for outer gH primers in the PCR assays were 
adequate and the final extension step was carried out at 72° C for 5 min. in all cases.
PCR assays in which inner gH primers and nested set of gH primer pairs were used to 
achieve amplification were quite sensitive. DNA from as few as 0.1 pfu of EHV-1 and 
10' 2 pfu of EHV-4 target could be successfully amplified. The amplification observed 
from such low number of plaque forming units of the virus may be due to the presence of 
non-infectious virus particles or the viral DNA in the infected tissue culture supernatants
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since plaque purified viruses were not used in the virus titration experiments. 
Amplification from equal to or greater than 10*9 pg of recombinant plasmids containing 
EHV-1 or EHV-4 target was observed using inner gH primers. The nested PCR was one 
order of magnitude more sensitive than the PCR assays in which inner gH primer pair was 
used. The assays in which outer gH primer pair was used was one order of magnitude less 
sensitive than the ones in which inner gH primer were used.
The assays in which gC primers were used were also quite sensitive. Amplification from as 
low as 10"4 pfu of EHV-4 target was achieved which again may be attributable to the non- 
infectious virus or viral DNA. The amplification was observed from 0.1 pfu of EHV-1 
target However, this was not the cut-off point since titration beyond this point was not 
carried out.
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4.1 INTRODUCTION
Equid herpesviruses 1 and 4 (EHV-1 and EHV-4) formerly known as Equine herpesvirus- 
1 subtype 1 and 2 respectively, are alphaherpesviruses responsible for great economic 
losses within the horse breeding industry. As discussed in Chapter 1, EHV-1 is associated 
with abortion, respiratory disease and neurological disease. EHV-4 is primarily a 
causative agent of respiratory disease although occasional EHV-4 induced abortions (Allen 
and Bryans, 1986) and neurological disease have been reported (Meyer et a l, 1987). 
Diagnosis of infections with these agents in live animals is achieved by virus isolation 
from nasopharyngeal secretions and blood or from foetal tissues in the case of abortion. 
Diagnosis by serological methods is less definitive and requires both acute and 
convalescent serum samples. Also, being antigenically quite similar, the two viruses can 
not be differentiated readily by conventional serological methods using polyclonal antisera 
(Thomson et al., 1976). Alternative diagnostic methods such as DNA fingerprinting in 
combination with Southern blot hybridisation (Chowdhury et al. , 1986a) and monoclonal 
antibody typing have been used for efficient screening of a large number of field isolates 
(Yeargan et a l, 1985). EHV-1 and EHV-4 like other members of the family 
herpesviridae, may establish latent relationship with their equine host as reflected by co­
cultivation (Scott et a l, 1983; Allen and Bryans, 1986) and reactivation studies (Edington 
et a l, 1985; Browning et al. , 1988b). The shedding of the virus by silently infected carrier 
animals with appropriate stimuli makes total disease eradication highly unlikely, 
diminishes the effectiveness of disease control by chemotherapy or immunotherapy and 
complicates the design for control of these infections by vaccination. Rapid and more 
sensitive tools are therefore, required for identifying carrier horses in equine population. 
The recently developed technique polymerase chain reaction is a powerful and exquisitely 
sensitive technique that has been widely used to detect various human and animal 
pathogens as discussed in section 3.1.1.
104
Ballagi-Pordany et a l, (1990) applied PCR technique to the detection of EHV-1 specific 
DNA sequences in the infected cell culture and tissue specimens obtained from aborted 
foetuses employing primers derived from EHV-1 homologue of HSV-1 gene encoding 
glycoprotein gC (EHV-1 gpl3). The specificity of the amplified EHV-1 DNA was 
established by hybridisation of the PCR products to an oligonucleotide probe labelled with 
biotin.
Recently, O'Keffe et al., (1991) successfully amplified EHV-1 or EHV-4 DNA sequences 
from unpurified DNA derived from cultures of equine fetal kidney cells infected with 
EHV-1 or EHV-4 using a primer pair derived from a conserved region of gB gene of 
EHV-1 and EHV-4. The amplified EHV-1 or EHV-4 DNA segments were distinguishably 
by restriction length polymorphism analysis following digestion with PvuYL restriction 
enzyme.
The application of PCR technique to the detection of EHV-1 and EHV-4 DNA sequences 
in the nasopharyngeal secretions of clinically affected and asymptomatic in-contact horses 
is described in this chapter.
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CHAPTER 4.0
DIAGNOSIS OF EHV-1 AND EHV-4 INFECTIONS
4.2 MATERIALS AND METHODS
4.2.1 Samples
Ninety-eight nasopharyngeal swab samples were collected from horses with suspected 
EHV-1 or EHV-4 induced respiratory or neurological disease and their cohorts. In­
contacts of a mare which aborted due to EHV-1 infection were also sampled. The nasal 
swab samples were collected in 5 ml transport medium (phosphate buffered saline (PBS) 
supplemented with 2 per cent foetal calf serum and antibiotics, penicillin, streptomycin 
and fungizone), sonicated and stored at -20°C. Sample aliquots in different batches were 
transported from Irish Equine Centre, Eire on ice to the Department of Veterinary 
Pathology, University of Glasgow. The details of the origin of samples of different 
batches are given in Table 4.1. The samples were aliquoted as 20pl aliquots and stored at 
-70°C until required for PCR analysis. Adequate care was taken to avoid cross­
contamination among samples while aiiquoting them. The measures taken to prevent 
contamination and cross contamination are discussed under PCR quality control. The 
virus isolation and serological analysis were performed by the Irish Equine Centre. Eire, 
and PCR analysis was carried out by the author. The PCR assays were conducted blind 
and decoded later.
4.2.2. Virus isolation
Sub-confluent monolayers of rabbit kidney cells (RK-13: Flow Laboratories) and equine 
embryonic lung cells (EEL: Dr J. Mumford, Animal Health Trust, Newmarket) were 
inoculated with nasal secretions and maintained in minimum essential medium (MEM) 
supplemented with non-essential amino acids, 2mM glutamine, 100 i.u./ml of penicillin 
and 100p.g/ml of streptomycin and 2 per cent foetal calf serum. Samples were passaged 
for a minimum of two weeks and cultures examined daily for cytopathic effects. Virus 
type was identified by immunofluorescence with a pool of EHV-1 or EHV-4 specific 
monoclonal antibodies (Yeargan et al., 1985) provided by Dr. J. Mumford.
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4.2.3. Analysis of the samples by PCR
The methods of Mullis and Faloona (1987) and Saiki et al., (1988) were followed with 
suitable modifications. Specific regions of EHV-1 and EHV-4 gene homologues of HSV- 
1 genes encoding thymidine kinase (TK) and glycoproteins gC and gH were amplified 
using primers derived from conserved regions of these genes (Allen and Coogle, 1988; 
Robertson and Whalley, 1988; Nicolson et al., 1990a,b; Nicolson and Onions, 1990) as 
discussed in chapter 3. The amplified products were distinguished by type-specific probes 
derived from the EHV-1 and EHV-4 gpl3 (gC) and gH genes. The respective positions of 
the primers and probes on the corresponding genes and their nucleotide sequences are 
summarised in Table 4.2.
A 20|-d sample aliquot was steamed for 10 minutes to disrupt cell membranes and denature 
virion proteins. PCR reaction mixture 30pl was added such that the reaction contained 50 
pmol of each primer, 200pM of each dNTP, 3 units of TSP-II (Cambio) or 1.75 units of 
Ampli Taq DNA polymerase (Cetus) enzyme and an appropriate reaction buffer 
containing final concentration of MgCl2 as 2.5mM in assays using outer pair of gH 
primers and 1.5mM in assays in which inner set of gH and gC primers were utilised. 
Thermal cycling was carried out in a Hybaid intelligent heating block using the optimum 
conditions (Table 4.3). Samples were analysed blind initially. PCR positive samples and 
samples of interest were investigated further.
4.2.3.1 Polyacrylamide gel electrophoresis and electroblotting
A 12|j.l sample of PCR amplified product in gel loading buffer was loaded onto a 6 per 
cent polyacrylamide gel 1.5mm thick and electrophoresed at a constant current of 35mA 
for about 3h. The DNA was electroblotted onto a nylon membrane, baked at 80°C for 2 
h as described in Chapter 2
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4.2.3.2 Labeling of the oligonucleotide probes
T h e  o l i g o n u c l e o t i d e  p r o b e s  w e r e  e n d - l a b e l l e d  t o  h i g h  s p e c i f i c - a c t i v i t y  w i t h  c r u d e  
[ y 3 2 p ] - A T P  u s i n g  T 4  p o l y n u c l e o t i d e  e n z y m e  a s  d e s c r i b e d  i n  c h a p t e r  2.
4.2.3.3 Hybridisation
Depending upon the size of the membrane, pre-hybridisation buffer (10-20) ml containing 
denatured salmon/heiring sperm DNA at the rate of 250 pg/ml was added on to the baked 
membranes, placed in polythene bags, bubbles removed completely. The bags were 
double-sealed and pre-hybridisation carried out overnight at 37°C. An appropriate amount 
of the labelled probe in fresh pre-hybridisation buffer containing denatured salmon or 
herring sperm DNA was added to prehybridisation buffer through cut comer in the bag. 
All the bubbles were removed carefully, bag double-sealed and hybridisation was allowed 
for 12-16 h at 37°C.
4.2.3.4 Washing
The membranes were washed thrice with 6 x SCC at room temperature followed by three 
quick washes with 6 x SSC, 0.1% SDS. Three 30 minutes washes were performed at 50°C 
and 45°C for EHV-4 and EHV-1 specific gC probes and at 55°C and 42°C for EHV-1 and 
EHV-4 specific gH probes. The final washing was carried out at melting temperature of 
the respective probes in 2 x SSC, 0.1% SDS for two min. The membranes were rinsed 
with 2 x SSC, air-dried to dampness, sealed in plastic bags and autoradiographed.
4.2.2.5 Autoradiography
The membranes were exposed to Amersham MP film at -70C in the presence of 
intensifying screen in light proof cassette, and the film was developed in Kodak X - 
OMAT film processor.
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4.2.2.6 Polymerase chain reaction quality control
Strict anti-contamination procedures were followed as described in 3.2.7. Nasopharyngeal 
swab samples were handled in a laboratory in which EHV DNA, EHV positive control 
virus or amplified PCR product was not handled. A positive displacement pipette was 
dedicated to sample handling and gloves changed between samples. In order to prevent 
cross-contamination between samples during aliquoting, one sample was handled at a time, 
gloves changed and the safety cabinet swabbed with 70% ethanol before handling next 
sample. Splashes were avoided and the pipette tips gently pushed into a beaker containing 
water in order to prevent generation of aerosol in the working area. The aliquoting of 
different batches of samples was done on separate occasions.
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4.3  RESULTS
4.3.1 Electrophoresis and hybridisation of PCR amplified products
Amplification using gH primers yielded bands of 173 bp and 152 bp length for EHV-4 and 
EHV-1 respectively in virus controls and virus positive samples corresponding to ds DNA 
fragments terminating at the primer sites (Fig. 4.1). The gH probes were specific and 
could distinguish between EHV-1 and EHV-4 amplified DNA (Fig. 4.2a, b). Bands of 
greater size were also observed on probing. It is likely that these correspond to minor PCR 
products of early cycles or DNAs of different secondary structures which clearly possess 
the sequence element recognised by specific probe. Bands of 314 bp and 311bp length 
were observed for EHV-4 and EHV-1 amplified DNA using gC primers (Fig. 4.3). The gC 
probes distinguished EHV-1 and EHV-4 specific amplified DNA (Fig 4.4a, b).
4.3.2 Comparison of PCR and virus isolation data
The PCR assays were conducted blind initially, decoded later and results compared with 
virus isolation data. The comparative data is shown in Table 4.4.
Six cases of EHV-4 and a single case of EHV-1 infection were diagnosed by virus 
isolation. All six EHV-4 samples were PCR positive and typed as EHV-4. The EHV-1 
DNA in virus-isolation positive sample (84916) was amplified in PCR assays only once 
and typed as EHV-1 (Table 4.5). The attempts to re-isolate virus from this sample were 
unsuccessful. As is evident from the table 4.4, ten cases of EHV-4 infection and two cases 
of EHV-1 infection were diagnosed by PCR. Of these, one EHV-1 and four EHV-4 
positive samples were negative by virus isolation.
Inconsistent amplification was observed in two cases of EHV-1 DNA (samples 84747 and 
84916) and five of EHV-4 DNA (samples 85325, 85327, 85615, 87313, 87319) using 
different primer pairs. The details are given in Table 4.5.
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4.3.3 Batchwise analysis of samples by PCR and virus isolation 
In batch 1, one sample (81588) was typed as EHV-4 in PCR assay. This sample was 
EHV-4 positive by virus isolation. The amplification of EHV-4 specific DNA using gC 
primers and EHV-4 gC specific probes is shown in fig.4.4 a,b. Batches 2, 3 and 4 did not 
contain any virus isolation-positive sample. All the samples in these batches were found 
negative by PCR also.
The samples taken from six yearlings in batch 5 (samples 85324, 85325, 85326, 85327, 
85328 and 85329) were positive for EHV-4 by PCR analysis. These samples were 
amplified consistently using inner gH (Fig. 4.2a) and gC primers. With nested set of 
primers, the EHV-4 DNA was consistently amplified, except in samples 85325 and 85327 
in which it was amplified on three out of four occasions. The virus was isolated from two 
(85324 and 85328) of the six cases.
All the samples in batch 6 (A) were negative in both PCR and virus isolation assays. EHV- 
1 DNA was amplified in one sample (84747) only on one occasion with nested set of 
primers in batch 6B (Fig. 4.5). Virus was not recovered from this sample in cell culture. 
Sample 84916 in batch 6C, which was taken from same horse as 84747 (horse C l, Table 
4.5), was also positive for EHV-1 DNA inconsistently. The virus was recovered from this 
sample in cell culture but re-isolation was unsuccessful.
Batch 7 consisted of EHV-1- or EHV-4-positive samples (by virus isolation) and in 
addition virus isolation negative sample 84747 (see Table 4.1, Fig. 4.1). Using gC primers, 
inconsistent amplification was observed in some cases (Table 4.5). One such instance is 
represented in Figures. 4.6a and b.
I l l
Table 4.1
Details of the origin of nasal swab samples (batchwise)
Sample 
Batch No.
Clinical History
1 In contacts (mares and foals) of a mare that aborted due to an EHV-1 
infection. Sample 81588 yielded EHV-4 in cell culture.
2
Periodic samples taken over a period of several weeks from a mare that was 
imported from a yard in which there was a suspected outbreak of EHV-1 
paralysis. Samples were also supplied from different premises suspected for 
cases of EHV-1 paralysis. Virus was not recovered from any sample in 
culture.
3 Samples were from suspected outbreak of EHV-1 paralysis. This batch 
comprised some samples as mentioned in batch 6A (see batch 6) In addition 
two samples were collected from horses showing symptoms of respiratory 
disease from which EHV-2 was isolated in cell culture but both were negative 
for EHV-1 or EHV-4. All samples were negative for EHV-1 and EHV-4 in 
cell culture.
4 There was serological evidence suggestive of EHV circulation in this yard. 
Virus isolation negatives were analysed in batch 4; 1 virus isolation positive, 
84615, was analysed in batch 7.
5 Samples were collected from yearlings suffering from upper respiratory tract 
disease. All of these animals were housed in the same yard. EHV-4 was 
isolated from two of them (85324 and 85328).
6 The samples were collected from nine different horses on three separate 
occasions: A. 24th November 1989; B. 10th January 1990 and C. 29th January 
1990. All the horses had a history of poor performance. Virus was not 
isolated from any horse in group A. One horse in this group showed clinical 
signs of the disease, e.g. tripping and blindness on 5th December and was put 
down. All the horses except one seroconverted to EHV-1 between 13th 
December and 10th January. All the samples in group B were negative for 
EHV-1 and EHV-4 by virus isolation. In group C, EHV-1 was isolated from 
one horse (sample 84916) and others were negative.
7 All virus isolation, EHV-1 or EHV-4, positive horses, from batches 1 to 6 plus 
I additional sample, 84747, from a horse in group 6C. See Table 4.5
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Table 4.3
Reaction Conditions used in PCR assays
Primers Denaturation 
Temp Time
Annealing 
Temp Time
Extension 
Temp Time
No. of Cycles
gC 94 10 50 10 72 30 35
Inner gH 94 10 50 10 72 30 35
Nested gH
i) Outer gH 94 10 50 10 72 40 20
ii) Inner gH 94 10 45 10 72 30 25
TABLE 4.4 
Comparison of PCR and virus isolation data
Total 
number of 
samples
Positive by 
PCR
Negative 
by PCR
Positive by
virus
isolation
Negative 
by virus 
isolation
Positive by 
PCR, 
negative 
by virus 
isolation
Negative 
by PCR, 
positive by 
virus 
isolation
98 12 86 7 91 5 0
TABLE 4.5
Details of EHV-1 and EHV-4 positive samples as 
diagnosed by PCR and/or virus isolation
Sample
No.
Sample
batch
number
Horse
Virus
isolation
data
PCR Data 
Nested gH Inner gH gC
81588 1/7 A1 EHV-4 EHV-4 EHV-4 EHV-4
85324 5/7 B1 EHV-4 EHV-4 EHV-4 EHV-4
85325 5 B2 Negative EHV-4a EHV-4 EHV-4
85326 5 B3 Negative EHV-4 EHV-4 EHV-4
85327 5 B4 Negative EHV-4& EHV-4 EHV-4
85328 5/7 B5 EHV-4 EHV-4 EHV-4 EHV-4
85329 5 B6 Negative EHV-4 EHV-4 EHV-4
84747 6B/7 Cl Negative EHV-4* - -
84916 6C/7 Cl EHV-1 EHV-1 g - -
84615 7 D1 EHV-4 EHV-4 EHV-4 EHV-4C
87313 7 El EHV-4 EHV-4 EHV-4 EHV-4-d
87319 7 E2 EHV-4 EHV-4 EHV-4 Negative
Samples from cohorts are grouped and each horse identified by a cohort-specific letter (A-E) and a 
horse-specific number (within the cohort). Inconsistent amplification is represented by the letters a 
through to g.
a’b Processed four times with nested gH, once with inner gH and twice with gC primers.
Negative on one occasion with nested gH, otherwise positive.
c Processed three times with nested gH, once with inner gH and three times with gC primers.
Negative on one occasion using gC primers, otherwise positive.
d Processed as for 84615. Negative on two occasions using gC primers, otherwise positive.
e Processed as for 84615. Positive using gH primers, negative using gC primers.
* Processed six times with nested gH, twice with inner gH and once with gC primers.
g Processed five times with nested gH, once with inner gH and once with gC primers. Positive
on one occasion only, using nested set of gH primers.
Figure 4.1
PCR analysis of samples of batch 7 using inner gH primer pair
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
152bp-
-173bp
Fig. 4.1 PCR products from nasal swab samples of batch 7, from virus controls 
and negative sample controls were electrophoresed on polyacrylamide gel. A band of 
173bp length was observed in EHV-4 positive samples 87319 (lane 7), 81588 (lane 9), 
87313 (lane 11), 84615 (lane 13), 85324 (lane 15), 85328 (lane 17) and EHV-4 virus 
control (lane 19). Bands of 152bp and an additional band of higher molecular weight 
were observed in EHV-1 virus control (lane 1). Inconsistent EHV-1-positive samples 
84916 (lane 3) and 84747 (lane 5) were negative in this instance (see also Figure 4.2 
(b)). EHV-1 and EHV-4 negative samples were loaded in lanes 4, 6, 8, 10, 12, 14 and 
16 and primer control in lane 18. <I>X174 HaeUl DNA marker is in lane 20.
Figure 4.2(a and b)
Specificity of EHV-1 and EHV-4 specific gH probes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Fig. 4.2 (a) Autroradiograph showing hybridisation of reaction products of batch 5 
samples to EHV-4 specific gH probe. Positive signals were observed in samples 
85324 (lane 3), 85325 (lane 5), 85326 (lane 7), 85327 (lane 9), 85328 (lane 11), 
85329 (lane 13) and in EHV-4 virus control (lane 1). Probe did not hybridise to EHV- 
1 virus control (lane 17), EHV-1 and EHV-4 -ve samples (by virus isolation and 
PCR) in lanes 4,6,8,10 and 12 or primer control in lane 15.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Fig. 4.2 (b) Autoradiograph showing probing of reaction products of batch 7 
samples with EHV-1 specific gH probe. The blot was derived from gel 4.1. Probe 
hybridised only to DNA amplified in EHV-1 control (lane 1). Inconsistently EHV-1 
+ve samples 84916 and 84747 were negative in this instance. Probe did not hybridise 
to EHV-4 +ve samples or to EHV-4 virus control.
Figure 4.3
PCR analysis of samples of batch 7 using gC primers for amplification (PAGE
analysis)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Fig. 4.3 PCR products were electrophoresed on a polyacrylamide gel and 
stained with ethidium bromide. EHV-4 positive samples 81588 (lane 
12), 85324 (lane 14) and 85328 (lane 16) and plasmid containing BamYU. G 
of EHV-4 (lane 17) yielded bands of the expected size of 314 bp length. 
Amplification was not achieved in this instance in the case of samples 87319 
(lane 6), 87313 (lane 8) and 84615 (lane 10). A band of the expected size of 
311 bp was seen on amplification of sequence in plasmid containing EHV-1 
BamHI H (lane 1). Amplification was not observed in samples 84916 (lane2) or 
84747 (lane 4). EHV-1 or EHV-4 negative samples (by PCR and virus isolation) 
are in lanes 3, 5, 7, 9, 11, 13 and 15, primer control in lane 18, dye control in 
lane 19 and <j)X174 Hae III DNA marker in lane 20.
Figure 4.4 (a and b)
Analysis of samples of batch 1 using gC primers for amplification (specificity of 
EHV-1 and EHV-4-specificgC probes)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
I i
Fig. 4.4 (a) Autoradiograph of reaction products probed with EHV-4-specific gC 
probes. Batch 1 samples are in lanes 1 to 11, sentinel controls in lanes 12-15, EHV- 
1 virus control in lane 16 and EHV-4 virus control in lane 17. Plasmid containing 
EHV-4 BamHI N, a negative DNA control, is in lane 18. Probe hybridised to EHV- 
4-specific DNA sequences in batch 1 sample 81588 (lane 2) and in EHV-4 virus 
control (lane 17).
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Fig. 4.4 (b) Autoradiograph of an identical blot to 4.4 (a) probed with an EHV-1- 
specific gC probe. The probe hybridised to EHV-l-specific sequences in the positive 
control (lane 16) and not to EHV-4-specific DNA sequences in positive sample 
81588 (lane 2) and in EHV-4 virus control (lane 17).
Figure 4.5
PCR analysis of six samples of batch 6 using a nested set of primers for
amplification
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Fig. 4.5 A nested set of primers was used for amplification of samples in
batch 6. The reaction products were probed with an EHV-1-specific gH probe. 
Virus control (EHV-1) in lane 1 and inconsistently amplified sample 84747 (lane 2) 
were positive. All other reaction products were negative : samples 84916 (another 
inconsistently amplified sample) (lane 3), 84914 (lane 4), 84745 (lane 5), 84744 
(lane 6), 84749 (lane 7); sentinel control (lane 8), negative DNA control (BamYYi 
N of EHV-4) (lane 9), primer control (lane 10) and EHV-4 in lane 11.
Figure 4.6 (a and b)
PCR analysis of samples in run A of batch 7 using gC primers for amplification
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Fig. 4.6 (a) Autoradiograph showing probing of reaction products of batch 7 samples (run A) 
with an EHV-4-specific gC probe. The details of the samples in different lanes are presented in 
Figure 4.3. Samples 81588 (lane 12), 85324 (lane 14) and 85328 (lane 16) and EHV-4 DNA 
control (EHV-4 BamWl G) (lane 17) were EHV-4 positive, whereas samples 87319 (lane 6), 
87313 (lane 8) and 84615 (lane 10) were EHV-4 negative.
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Fig. 4.6 (b) Autoradiograph showing probing of reaction products of batch 7 samples (run B) 
with an EHV-4-specific gC probe. Samples 81588 (lane 3), 87313 (lane 5), 84615 (lane 7), 
85324 (lane 9) and 85328 (lane 11) and EHV-4 DNA control (BamWl G EHV-4 DNA) (lane 
16) were EHV-4 positive. Amplification in sample 87319 (lane 13), which was achieved using 
gH primers for amplification was not observed in this run. Sample 84916 (lane 1) and negative 
sample controls in lanes 2, 4, 6, 8, 10 and 12 and primer control in lane 14 were negative.
4.4 DISCUSSION
PCR technique has been applied to detect EHV-1 and EHV-4 DNA sequences in the 
nasopharyngeal secretions of horses which had been defined as negative, EHV-1 positive 
or EHV-4 positive by virus isolation and immunofluorescence using EHV-1 or EHV-4 
specific antisera. The primers were selected from conserved regions of EHV-1 and EHV- 
4 genomes such that the same primer pair could amplify the genome segment of both 
EHV-1 and EHV-4. To distinguish the amplified EHV-1 and EHV-4 DNAs, the 
oligonucleotide hybridisation probes were selected from divergent regions of the genomes, 
internal to the amplified target sequences. These probes hybridised specifically to either 
EHV-1 or EHV-4 DNA amplified in positive control (EHV-1, Ab-1 or EHV-4 strain 
1942) as well as in postive field samples.
A general concordance between PCR and virus isolation data was seen as 93 of the 98 
samples were diagnosed identically by both the methods. The remaining five samples 
comprised five virus isolation-negative/PCR-positive cases. Of 91 samples defined as 
EHV-1 or -4 negative by virus isolation, 86 were negative, four typed as EHV-4 and one 
typed as EHV-1 by PCR. The four PCR-positive virus isolation-negative samples 85325, 
85326, 85327 and 85329 were taken from horses housed in the same yard as two other 
horses identified as EHV-4 positive by both vims isolation and PCR (85324 and 85328). 
All the horses in batch 5 exhibited clinical signs of upper respiratory tract disease. This 
result is encouraging in that it indicated increased sensitivity of PCR over virus isolation as 
a diagnostic tool. The additional EHV-1 positive sample is discussed below.
Analysis of the samples from horse Cl proved particularly interesting. Sample 84747 
taken after seroconversion of the horse, was vims isolation negative. Yet EHV-1 DNA 
was detectable in one sample aliquot by PCR. This suggests that EHV-1 infection was in 
progress but that insufficient infective virus was present in the sample to produce a
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cytopathic effect within 2 weeks in tissue culture. As for the batch 5 horse cases, this is 
indicative of a greater diagnostic potential of PCR. A sample taken 19 days later from the 
same horse, 84916, was EHV-1 positive by virus isolation and one aliquot was PCR- 
positive. Re-isolation of the virus in cell culture was unsuccessful. There are two possible 
explanations for this situation. The amount of viral DNA might be so low that DNA was 
present in only one PCR aliquot, whereas 20pl of sample is used per PCR reaction, 500pl 
is used for virus isolation. Alternatively, it is possible that the EHV-1 strain involved, a 
paralytic isolate may possess sequence variation across the primer sites. The latter 
possibility can be investigated by cloning and sequencing of amplified DNA.
Using inner gH and nested set of the primers, sample 87319 (horse E2) proved positive for 
EHV-4 DNA but amplification was not achieved with gC primers. Samples from a cohort, 
Horse E l; sample 87313) and from horse D1 (sample 84615) were positive by virus 
isolation and by PCR using gH primer sets. However, amplification using gC primers was 
inconsistent. These results suggest that horses D l, E l and E2 were infected by an EHV-4 
strain with variation in the gC gene sequence relative to that of strain 1942 from which the 
primers were derived.
Our results indicate, as do those of Ballagi - Pordany and co-workers (1990) that PCR 
used on crude clinical samples can be applied to the rapid diagnosis of EHV-1 and EHV-4 
infection. We also have evidence that as might be expected, PCR is a more sensitive 
diagnostic technique. In addition to its increased sensitivity and decreased sample analysis 
time, a PCR diagnostic laboratory probably would be more useful and economical than the 
existing virus isolation and serological facilities. However, it is essential that strict 
procedures are followed as detailed here and elsewhere (Jarrett et al., 1990) to avoid 
contamination. A typical PCR reaction can generate as many as 1012 molecules of 
amplified DNA (Mullis and Faloona, 1987). In other words, a lOOp.1 aliquot from an 
Olympic size swimming pool in which the reaction products have been uniformly
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distributed would yield as many as 400 amplifiable DNA molecules (Kwok and Higuchi, 
1989). The PCR reaction products thus serve as potent source of contamination leading to 
false positive results.
The PCR technique ultimately could be used to identify particular strains of virus using the 
primer sets from the divergent parts of the EHV-1 genome. The strains associated with 
paralytic and abortigenic disease could potentially be differentiated. Given its sensitivity, 
PCR also has particular application to the study of EHV-1 and EHV-4 latency.
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CHAPTER 5.0
EXPERIMENTAL INFECTIONS OF SPF FOALS WITH 
EHV-1 AND EHV-4
5.1 INTRODUCTION
As an extension of the previous study (Chapter 4), experimental infections of specific- 
pathogen (EHV-1 and EHV-4)-free foals raised by the Department of Clinical Veterinary 
Medicine at the University of Cambridge were planned. An outline of the experimental 
design is presented in Figure 5.1. Precisely, two groups, each comprising two foals, were 
infected with either EHV-1 strain Ab4 or EHV-4 strain MD. All the foals were 
subsequently challenged with EHV-1 Ab4. Nasal secretions and peripheral blood 
mononuclear cells collected from the foals were analysed by PCR and the results were 
compared with the results of isolation of virus from nasal secretions and co-cultivation 
studies of blood leucocytes. PCR analysis was carried out by the author and the virus 
isolation and co-cultivation work was carried out by the research group led by Dr. Hugh 
Field at the Department of Clinical Veterinary Medicine, Cambridge. The objectives of 
these studies were many. Firstly, to further evaluate the potential of PCR technique as a 
novel diagnostic tool for EHV-1 and EHV-4 infections by comparing the relative 
sensitivity of the PCR and virus isolation. Secondly, to study the pathogenetic 
mechanisms of EHV-1 and EHV-4 infections particularly to determine if EHV-4 can cause 
leucocyte-associated viraemia during acute primary infections since EHV-4 has been 
reported to induce abortions (Sabine eta l., 1981).
The earlier concept in the pathogenesis of EHV-4 infection was that the virus is localised 
in the respiratory tract and the draining lymph nodes and does not penetrate any further 
(Allen and Bryans, 1986). Recently, Welch and her colleagues (1992) have shown that 
EHV-1 becomes latent in peripheral blood leucocytes (PBLs) and lymphoid tissues 
draining the respiratory tract of ponies following experimental EHV-1 infection. These 
workers also detected latent EHV-4 in the PBLs and lymphoid tissues of these ponies, the 
origin of which they presume to be preceding natural infection. The studies on EHV-1 and
115
EHV-4-free foals should reflect a clearer view of experimental EHV-1 and EHV-4 
infections in these foals.
The third objective of the study was to determine the effect of heterologous challenge, i.e., 
whether the challenge virus could reactivate the virus inoculated to produce the primary 
infection, should the latter enter a latent phase in the host foal (reactivation of EHV-4 by 
EHV-1 in this particular situation). Reactivation of heterologous strains could lead to 
complex epidemiological patterns and would promote a re-evaluation of the interaction of 
EHV-1 with EHV-4.
One of the main objectives of the study has been to obtain an approximation of the number 
of leucocytes positive for the infectious virus and viral DNA at various days post primary 
and secondary infections of the SPF foals. Such a study may be useful in distinguishing 
acute from latent infections when combined with nasal shedding of the virus. After having 
evaluated the potential of PCR to identify latently infected horses, the technique can also 
be applied to investigate the site of latency in tissues and tropism of the virus for specific 
peripheral blood leucocyte type(s) in conjunction with fluorescence activated cell sorting 
(FACS) analysis.
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5.2 MATERIALS AND METHODS
5.2.1 Specific-pathogen-free (SPF) foals
The equine colostrum-deprived specific-pathogen (EHV-1 and EHV-4)-free foals obtained 
from Welsh mountain pony mares were raised by the Department of Clinical Veterinary 
Medicine at Cambridge University following the procedure as described by Chong et al. 
(1991). These foals were designated as F6 , F l l ,  F13; and F12 and F14 (Fig. 5.1) and were 
transferred from the positive pressure containment unit to two different locations 7-8 km 
apart before infecting them.
5.2.2 Prim ary infection of SPF foals
EHV-1 strain Ab4 passaged 11 times in rabbit kidney cells (RK-13) was used to infect one 
group of foals (F ll and F13). Each foal was infected by intranasal instillation of 10/ pfu 
of the virus in 2 ml of minimum essential medium (MEM) with a plastic pasteur pipette. 
The EHV-1 strain Ab4 was originally isolated from a field case of paresis (Patel and 
Edington, 1983) and subsequently has also been shown to cause abortion in pregnant 
mares.
In another group, each SPF foal (FI2 and F14) was infected by similar intranasal 
instillation of 107 pfu of EHV-4 strain MD passaged three times in equine embryonic lung 
(EEL) cells. This strain was provided by Dr. R. Killington of Leeds University. EHV-4 
strain MD was originally isolated from the lung of a field case with respiratory disease.
Both the groups were housed separately, as mentioned earlier, so as to avoid cross- 
infections. Following infection, these foals were observed for the development of clinical 
signs and their rectal temperatures were recorded regularly.
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5.2.3 Collection of samples
Nasal swab and blood samples were collected from all the foals two days prior to infecting 
them and subsequently at days, 1, 3, 5, 8,11,15 and 18 post-infection.
5.2.3.1 Nasal Swabs
Nasal swab samples were collected with sterile nasal swabs (Virocult, Medical Wire and 
Equipment Co. Corsham, UK) in 3 ml of transport medium (Dulbecco's Modified Eagle's 
Medium (DMEM) containing 1% foetal calf serum, 25 mM hydroxyethylpiperazine ethane 
sulphonic acid (HEPES) buffer, 100 pg/ml gentamicin, 400 units/ml penicillin, 400 ,ug/ml 
streptomycin, 2.5 qg/ml Fungizone and 2 mM L-glutamine). The nasal swabs were 
collected before and after collection of nasal mucus aspirated from the nasopharynx.
5.2.3.2 Nasal Aspirates
For virus isolation, mucus from the nasopharynx was collected via plastic mucus extractors 
(Unoplast, Hundested, Denmark) connected to a foot pump to provide gentle suction. 
Each nasal aspirate sample was diluted in 1 ml virus isolation medium (Eagle's minimal 
essential medium (EMEM) with antibiotics). Nasal aspirates for analysis by PCR were 
also collected in a similar manner, but in 1.5 ml of transport medium (DMEM) as for nasal 
swabs.
5.2.3.3 Blood
50 ml of venous blood was collected into blood collection tubes without any anticoagulant 
(Vacutainer, Becton Dickinson) and transferred quickly to 50 ml Falcon tubes containing 
1,000 units of preservative-free heparin (Leo) and mixed by gentle rotation to prevent 
coagulation of the blood.
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5.2.4 Processing of samples
5.2.4.1 Nasal swab samples
The samples were transported on ice and processed in an EHV-1 and EHV-4-free 
laboratory at Addenbrooke’s Hospital, Cambridge. The nasal swab samples were frozen, 
thawed and cleared by centrifugation at 2,000 rpm for 30 min. The supernatant was 
collected and aliquoted for PCR. Six 20 pi aliquots were kept for PCR and the rest 
dispensed in 500 ml aliquots, stored at -70 °C until use.
5.2.4.2 Nasal aspirates
These samples were stored at -70 °C at Addenbrooke's hospital and transported to 
Glasgow and were processed in a laboratory free of EHV-1 and EHV-4 in a manner in 
which nasal swab samples were processed .
5.2.4.3 Blood samples
Out of 50 ml of heparinised blood, 5 ml was used for separation of plasma and the rest 
used for isolation of peripheral blood mononuclear cells (PBMCs).
5.2.4.4 Isolation of PBMCs
The blood was diluted in two volumes of Hank's balanced salt solution (HBSS) without 
calcium and magnesium. The PBMCs were separated on Ficoll-Paque (Pharmacia). The 
differential migration during centrifugation results in the formation of layers which 
contain different cell types. The bottom layer contains erythrocytes which have been 
aggregated by the Ficoll and therefore, sediment completely through the Ficoll-Paque. 
The layer immediately above the erythrocyte layer contains mostly granulocytes which at 
the osmotic pressure of Ficoll-Paque solution attain a density great enough to migrate 
through the Ficoll-Paque layer. Because of their lower density, the lymphocytes are found 
at the interface between the plasma and the Ficoll-Paque with the other slowly sedimenting 
particles (platelets and monocytes).
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Precisely, 20 ml volume of the diluted blood was slowly layered onto 15 ml of Ficoll- 
Paque in a 50 ml Falcon tube, taking care that the two did not mix. Following 
centrifugation at 1,800 rpm for 30 min at room temperature, the PBMCs were recovered 
from the interface. The upper layer was first drawn off carefully, leaving the PBMCs 
undisturbed at the interface. The cells were collected from the interface into a tube with a 
minimum amount of Ficoll-Paque and supernatant. Removing excess Ficoll-Paque can 
cause granulocyte contamination and removing excess supernatant results in unnecessary 
contamination by plasma proteins. The cells were resuspended in three volumes of HBSS 
without calcium and magnesium, followed by their centrifugation at 800 rpm for 10 min. 
The supernatant was taken off and the cells washed thrice with 10 ml of HBSS. The cells 
were finally suspended in 2 ml of HBSS, counted and aliquoted.
5.2.4.5 Counting of PBMCs and their pelleting
The cells were counted in a haemocytometer chamber and aliquots of 1 x 106, 5 x 105, 1 x 
105, 5 x 104, 1 x 104, 5 x 10^, 1 x 10  ^ cells were made in sterile 1.5 ml eppendorf tubes. 
The PBMCs were pelleted by centrifugation at 13,000 rpm for 10 sec in a microcentrifuge. 
The supernatant was drawn off very slowly and carefully without disturbing the cell pellet. 
The cell pellets were stored frozen at -70°C until their use in PCR. The remainder of the 
cells were stored in storage medium (RPMI 1640 medium containing 400 pg/mi 
streptomycin and 400 units/ml penicillin, 20% foetal calf serum and 10% dimethyl 
sulphoxide, DMSO, Sigma) in liquid nitrogen.
5.2.5 Challenge
EHV-4-infected foals (F12 and F14) were given heterologous challenge by instillation of 
107 pfu of EHV-1 strain Ab4 in the nasal cavity, whereas EHV-1-infected foals F13 and 
F6 were given homologous challenge in a similar manner. Foal F6 was a replacement for 
F ll .  The latter, unfortunately could not be used for challenge studies. Foal F6 was 
infected with EHV-1 Ab4 in a different experiment 20 days prior to primary infection of
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the foals in the present study. This foal was given three consecutive intravenous injections 
of dexamethasone (2 mg/kg) along with primary EHV-1 infection. The steroid had no 
effect on the course of the primary infection (Hugh Field, personal communication).
5.2.5.1 Collection of samples and their processing
Nasal swab and blood samples were processed in a similar way as from primary infection. 
The samples were collected two days prior to challenge i.e. 82 days after primary infection 
and then at day 1, 3, 5, 8 , 12, 17 and 26 post challenge. The nasal aspirates samples for 
PCR analysis were not collected as during primary infection but the samples which were 
utilised for virus isolation were analysed by PCR.
5.2.6 Reactivation studies
In an attempt to reactivate latent EHV-1 and or EHV-4, the foals were given three 
intravenous injections of Dexamethasone (Dexadreson, Intervet Laboratories Ltd., 
Cambridge, UK) at the dose rate of 2 mg/kg on three consecutive days, on days 29-31 post 
challenge. The nasal swab and blood samples were collected from the foals a day after the 
first and the second injections, i.e., on days 30 and 31 post challenge. These samples were 
processed in the similar way as for primary infection and challenge studies.
5.2.7 Prevention of cross contamination of samples during collection and processing
Gloves were frequently changed between handling of two different samples during 
collection as well as processing of the samples in the safety cabinet. One sample was 
handled at a time, as far as possible, in the safety cabinet. The pipette tips were plunged 
slowly in water avoiding splashes. Positive displacement pipette tips were used wherever 
possible. Other measures were also taken, which are described under Quality control for 
PCR.
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5.2.8 Sacrifice of foals and collection of tissues
AH four foals (F6 , FI 3, FI 2 and F14) were euthanased 134 days after the primary 
infection or 50 days after challenge. Blood in 50ml volume was collected from each foal 
in preservative-free heparin as described earlier for separation of PBMCs before putting 
them down. The PBMCs were isolated and pellted as described. Various tissues, such as 
nasal epithelium, oropharynx, trachea, submandibular and deep cervical lymph nodes, 
spleen, liver, aorta, kidney, bone marrow and nervous tissue, were collected for future 
investigations.
5.2.9 Transportation of samples
The samples were transported to the Veterinary School, Glasgow, on dry ice for analysis. 
The cells in storage medium were transported in a shipper containing liquid nitrogen.
5.2.10 Virus isolation from nasal aspirates
The virus isolation work was carried out by the Cambridge group. The nasal aspirate 
samples were mixed thoroughly on a vortex, sonicated at 4°C and centrifuged at 3,000 rpm 
for 10 min. For titrations, 0.6 ml of the supernatant was used (0.3 ml neat and 0.3 ml for 
serial dilutions). The neat sample and its serial dilutions were plated onto monolayers of 
RK-13 and equine embryo lung (EEL) cells. Virus was allowed to adsorb for 45 min at 
37°C, after which monolayers were overlaid with EMEM plus 1% carboxymethyl 
cellulose (CMC) and 1% foetal calf serum. Plaques were allowed to develop for 2-7 days, 
stained with crystal violet and counted. Cultures that did not show cytopathic effects after 
7 days were repassaged.
5.2.11 Co-cultivation of leucocytes
This work was also carried out by the research group led by Dr Hugh Field at Cambridge. 
Leucocytes from the infected foals were prepared as described by Awan et al. (1990) and 
plated onto RK-13 monolayers for EHV-1 or EEL monolayers for EHV-4, incubated at
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37°C for 45 min and then overlaid with CMC-containing medium. Plaques were allowed 
to develop over 2 weeks, during which the monolayers were fed with additional EMEM 
supplemented with 10% neonatal calf serum. The infectious centres were enumerated 
after crystal violet staining.
5.2.12 Polymerase chain reaction
Inner gH primers (Chapter 3 and 4) were used in the amplification process in this study. 
The processed aliquots of nasal swab samples and PBMCs were analysed by PCR. The 
cell pellets containing 5 x 104 and larger cell numbers in duplicate were resuspended in 25 
pi of a buffer containing 0.45% Nonidet P40 and 0.45% Tween 20. The samples were 
overlaid with about 75 pi of mineral oil (Sigma) and digested with 60 pg/ml of proteinase 
K at 56°C for 1 h. Cell pellets containing less than 5 x 104 cells were resuspended in 25 pi 
of water, overlaid with mineral oil and frozen and thawed once. The cell pellets were 
handled in the order of increasing number starting from 1 x 10  ^cells. Water controls were 
kept between the samples and carried along throughout the process so as to ensure that the 
amplification in the positive samples was not due to an exogenous DNA source.
All reagents used in the PCR reaction mixes were PCR core reagents (Cetus). EHV-1 or 
EHV-4 specific gH gene segments were amplified using 2.5 units of Ampli Taq DNA 
polymerase in a 50 pi reaction mixture containing 50 pmol of each primer and 200 M of 
each deoxyribonucleoside triphosphate in PCR buffer II (10 mM Tris pH 8.0, 50 mM KC1) 
containing 1.5 mM MgC^. Reaction mixes were prepared in a laboratory designated to 
handle PCR reagents and stored at -20°C in an area where the reaction mixes and other 
materials used in PCR were routinely stored, as described in Chapter 4. Samples were 
boiled for 10 min prior to the addition of reaction mixes in a designated laboratory. The 
bottom of the tubes was lightly smeared with high vacuum silicone grease (Sigma) before 
placing them on the thermal block (Hybaid, and Genesys Instruments, Cambridge). The 
thermal cycling conditions for amplification process in PCR assays were similar to those
123
described in Chapter 3and 4, except that the annealing temperature was lowered to 40°C. 
Thirty five cycles were used for amplification.
5.2.13 Analysis of PCR products
Reaction products from PCR experiments (15pl-18pl) in gel loading buffer were 
electrophoresed on a 6% polycrylamide gel in a vertical gel electrophoresis apparatus 
(Bio-Rad) under a constant current of 25-30 mA, blotted onto nylon membrane and baked 
for 2 h at 80°C. The filters were incubated at 42°C and 58°C for subsequent hybridisation 
with EHV-4 and EHV-1-specific probes, respectively, in 10 ml of Quikhyb solution 
(Stratagene) for a minimum of 30 minutes in hybridisation tubes of a mini-hybridisation 
oven (Hybaid). EHV-1 and EHV-4 specific probes were end-labelled with (y^PlATP. 
The labelled probe containing 1 x 107 cpm/10 ml of final volume was added to one ml of 
Quikhyb solution containing 250 pg/ml of denatured herring sperm DNA and then added 
to the prehybridisation solution in the hybridisation tube. The hybridisation was carried 
out for a minimum of 2 h at the specified temperatures (42°C for EHV-4 and 58°C for 
EHV-1-specific probes).
The filters were given three quick washes with 2 x SSC followed by another three with 2 x 
SSC, 0.1% SDS at room temperature. Three thirty minute washes in 2 x SSC, 0.1% SDS 
were performed at 45°C and 58°C for EHV-4 and EHV-1-specific hybridisations, 
respectively. The filters were finally washed with 2 x SSC, 0.1% SDS at the melting 
temperature of the respective probe, rinsed with 2 x SSC, air-dried to dampness and sealed 
in plastic bags. Membranes were exposed to Amersham MP film at -70°C in the presence 
of an intensifying screen.
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5.2.14 Quality control for PCR
Given the extreme sensitivity of the PCR technique, and nature of the experiment, 
stringent and rigorous procedures were followed to avoid contamination with previously 
amplified DNA or an exogenous source of DNA and or cross-contamination of the 
samples at each stage right from the collection till the analysis of the samples. All the 
reagents for the collection and processing of the samples were aliquoted in a laboratory 
free from EHV-1 or EHV-4 at Glasgow, transported to Addenbrooke's hospital where the 
samples were later processed, stored at 4°C in a cold room and taken out as and when 
required. The unused reagents after processing were discarded. The gloves were changed 
while entering the storage area. During collection of the samples, the gloves were changed 
between samples, even while collecting blood and nasal swab samples from the same foal. 
In the laboratory, the blood samples were handled prior to nasal swab samples. As far as 
possible, one sample was handled at a time in the safety cabinet, gloves changed and the 
area swabbed before handling another sample. The pipettes were gently immersed in 1% 
Virkon solution and pipette tips also plunged gently to avoid splashes. The visible 
splashes were immediately cleared off and area swabbed thoroughly with 70% ethanol. 
While setting up reactions in a PCR assay, gloves were changed between samples and 
appropriate water controls were kept and carried along as an indication of contamination 
and a DNA-free control or reagent control was also included in the experiment. All other 
contamination avoidance procedures as described in sections 3.2.7 and 4.2.2.6 were also 
followed.
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5.3 RESULTS
5.3.1 PCR analysis of controls
As mentioned in the previous chapter, EHV-1 strain Abl and EHV-4 strain 1942 were 
used as positive controls in the PCR experiments. The strains used for infecting the SPF 
foals in the present experiment were different, i.e. EHV-1 strain Ab4 and EHV-4 strain 
MD. Using gH primers derived from EHV-4 strain 1942, specific DNA sequences of 
EHV-1 strain Ab4 and EHV-4 strain MD were successfully amplified. The latter strain 
yielded bands of the same size(s) on electrophoresis (5.2.a) and hybridisation with the 
EHV-4-specific probe as did EHV-4 strain 1942 (Fig 5.2 a,c). Similarly, the sizes of 
bands of DNA sequences amplified within the nasopharyngeal secretions of SPF foals 
infected with EHV-1 strain Ab4 in another experiment prior to infecting foals used for 
primary infection in the present study (data not shown) were also similar to that observed 
for strain Abl (Fig. 5.2 a, b).
No amplification was observed with two different strains of EHV-2 (strain 89289 and 
89299) kindly provided by Dr. Ann Cullinane, Irish Equine Centre, Johnstown, Ireland. 
Since the samples were processed in a laboratory where HHV-6 was routinely handled for 
research purpose, HHV-6-infected J-JHAN cells were analysed by PCR. Non-specific 
bands were observed while using these cells as targets (Fig 5.2a). EHV-1 or EHV-4 
specific probes hybridised only to EHV-1 or EHV-4 specific amplified DNA sequences. 
The results are shown in Fig. 5.2 b and c.
5.3.2 Confirmation of EHV-1 and EHV-4 free status of the SPF foals
The nasal secretions and PBMCs collected from all the four foals (F ll, F12, F13 and F14) 
two days prior to experimentally infecting them with either EHV-1 or EHV-4 were found 
negative for these viruses both by PCR and virus isolation. Non-specific or spurious 
amplification was observed in samples (fig. 5.3a), as the reaction products of the samples
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did not hybridise to EHV-1- and EHV-4-specific probes (fig. 5.3b). The foals were also 
negative for presence of complement fixing and neutralising antibodies to EHV-1 and 
EHV-4 in their sera until infected (Hugh Field, personal communication). These results 
thus, confirm the EHV-1 and EHV-4-free status of these foals.
5.3.3 Rectal temperatures of the foals following primary infection
The rectal temperatures of the foals at 2 days prior to infection and at different days post­
infection are shown in Fig. 5.4. EHV-1 infected foal F l l  had a temperature as high as 
106.4°F at day 5 p.i., which returned to normal by day 9. In another EHV-1-infected foal, 
F13, the rise in temperature was observed between days 1 and 9 p.i., the maximum 
temperature being at day 1 p.i. (106.0°F) and was normalised by day 9. High rises of 
temperature were not recorded in EHV-4-infected foals. F14 had a temperature of 
104.0°F and 102.0°F at days 1 and 4 p.i., respectively. The temperature of F12 was 
102.0°F at day 8 p.i.
5.3.4 Clinical signs
All the SPF foals were apparently normal and healthy prior to infecting them. They had 
very small lymph nodes, their ocular mucous membranes were pink and normal in 
appearance and they had no serous, purulent or mucopurulent nasal discharge. Following 
infection, EHV-1-infected foals had pyrexia, the peak rectal temperature reaching as high 
as 106.4°F as described earlier, their nasal discharges were serous (F ll) and mucopurulent 
(F13) at 1 day p.i. and were purulent till day 12 and day 8 p.i. respectively, turned to 
serous thereafter and were normal by day 18. The submandibular lymph nodes were 
markedly enlarged between days 2-8 p.i. and gradually regressed thereafter. The ocular 
mucous membranes of the infected foals turned to red or flush red with serous discharge 
and granularity till 8 day p.i. and returned to normal by day 18. EHV-4 infected foals 
exhibited relatively milder clinical signs, the onset of the symptoms was slower which 
persisted for a relatively shorter period.
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5.3.5 Excretion of the virus in nasopharyngeal secretions following prim ary infection.
5.3.5.1 Detection by PCR
The results of PCR analysis for the detection of viral DNA in and isolation of the virus 
from nasal secretions of foals at different days post infection are presented in Table 5.1 to 
5.4. Foal F l l  excreted virus regularly till day 18 as detected by PCR, the maximum 
period of observation (Table 5.1; Fig. 5.5a, b) and so did foal F13 (Table 5.2). However, 
the viral DNA was not detected in nasal swab samples collected from the latter foal till day 
5 p.i., but was detected in nasal aspirates samples. The sediments left after processing of 
day 3 nasal swab sample after giving two cycles of freezing and thawing, however, proved 
PCR positive.
EHV-4 specific sequences were detected in the nasal excretions of foal F I2 till day 18 
regularly except at day 15 (table 5.3). The detection of EHV-4 -specific DNA in the nasal 
aspirate samples of this foal is presented in fig. 5.6. Foal F14 excreted virus till 15 days 
p.i. regularly except at day 11 as demonstrated by PCR (table 5.4). The swab samples of 
F12 and F14 at days 3 and 5 were PCR negative (table 5.3 and 5.4) but their sediments left 
after processing proved PCR positive when analysed after two cycles of freezing and 
thawing.
53.5.2 Virus isolation data
The virus isolation work was carried out by the Cambridge group. The results of the virus 
recovery from nasopharyngeal aspirates and the precise virus titres in positive cases are 
shown in Table 5.5. EHV-1 was recovered from the nasopharyngeal secretions of foals 
F l l  and F13 on all days till day 11 after infection. EHV-4 was recovered till day 8 (F12) 
and day 11 (F14).
128
5.3.5.3 Comparison of PCR and vims isolation data
The comparative analysis of nasal secretions by PCR and virus isolation revealed that the 
former technique is more sensitive (Table 5.1 to 5.4). In the terminal phase of infection, 
the vims being excreted in very low amounts was not recoverable in cell culture, but could 
be detected by PCR (Table 5.5).
5.3.6 Analysis of leucocytes (Primary infection)
5.3.6.1 Detection of viral DNA in PBMCs by PCR
The results of PCR analysis of PBMCs are presented in Tables 5.1 (F ll), 5.2 (F13), 5.3 
(F12) and 5.4 (F14). The peak of infection in F l l  was observed on day 5 p.i., at which 
time EHV-1 DNA was detectable in 5 x 103 PBMCs (Fig 5.7 a, b), and in F13 on day 8 
p.i., at which time 5 x 104 cells gave a positive signal (Fig 5.8). The infection appeared to 
subside gradually and by day 15 p.i. no amplification was observed.
In both EHV-4-infected foals, viraemia was observed till day 15 p.i. Less severe infection 
was observed in F12, as the proportion of EHV-4-infected PBMCs was low; signal was 
not observed in less than 5 x 105 cells throughout the course of infection till day 15 p.i. 
except at day 8 where PBMCs were negative for EHV-4 (Table 5.3). The analysis of day 
5 cells is presented in Figure 5.5 a, b as an example. The peak of infection in F14 was 
observed at day 11 p.i. and EHV-4 DNA could be amplified from as few as 5 x 10^ cells 
(Table 5.4).
5.3.6.2 Analysis of leucocytes by co-cultivation
The co-cultivation work was carried out by the Cambridge group. EHV-1 viraemia was 
observed at days 3, 5 and 11 p.i. in F l l  (Table 5.1) and at day 11 p.i. in F13 (Table 5.2). 
No cell-free virus was detected. The titre of infectious centres ranged from 1 positive cell 
in 106 to 105 leucocytes. However, no EHV-4 viraemia was detected at any day p.i. in 
either of the two EHV-4-infected foals (FI2 and F14) (Table 5.3 and 5.4).
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5.3.7 Challenge Studies
5.3.7.1 Rectal temperatures
No rise in body temperatures of the EHV-1:EHV-1-infected foals (F6 and FI3) was 
observed at any day p.i. A temperature of 102.2°F was observed at day 7 p.i. in one of the 
EHV-4:EHV-1 infected foals (F12). However, there was no elevation in the body 
temperature of F14 at any day post challenge (Fig. 5.10).
5.3.7.2 Clinical signs
The clinical signs were very mild in comparison with those observed during acute primary 
infection. The lymph nodes were enlarged in both the groups of animals, relatively more 
in EHV-1:EHV-1 infected foals. The nasal discharge varied from serous to purulent. The 
conjunctivae were granular and their colour varied from pink to red and flushed red.
5.3.7.3 Excretion of the virus following challenge 
Analysis by PCR
EHV-1 DNA was not detectable in the nasal swab samples of F6 on any day post­
challenge (Table 5.6), but it could be detected in the nasal swab sample of F13 at day 1 
p.i., but not thereafter throughout the period of observation (26 days) (Table 5.7). After 
concentrating the sample by ultracentrifugation at 45,000 rpm (Beckman) for 1.5 h, EHV- 
1 DNA was detectable in nasal swab samples of F12 taken at day 1 p.i. (Table 5.8) and of 
F14 at days 1 and 5 p.i. (Table 5.9). The nasal aspirate samples of F I2 and F14 which 
were utilised for virus isolation were also analysed by PCR. Their analysis revealed that 
EHV-1 DNA was present in nasopharyngeal secretions of both the foals at all days post­
challenge (Tables 5.8 and 5.9). The detection of EHV-1-specific DNA in nasal aspirates 
of F14 is presented in Figure 5.11.
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Analysis by virus isolation
The virus isolation was carried out by the Cambridge group. EHV-1 was isolated at day 1 
p.i. from nasal aspirates of all the foals. The virus was additionally recovered at day 8 and 
17 p.i. from foal F14 (Table 5.9).
5.3.7.4 Analysis of PBMCs/leucocytes 
Analysis o f PBMCs by PCR
Foals F6 and F13 received homologous challenge with EHV-1. The viral DNA was 
detected in 5 x 105 PBMCs of F6 at day 3 p.i., but the samples were negative thereafter 
(Table 5.6). EHV-1 DNA was not detectable in the PBMCs of F13, except at day 12, 
when a weak signal was observed in 1 x 106 cells (Table 5.7).
EHV-4-specific DNA was detectable in PBMCs of both heterologously challenged foals 
F12 and F14, 82 days after primary infection with EHV-4, i.e. two days prior to challenge 
with EHV-1. Following EHV-1 challenge, EHV-4 DNA was detectable in cell pellets 
containing up to 5 x 1(P cells at days 1, 3 and 5 post challenge and in 1 x 106 cells at day 
8 , but not subsequently in the PBMCs of F12 (Table 5.8). The analysis of day 1 cells of 
F12 is presented in Figure 5.12 a, b, c. EHV-1 DNA was detectable in up to 1 x 1(P cells 
at day 8 and up to 5 x 1CP cells at each of days 12 and 17, but not thereafter. In the case of 
F14, EHV-4 DNA was amplified from 5 x 1(P cells 2 days prior to EHV-1 challenge and 
at days 1 and 3; from 1 x 105 cells at day 5 and from 1 x 106 cells at day 8 post challenge. 
EHV-1 DNA was detected in 5 x 104, 5 x 10 ,^ 5 x 105 and 1 x 106 cells at days 5, 8, 12 
and 17, respectively, post challenge, but not thereafter (Table 5.9). The analysis of 
PBMCs of F12 and F14 obtained at day 5 are presented in Figure 5.13.
Analysis o f PBMCs by Virus isolation!co-cultivation o f leucocytes
Infectious centres were not demonstable at any day post challenge in the case of F12, but 
F14 was positive for infectious centres at day 5 p.i. (Table 5.9)
131
5.3.8 Reactivation studies
Following two corticosteroid treatments, EHV-1 DNA was not detected in nasal swab 
samples and PBMCs of EHV-1: EHV-1 challenged foals F6 (Table 5.10) and F13 (Table 
5.11). EHV-1- or EHV-4-specific DNA was not detectable in the nasal swab samples of 
EHV-4: EHV-1 challenged foal F12. However, EHV-1 DNA was detected in up to 5 x 
104 cells of this foal on the second day of treatment, whereas EHV-4 DNA was not 
detectable. On the contrary, EHV-1-specific DNA was not detected after two treatments, 
ie. on the third day of the treatment, but EHV-4-specific DNA could be amplified from up 
to 5 x 10^ cells (Table 5.12, Fig. 5.14). EHV-1 and EHV-4 DNA was detectable in the 
concentrated nasal swab samples of F14 after two treatments. EHV-1 DNA was detected 
in 1 x 105 PBMCs of this foal on the second day of treatment (Figure 5.15) and in 5 x 104 
cells on day 3 (Figure 5.16). EHV-4-specific sequences could also be amplified from up 
to 5 x 105 cells of F14 on the same day (Table 5.13). Nasal aspirate samples of F12 and 
F14 collected at days 3 and 5 for virus isolatiion were also analysed by PCR. Their 
analysis revealed that EHV-1 DNA was present in the nasal secretions of both the foals on 
these days.
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Figure 5.1
SPFFOAL STUDY
I I
Group I (F ll and F13) Group 2 (F12 and F14)
i I
Primary infection Primary infection
EHV-1 strain Ab4 EHV-4 strain MD
107 pfu/foal 107 pfu/foal
A I
Collection of samples Collection of samples
Nasal secretions and blood Nasal secretions and blood
(Day -2,1, 3, 5, 8,11,15 and 18 post infection)
I I
Challenge Challenge (84 d.p.i.)
107 pfu/foal 107 pfu/foal
EHV-1 strain Ab-4 EHV-1 strain Ab4
Foals F6 and F I3 (104 and 84 d.p.i) F12 and F14
(FI 1 replaced by F6)
I I
Collection of samples Collection of samples
(Nasal secretions and blood) (Nasal secretions and blood)
(Day -2,1, 3, 5, 8,12,17 and 26 post challenge)
I I
Dexamethasone administration Dexamethasone administration
(29-31 days post challenge) (29-31 days post challenge)
I I
Collection of samples Collection of samples
Day 30 and 31 Day 30 and 31
Fig. 5.1 Experimental strategy for infections of SPF foals with EHV-1 and EHV-4
Figure 5.2 (a)
FCR analysis of controls (PAGE analysis)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Fig. 5.2 (a) PCR reaction products were loaded as follows : Lane 2,4 EHV-1 Abl, 6 
EHV-2 strain 89289, 8 EHV-2 strain 89299, 10 HHV-6-infected J-JHAN cells, 12 
EHV-4 strain 1942, 14 EHV-4 strain MD, 16 primer control. d>X174 marker was 
loaded in lane 17. A band of the expected size of 173 bp was observed in amplified 
DNA of EHV-1 strain Abl (lanes 2 and 4). An additional band of high molecular 
weight is also seen. EHV-4 strain 1942 (lane 12) and EHV-4 strain MD (lane 14) 
also yielded a band of the expected size of 152 bp. An additional band of high 
molecular weight is also seen. Nonspecific amplification is observed in HHV-6- 
infected J-JHAN cells (lane 10). Amplification is not observed with 
strains 89289 (lane 6) and 89299 (lane 8) of EHV-2.
Figures 5.2 (b and c)
PCR analysis of controls (probe-specific hybridisations)
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Fig. 5.2 (b and c) Autoradiographs of identical blots of PCR reaction products as 
detailed in Fig 5.2 (a) probed with an EHV-1-specific probe labelled with y 3-P 
dATP (Fig 5.2b) and with an EHV-4-specific labelled probe (Fig 5.2 c). The EHV-1 - 
specific probe hybridised only to EHV-1 virus controls (lanes 2 and 4) and the EHV- 
4-specific probe to EHV-4 virus controls only (lanes 12 and 14).
Figure 5.3 (a)
PCR analysis of nasal swab samples and PBMCs of foals at day -2 
(primary infection) (PAGE analysis)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Fig. 5.3 (a) The PCR products of nasal swab samples and PBMCs of foals F12, 
F14; F I3 and F l l  collected 2 days prior to infection were run on a polyacrylamide 
gel. Products of swab samples of these foals were loaded in lanes 3, 8, 13 and 17, 
respectively and PBMCs (1 x 106, 5 x 105 and 1 x 105) in lanes 4, 5, 6 (FI2), lanes 
9, 10 and 11 (F14); lanes 14, 15, 16 (F13), respectively. 1 x 106 and 5 x 105 PBMCs 
in lanes 18 and 19 (F ll). EHV-1 and EHV-4 virus controls in lanes 1 and 20; (f) 
XHaeIII marker in lane 12.
Figures 5.3 (b and c)
PCR analysis of nasal swab samples and PBMCs of foals at day -2 (primary 
infection); probing of amplified products with EHV-1-specific (Fig 5.3 b) and 
EHV-4-specific gH probe (Fig 5.3 c).
1 2 9 10 11 12 13 U  15 16 17 18 19 20
«
Fig 5.3 b Autoradiograph of PCR products probed with an EHV-1-specific gH 
probe. The probe hybridised to EHV-1 virus control (lane 1).
1 2 3 4  5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Fig. 5.3 (c) Autoradiograph of PCR products probed with an EHV-4-specific gH 
probe. The probe hybridised to the EHV-4 virus control (lane 20).
Figure 5.4
Rectal temperatures of SPF foals (primary infection)
R ecta l  t e m p e ra tu re  ( F)
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Figure 5.5 (a)
PCR analysis of nasal secretions of foal 11 obtained at different 
days post prim ary infection (PAGE analysis)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Fig. 5.5 (a) The PCR products of nasal secretions of foal 11 obtained at different 
days post primary infection were loaded as follows - days 1, 3, 5, 8, 11, 15 and 18 
(concentrated sample) in lanes 3, 5, 7, 9, 11, 13 and 15. PCR products of EHV-1 
and EHV-4 targets were loaded in lanes 1 and 18 respectively, PCR'd sentinel 
controls in lanes 4, 6, 8, 10, 12 and 14 and primer control in lane 16; §XHael\\ 
marker in lane 19. Besides bands of expected size of 152 bp (EHV-1) and 173 
(EHV-4), bands of higher molecular weight are seen.
Figure 5.5 (b)
PCR analysis of nasal secretions of foal 11 (F ll)  obtained at 
different days post primary infection (PAGE analysis)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Fig. 5.5 (b) Hybridisation of EHV-1 gH probe to the EHV-1 specific sequences in 
PCR products of nasal swab samples of F 11 at days 1, 3, 5, 8, 11, 15 and 18 (lanes 
3, 5, 7, 9, 11, 13 and 15) and to EHV-1 virus control in lane 1.
Figure 5.6
PCR analysis of nasal aspirate samples of foal F12 (primary infection).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
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Fig. 5.6 Autoradiograph showing probing of immobilised reaction products of
nasal aspirate samples of foal F12 taken at various days after primary infection. The 
samples of day 1 (lane 3), day 3 (lane5), day 5 (lane 7), day 8 (lane 9) gave a strong 
positive signal as did EHV-4 virus control in lane 1. A weak or faint signal can be 
seen in the day 11 sample (lane 11). The samples of day 15 (lane 13) and day 18 
(lane 15) were negative on probing. Probe did not hybridise to products amplified 
from target EHV-1 (lane 19). Sentinel controls in lanes 4,6,8,10,12 and 14 and 
primer control in lane 16 were negative.
Figure 5.7 (a)
PAGE analysis of PCR products from PBMCs of foal 11 (day 5) 
post prim ary infection.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
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Fig. 5.7 (a) PAGE analysis of PCR products of PBMCs of foal 11 (day 5) after 
primary infection. In lane 1 is EHV-1 virus control and in lane 18 EHV-4 virus 
control. The products of PBMCs are loaded as 1 x 106 (lane 3), 5 x 1CP (lane5), 1 x 
105 (lane 7), 5 x 104 (lane 9), 1 x 104 (lane 11), 5 x 103 (lane 13) and 1 x 103 (lane 
15). Sentinel controls in lanes 4, 6, 8, 10, 12 and 14 and primer control in lane 16 
were negative. 0X174 HaeUl DNA marker is in lane 19. Besides specific bands, 
multiple nonspecific bands were seen in lanes loaded with PCR products of PBMCs.
Figure 5.7 (b)
PCR analysis of reaction products from PBMCs of foal 11 (day 5) post prim ar' 
infection (Probing with an EHV-1-specific gH probe).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Fig. 5.7 (b) Probing of blot of gel 5.7 (a) with an EHV-1-specific gH probe. EH\- 
1-specific sequences in the PBMCs of foal FI 1 (day 5 post primary infection) weie 
detected in cell pellets containing up to 5 x 103 cells, i.e. in 1 x 106 (lane 3), 5 x 1(5 
(lane5), 1 x 105 (lane 7), 5 x 104 (lane 9), 1 x 104 (lane 11) and 5 x 103 (lane 13). 
Sentinel controls (lanes 4,6,8,10,12) and primer control (lane 16) were negative.
Figure 5.8
PCR analysis of PBMCs of foal F13 obtained at 8 days post primary infection
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Fig. 5.8 Probing of the blot containing immobilised reaction products of PBMCs of 
F I3 day 8 post primary infection with EHV-1 specific gH probe. A positive signal 
can be observed with : EHV-1 virus control (lane 1) and PBMCs 1x10^ (lane 3), 
5x10^ (lane 5), 1x10^ (lane 7) and 5x10^ (lane 9). PBMCs 1x10^ (lane 11), 5xl03 
(lane 13) and lx l0 3 (lane 15) were negative. The sentinel water controls in lanes 4, 
6, 8, 10, 12 and 14, a negative cell control (5xl03 PBMCs of F I3 day -2) in lane 16 
and a primer control in lane 17 were all negative. EHV-4 control in lane 18 did not 
hybridise to EHV-1 specific probe.
Figure 5.9 (a)
PCR analysis of PBMCs of foal F12 collected 5 days after primary infection
with EHV-4 (PAGE analysis).
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Fig. 5.9(a) PAGE analysis of PCR products of PBMCs of foal F12 at day 5 
following primary EHV-4 infection. The reaction products from PBMCs 1 x 106 
(lane 3), 5 x 105 (lane 5), 1 x 105 (lane 7), 5 x 104 (lane 9), 1 x 104 (lane 11), 5 x 103 
(lane 13) and 1 x 103 (lane 15) yielded multiple bands. Sentinel controls are in lanes 
4, 6, 8, 10, 12 and 14 and primer control in lane 16. EHV-4 virus control is in lane 1. 
EHV-1 virus control is in lane 18. tyXHaelll DNA marker is in lane 19.
Figure 5.9 (b)
PCR analysis of PBMCs of foal F12 collected 5 days after primary infection 
with EHV-4 (probing of reaction products with EHV-4-specific gH probe).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
I
Fig. 5.9 (b) An autoradiograph showing probing of reaction products as detailed 
in Figure 5.9 (a) with an EHV-4-specific probe. A positive signal is evident in 
PBMCs at 1 x 106 (lane 3), and 5 x 105 (lane 5) and in the EHV-4 virus positive 
control in lane 1.
Figure 5.10
Rectal temperatures of SPF foals (secondary infection)
R ecta l  t e m p e ra tu re  ( F)
1 0 5
1 0 3
01
2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Days (0 = infection)
Foa! # 6  
~ Foal #13 
Foal #12 
Foal #14
Figure 5.11
PCR analysis of nasal aspirate samples of foal F14 (as utilised for virus
isolation) following EHV-1 challenge.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
“ 4
4
»; I* -  ~ * •  *1 •  »  •  » •  *  • *
Fig. 5.11 Probing of reaction products of nasal aspirate samples of foal FI4 
with an EHV-1-specific gH probe. The samples of days 1, 3, 5, 8, 12, 17 and 26 in 
lanes 4, 6, 8, 10, 12, 14 and 16 respectively, proved positive on hybridisation. The 
day -2 sample (lane 3), sentinel water controls in lanes 5, 7, 9, 11, 13 and 15 and 
primer control in lane 17 were negative. EHV-1 virus control is in lane 1 and EHV-4 
virus control in lane 19.
Figure 5.12 (a)
PCR analysis of PBMCs of foal F I2 at day 1 after EHV-l 
challenge (PAGE analysis).
1 2 3 4 5 6 7 8 9 10 11 12 13
rw1
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Fig. 5.12 (a) PAGE analysis of PCR reaction products of PBMCs of foal F12 at 
day 1 following secondary infection with EHV-1. Samples of reaction products of 
PBMCs: 1 x 106 (lane 3), 5 x 105 (lane 5), 1 x 105 (lane 7) and 5 x 104 (lane 9) 
yielded multiple bands. EHV-4 virus control in lane 1 and EHV-1 virus control in 
lane 12 yielded bands of expected sizes. Sentinel water controls are in lanes 4, 6 and 
8, primer control in lane 11. tyXHaeIII DNA marker is in lane 13.
Figure 5.12 (b and c)
PCR analysis of PBMCs of foal F12 at day 1 after EHV-1 challenge
1 2 3 4 5 6 7 8 9 10 11 12 13
Fig. 5.12 (b) Probing of blot 5.12 (a) with EHV-4-specific gH probe. A positive 
signal was observed in EHV-4 target (lane 1) and PCR products from lx l 06 (lane3), 
and 5xl05 (lane 5) PBMCs. No signal was observed in lxlO5 (lane 7) and 5xl04 
(lane 9). Sentinel controls in lanes 4, 6 and 8 and primer control in lane 11 were 
negative.
1 2 3 4 5 6 7 8 9 10 11 12 13
Fig. 5.12 (c) Probing of blot 5.12 (a) with EHV-1-specific gH probe. All PBMC 
samples and controls proved negative for EHV-1. A positive signal is observed in 
lane 12, EHV-1 target.
Figure 5.13
PCR analysis of PBMCs of foals F12 and F14 collected at day 5 following EHV-
1 challenge.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Fig. 5.13 Autoradiograph showing probing of PCR products of PBMCs of foals 
F I2 and F14 collected at day 5 after EHV-1 challenge. Probe hybridised to PCR 
products from EHV-1 (lane 1) and PBMCs at 1 x 106 (lane 10), 5 x 105 (lane 12), 1 
x 105 (lane 13), 5 x 104 (lane 15) and positive PBMC control 5 x 104 cells of foal 
FI 1 (day 8 primary infection) (lane 16). 10 pi reaction products were loaded in lane 
16 compared to 18 pi of reaction products of other samples. The samples of PBMCs 
of foal F I2: 1 x 106 (lane 2), 5 x 105 (lane 4), 1 x 105 (lane 5), 5 x 104 (lane 7) 
proved negative. EHV-4 target (lane 17) and sentinel controls in lanes 3, 6, 11 and 14 
were also negative.
Figure 5.14
PCR analysis of PBMCs of foal F12 taken after 2 treatments with 
dexamethasone (on day 3).
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Fig. 5.14 An autoradiograph showing probing of PCR products of foal F12 
taken on day 3 of commencement of corticosteroid treatment with an EHV-4-specific 
gH probe. A positive signal in 1 x 106 cells (lane 3), 5 x 1CP cells (lane 5) was 
observed. No signal was seen in 1 x 105 cells (lane 7), 5 x 104 cells (lane 9), 1 x 104 
cells (lane 11), 5 x 103 (lane 13) and 1 x 103 cells (lane 15). Sentinel water controls 
in lanes 4. 6, 8, 10, 12 and 14 were negative. EHV-1 virus control in lane 1 did not 
hybridise to EHV-4-specific gH probe. EHV-4 virus control is in lane 19.
Figure 5.15
PCR analysis of PBMCs of foal F14 collected at day 2 of 
dexamethasone treatment.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Fig. 5.15 Autoradiograph of a blot with immobilised reaction products of 
PBMCs of foal F14 (day 2 of dexamethasone treatment) probed with an EHV-1 - 
specific gH probe. A positive signal was observed in cells: 1 x 106 (lane 3), 5 x 1CP 
(lane 5), 1 x 1CP (lane 7). PBMCs: 5 x 104 (lane 9), 1 x 104 (lane 11), 5 x 103 (lane 
13), 1 x 103 (lane 15) were negative. Positive signals were also seen in EHV-1 virus 
control (lane 1) and positive PBMCs control : 5 x 105 cells of foal FI 1 at day 8 post 
primary infection (lane 17) and 5 x 1CP cells of foal F I3 at day 5 post primary 
infection (lane 18). An EHV-1-specific probe did not hybridise to the EHV-4 virus 
control in lane 19. Sentinel water controls in lanes 4, 6, 8, 10, 12 and 14 and primer 
control in lane 16 were negative.
Figure 5.16
PCR analysis of PBMCs of foal F14 collected at day 3 of dexamethasone
treatment.
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Fig. 5.16 Autoradiograph of a blot with immobilised reaction products of 
PBMCs of foal F14 (day 3 of dexamethasone treatment) probed with an EHV-1 - 
specific gH probe. A positive signal was observed in l x l 0 6 (lane 3), 5 x 105 (lane 
5), 1 x 105 (lane 7) and 5 x 104 (faint signal) (lane 9) PBMCs. No signal was 
observed in lx l04 (lane 11), 5xl03 (lane 13) and lx l0 3 (lane 15). EHV-1 virus 
control was loaded in lanes 1 and 18. Sentinel controls in lanes 4, 6. 8, 10,12 and 14 
and primer control in lane 16 were negative. The probe did not hybridise to the EHV- 
4 virus control in lane 2 or to EHV-4 +ve PBMCs (5xl05 PBMCs foal FI4, day 11 
post primary infection) in lane 17.
5.4 DISCUSSION
Equine herpes viruses 1 and 4 are endemically distributed within the horse population in 
the UK, as in other parts of the world. Since they are readily transmitted from the dam to 
the foal, it is sometimes difficult to distinguish primary and secondary infections. 
Thomson et al. (1978) used gnotobiotic foals obtained by hysterectomy to study the 
primary immune response. Since these animals are maintained in a sterile environment, 
without being exposed to ubiquitous organisms, their immune systems are unprimed and 
therefore not functionally equivalent to those of conventional foals. Fitzpatrick and 
Studdert (1984) studied cross-reactivity between EHV-1 and EHV-4 antigens in foals 
raised under SPF conditions. Seronegative foals have often been used for various studies 
but seronegativity as a criterion for EHV-1 or EHV-4-free status may not be sufficient in 
that the foals in many cases may acquire maternal antibodies together with inapparent 
herpesvirus infections during suckling.
Studies on the pathogenesis of EHV-1 and EHV-4 infections and immune response of the 
natural host would be more valuable if conducted on animals with clearly defined EHV- 
free status. Equine colostrum-deprived foals raised under SPF conditions as described by 
(Chong et al., 1991) have therefore, been used in the present study. Their EHV-1 and/or 
EHV-4 free status was established by the absence of these viruses in the nasal secretions 
and PBMCs of the SPF foals prior to infection by virus isolation and PCR analysis. Also, 
these foals were negative for complement-fixing and neutralising antibodies until they 
were infected. In the PCR experiments, specific regions of the EHV-1 and EHV-4 gene 
homologues of the HSV-gene encoding glycoprotein gH were amplified using primers 
derived from conserved regions of the EHV-1 and EHV-4 genes. The amplified products 
were probed with EHV-1 or EHV-4-specific probes. A single type-common set of primers 
derived from the gH gene of EHV-4 strain 1942 was used for amplification in PCR 
assays. The EHV-1 and EHV-4-specific sequences were distinguished by hybridisation of
133
the PCR products to type-specific probes, as described in chapters 3 and 4. It was 
ascertained that these primers successfully amplified the specific gene segments of the 
EHV-1 strain Ab4 and EHV-4 strain MD, the strains used for experimental inoculation of 
the SPF foals.
The strains used for experimental infections were isolates of known origin and 
pathogenicity. EHV-1 strain Ab4 was originally isolated from a field case of paresis (Patel 
and Edington, 1983) which has also been shown to cause abortion in pregnant mares. The 
EHV-1 strain Ab4 was further evaluated for its pathogenic potential in another group of 
SPF foals prior to inoculation of the foals used in the present study (Gibson et al., 1992).
The primer set did not amplify two different strains of EHV-2. This virus is an ubiquitous 
organism present in 89% of the horse population (Kemeny and Pearson, 1970) and has 
recently been shown to trans-activate the EHV-1 and HSV-1 immediately early genes 
(Purewal et al., 1992). It was, thus, ensured that the results of PCR analysis were not 
affected, even under circumstances where SPF foals would have acquired EHV-2 infection 
after their removal from the positive pressure containment unit. Nonspecific 
amplification, however, was observed when HHV-6-infected J JHAN cells were used as 
targets. The reaction products did not hybridise to EHV-1 or EHV-4-specific probes. The 
basis for inclusion of HHV-6 as a control was that all the* samples were -processed* in a 
laboratory where HHV-6 research was routinely being carried out
The foals used in the study were apparently normal and healthy prior to infection. After 
inoculation, they exhibited clinical signs typical of EHV-1 or EHV-4 infection. EHV-1 
infection was clinically evident as pyrexia during which the peak rectal temperatures as 
high as 106.0°F (F13) and 106.4°F (FI 1) were recorded. Other signs included serous 
nasal discharge which soon became mucoid or mucopurulent, serous ocular discharge and 
enlarged submandibular lymph nodes. The clinical picture observed is essentially similar
to that described by several workers (Doll et al., 1954; Allen and Bryans, 1986; Stokes et 
aL, 1991a; Gibson et al., 1992). EHV-4-infected foals exhibited relatively milder clinical 
signs, with no appreciable rise in their body temperatures. The onset of symptoms in these 
foals was slower, lasting for relatively shorter period. EHV-4 infections are generally 
mild to inapparent (Coignoul et al., 1984a). However, the virus has potential for causing 
severe respiratory disease in susceptible horses. The classical signs of EHV-4-induced 
serious respiratory disease often seen in field outbreaks can rarely be experimentally 
reproduced, even after inoculation of the same field isolate (Burrows and Goodridge, 
1978b).
The comparative studies on the excretion of virus in the nasopharyngeal secretions during 
primary infection revealed that PCR is more sensitive than the conventional method of 
virus isolation. Nasal samples from which virus was not recovered in cell culture proved 
positive when analysed by PCR, e.g. F l l  and F13 at days 15 and 18 p.i.; F12 at days 11 
and 18 p.i. and F14 at 15 p.i. (Tables 5.1 to 5.4). However, some stochastic effects have 
been observed while analysing samples by PCR. It may be argued that a 20 pi sample 
aliquot is used in a PCR experiment for achieving amplification as against 0.5 ml to 1.0 ml 
in cell culture. If the titre of the virus is very low, particularly during the initial and 
terminal phases of the infection, a 20 pi aliquot may not contain a single copy of 
amplifiable viral genome and hence the result may be interpreted as negative. Such 
stochastic effects were evidenced by (1) 10 fold concentration of 500 pi of sample by 
ultracentrifugation at 45,000 rpm led to successful amplification in a 20 pi aliquot of the 
sample, e.g. F l l  and F13 at day 18 p.i. and F14 at day 15 p.i. (2) amplification was 
achieved in one of the two aliquots examined. (3) In a few instances (F13 at day 3 p.i., 
F12 and F14 at days 3 and 5 p.i.), where the sediments left during processing of nasal 
swab samples were analysed by PCR, after giving them two cycles of freezing and 
thawing, also proved positive. Further, the volume of collection medium and the amount 
of nasal secretions collected for analysis would influence the outcome of PCR analysis. It
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may be emphasised here that the samples used for PCR and virus isolation were not 
identical for certain procedural differences and for possible risk of contamination. The 
samples collected for virus isolation were nasal aspirates collected via mucus extractors 
connected to a foot pump to provide gentle suction in 1 ml of virus isolation medium, 
whereas the samples used for PCR analysis consisted of nasal mucus collected with nasal 
swabs in 3 ml of virus transport medium (VTM). Nasal aspirates collected from primary 
infection, collected in 1.5 ml of VTM, were also analysed subsequent to analysis of nasal 
swab samples. There was disconcordance between PCR conducted on nasal swab samples 
and nasal aspirates. In general, aspirate samples were more likely to be positive. During 
primary infection, nasal aspirate samples from F13 on days 1, 3 and 5 and from F14 and 
F12 on days 3 and 5 were positive by PCR, whereas viral DNA could not be detected in 
nasal swab samples of these foals taken on the same days. However, the sediment proved 
positive in some instances, as mentioned earlier.
EHV-1 and EHV-4 viral DNA could be detected in nasal secretions of infected foals for 
similar lengths of time after primary infection. The EHV-1-infected foals (F ll and F I3) 
excreted virus regularly till day 18 p.i., as detected by PCR. The excretion pattern of 
EHV-4 appeared to be biphasic, at least in the case of F12: days 1-11 and then at day 18 
(Table 5.3). It would appear from the comparison of PCR and virus isolation data that, at 
the terminal phase of infection, virus was being excreted in very low amounts, as it was 
not recoverable in cell culture, but could still be detected by PCR. The relatively higher 
sensitivity of PCR versus virus isolation is also evident from the analysis of PBMCs of all 
the foals.
In view of their pathogenic potential, EHV-1 and EHV-4 differ significantly in their 
pathogenetic mechanisms. While EHV1 produces a systemic, viraemic disease with a 
potential for causing abortion or paralysis, EHV-4 infections have been considered to be 
restricted to the tissues of respiratory tract and draining lymph nodes (Allen and Bryans,
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1986) and alveolar macrophages (Patel et al., 1982). EHV-4 is also occasionally 
associated with abortion (Shimizu et al., 1959; Sabine et al., 1981). In light of these 
observations, it is logical to believe that EHV-4 may have the potential to infect circulating 
leucocytes. The present study provides a systematic approach to investigate the infectivity 
of EHV-4 to the PBMCs and to determine the proportion of infected PBMCs from the 
EHV-1 and EHV-4-infected foals during the course of primary infection.
The comparative analysis of PBMCs from the two groups of foals by PCR shows that 
EHV-1 causes relatively more severe infection of these cells than does EHV-4. As many 
as 5 x 103 cells of F l l  contained at least one amplifiable EHV-1 DNA molecule at the 
peak of infection at day 5 p.i. (Fll). In another EHV-1 infected foal (F13), 5 x 104 cells 
contained at least single amplifiable copy of EHV-1 DNA at the peak of infection, i.e. at 
day 8 p.i. The proportion of EHV-4-infected PBMCs on the other hand was relatively 
lower, particularly in the case of F12, from which less than 5 x 105 cells did not give a 
positive signal at any day during the course of primary infection. Of particular interest in 
this instance is the fact that the viraemia appeared to be biphasic. EHV-4 DNA was 
detectable at days 1-5 and then at day 15 i.e. the viral DNA was not detectable at day 8 
p.i.. In another EHV-4-infected foal (F14), the peak of viraemia was observed at day 11 
p.i. at which as many as 5 x 104 cells showed a positive signal in the PCR assay.
Inhibition of amplification in higher cell numbers (1 x 106 PBMCs) has been observed in 
some instances, which may be attributable to inhibitory substances such as erythrocytes 
(Higuchi, 1989). Such inhibition has also been observed by others (Jarrett et al., 1990). 
The inhibitory effects can be investigated by performing PCR assays with the DNA 
extracted from these cells. The commercially available DNA extraction kits (Turbogen, 
Microturbogen; British Biotechnology) may be used to extract DNA from PBMCs so as to 
avoid contamination by such inhibitory substances.
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The excretion of the virus from the nasopharynx of the foals correlates well with the 
PBMC-associated viraemia. Bryans (1969) recovered EHV-1 from the nasopharynx and 
buffy coat cells of young infected horses for up to 12 days post-inoculation. The onset of 
viraemia was observed 1 to 3 days after infection. However, EHV-4 was not recovered 
from leucocytes of infected foals.
Our results of PCR analyses of EHV-1 viraemia and excretion of the virus from the 
nasopharynx of infected foals during acute infection agree well with those reported by 
Scott et al. (1983). These workers detected the presence of EHV-1 in the PBMCs of 
experimentally infected pony foals for up to 14 days after infection by infectious centre 
assay, in which the intact cells were co-cultivated with equine monolayer cell cultures. 
The highest number of PBMCs harbouring virus was on day 4 p.i., when 43 infectious 
centres/2 x 106 cells were observed. The virus was recovered from nasal swab samples 
for up to 14-20 days p.i. In similar co-cultivation studies, Welch et al. (1992) recovered 
EHV-1 from PBMCs of four ponies between 4 and 8 days p.i., with sporadic isolation 
from two of them at 10 and 12 days p.i and only at day 11 p.i. from the fifth. The virus 
was consistently recovered from the nasal swab between 1 and 4 days p.i. and sporadically 
for up to 12 days. Gibson et al. (1992) observed a biphasic nasal excretion of the virus in 
SPF foals infected with 7.3 x 107 pfu of EHV-1 strain Ab4. The excretion was observed 
for 8-9 days in four foals and for 14 days in the fifth. Virus was not present in the nasal 
secretions of some foals between 5-7 days, but reappeared on days 8 and 9. The viraemia 
was detected by infectious centre assay between 6-9 days in the four foals, and on days 14 
and 16 in the fifth. In the present study, the viral DNA was regularly detected in the nasal 
secretions of EHV-1 infected foals till 15 d.p.i. The PCR assay has an advantage over the 
detection of virus by infectious centre assay in that it is more sensitive, since the virus is 
not detectable by co-cultivation if the leucocytes are disrupted or non-viable, whereas 
intact or viable cells are not an absolute requirement for PCR analysis.
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The homologous challenge studies (EHV-1:EHV-1) revealed that EHV-1 strain Ab4 
afforded complete protection to the foals against a homologous challenge given 84 days 
after the primary infection, as reflected by no elevation in their body temperatures 
following challenge and absence of other clinical signs. Both the EHV-1 challenged foals 
excreted virus in their nasal secretions at 1 day p.i.. EHV-1 DNA was detectable in 1 x 
106 PBMCs of F13 only at day 12 post-challenge and not on any other day post-challenge. 
Viral DNA was detectable in 5 x 105 cells of F6 only at day 3 p.i.
EHV-1 DNA was not detectable by PCR in the PBMCs collected two days prior to the 
challenge from either of the two homologously challenged foals. Two possibilities exist 
for explaining this situation. First, the virus might have been completely cleared by the 
host defences without providing an opportunity to the virus to enter a latent phase. Second, 
the proportion of PBMCs harbouring the virus might have been low, hence undetectable. 
The latter possibility can be explored by analysis of DNA extracted from higher cell 
numbers. However, this possibility appears to be unlikely in light of the fact that viral 
DNA was not detectable in PBMCs from foals administered dexamethasone for two 
consecutive days in an attempt to reactivate the virus, if any. The viral DNA was not 
detected in the nasal secretions of the foals by PCR.
In a homologous (EHV-1:EHV-1) challenge experiment conducted on seronegative 
weanling foals which were given a primary infection of 108 p.f.u. by the intranasal route 
and challenged 4 weeks later, the foals were resistant to challenge and only one out of the 
3 foals excreted virus at day 1 p.i. (Allen and Bryans, 1986). Gibson et al. (1992) also 
observed complete protection in SPF foals which were infected with 7.3 x 107 pfu of 
EHV-1 strain Ab4 and challenged with 1.7 x 107 pfu of the same viral strain 63 days later. 
The virus was recovered from the nasal secretions of all four foals only for 2 days p.i. and, 
additionally, on day 14 p.i. from the fifth foal. However, viraemia was not detectable in 
these foals by infectious centre assay or immunofluorescence.
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Edington and Bridges (1990) found protection in yearling ponies infected with strain Ab4 
of EHV-1 when challenged 5 months later with the same virus strain. The mean nasal 
excretion of the virus was reduced to 1.8 ± 0.4 days, as against 6.0 ± 1.0 days during 
primary infection. Viraemia was not detectable in these ponies. However 3 out of 6 ponies 
had mild pyrexia.
The heterologous (EHV-4:EHV-1) challenge studies are particularly interesting in that 
they provided information regarding the interactions between the two viruses in the host 
system. EHV-4 DNA was detected in the PBMCs of both the EHV-4 infected foals (F12 
and F14) two days prior to challenge or 82 days after primary infection with EHV-4. The 
proportion of PBMCs harbouring the virus remained constant till day 5 post challenge, i.e. 
5 x 105 cells contained at least one amplifiable EHV-4 DNA molecule (F12). At day 8, 
EHV-4 DNA could be amplified from 1 x 106 cells of both foals. The viral DNA was not 
demonstrable during the entire course of secondary infection thereafter.
EHV-1 DNA was detectable in the PBMCs of FI 2 till day 8 post-challenge at which 1 x 
105 cells gave a positive signal. The EHV-1 viraemia continued till day 17 and as many as 
5 x 105 cells at days 12 and 17 contained at least one amplifiable copy of EHV-1 genome. 
An almost similar course of infection was observed in another EHV-4:EHV-1-infected 
foal (FI4). EHV-1 viraemia was observed at days 5, 8, 12 and 17 p.i. At the peak of 
infection at day 5, a positive signal was observed with PCR products from 5 x 10  ^PBMCs 
and higher cell numbers. The infection subsided gradually and by day 17 EHV-l-specific 
DNA could be amplified from 1 x 106 cells. The viruses were not detectable thereafter till 
dexamethasone treatment. The failure to detect EHV-4 DNA on days 12, 17 and 26 post 
EHV-1 challenge is not fully clear. It seems logical to assume that, during EHV-1 
viraemia, the relative proportion of the cells harbouring latent EHV-4 would be fairly low 
and hence may not be detectable within the limits of sensitivity of the present study. It is 
also possible that the primers would bind readily to those targets which are present in large
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excess, particularly during the first few cycles. The reaction products of these cycles 
would act as targets for further amplification. Alternatively, the rarer target may not be 
amplified at all, or its amplification may lead to undetectable levels of DNA in the sample. 
Another possibility is that EHV-4 may be reactivated by superinfection with EHV-1, 
leading to partied expression of EHV-4 antigens on the surface of cells harbouring EHV-4. 
Such cells may be eliminated by the host immune response, as the two viruses share 
extensive crossreactive antigens. However, both EHV-1 and EHV-4 had persisted in the 
bodies of the foals as evidenced by the detection of EHV-1 and EHV-4-specific DNA 
sequences in the PBMCs of these foals following immunosuppression with 
dexamethasone.
A discordance has been observed between the PCR analysis of nasal swab samples and 
recovery of the virus from nasopharyngeal aspirates of foals F I2 and F14 following 
challenge with EHV-1. The viral DNA was detectable by PCR in the nasal swab sample 
of F14 at day 5 post-challenge which correlated to its detection in the PBMCS. However, 
the virus was not recovered from the corresponding aspirate sample of F12. Conversely, 
virus was recovered from the aspirate samples of this foal on days 8 and 17 post-challenge 
but the viral DNA was not detectable by PCR on the corresponding swab samples. The 
aliquots of nasopharyngeal aspirates from EHV-4:EHV-1 challenged foals FI 2 and F14 as 
utilized for virus isolation were also analysed by PCR. Their analysis revealed the 
presence of EHV-1 DNA in the aspirate samples of both the foals on all days following 
challenge. It may be emphasised that the aspirated samples were handled in the laboratory 
where isolation of EHV-1 and EHV-4 and research work on these viruses were being 
carried out routinely. Rigorous protocols to prevent contamination from exogenous 
sources of DNA and to avoid cross-contamination among nasal secretions and blood 
samples were not possible in this instance. The results of analysis of such samples by PCR 
is, therefore, difficult to authenticate. It appears from the analysis of nasal swab samples 
and samples of PBMCs that, following challenge of EHV-4 infected foals with EHV-1,
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there is limited replication of the latter virus in the nasal epithelium, perhaps because of 
local mucosal immunity. The onset of EHV-1 viraemia is therefore delayed. Despite 
EHV-1 viraemia, the nasal excretion of the virus is significantly reduced. These findings 
are consistent with the hypothesis that infection with EHV-4 affords protection against 
EHV-1. It would be interesting to investigate the interaction of the two viruses if the 
challenge pattern is reversed. The slow onset of viraemia and its quick disappearance 
could be related to partial protection against EHV-1 challenge afforded by the earlier 
EHV-4 infection.
In their studies, Edington and Bridges (1990), observed one way protection between EHV- 
1 and EHV-4 when two groups each comprising six sibling ponies were sequentially 
infected with EHV-1 or EHV-4. Two sequential infection with EHV-1, five months apart, 
resulted in complete protection against heterologous challenge 4 months later. On the 
other hand, two exposures of EHV-4 at 5 month interval did not significantly reduce nasal 
excretion of the virus or pyrexia when challenged with EHV-1 four months later. All the 
ponies in the latter group had pyrexia and some exhibited symptoms like coughing and 
nasal discharge. A biphasic pattern of virus excretion and viraemia was observed in this 
group. The mean nasal excretion of the virus was recorded as 5.2 ± 1.1 days and mean 
duration of viraemia as 2.3 ±0.5 days.
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CHAPTER 6 
GENERAL DISCUSSION
6.0 GENERAL DISCUSSION
EHV-1 and EHV-4 infections are major challenges to the horse breeding industry 
throughout the world. The respiratory disease caused by both these viruses is responsible 
for poor performance of the horses on race tracks. The loss of foeti due to abortions 
induced by these agents, neonatal foal mortality and deaths due to EHV-1 induced 
neurological disease cause heavy economic losses. The major problems encountered in the 
prevention and control of EHV-1 and EHV-4 infections are: the lack of sensitive 
diagnostic tools for rapid detection of these pathogens in the productive and latent 
infections of horses, incomplete understanding of the pathogenesis and epidemiology of 
these viral infections and of protective immune mechanisms. Besides, the immunity to 
natural infection and to vaccination with the currently available vaccines is transient and 
the horses can be re-infected within 3-6 months of the previous exposure.
In the routine diagnosis of EHV-1 and EHV-4, the conventional method of virus isolation 
is the 'gold standard'. The outcome of the isolation of the virus in cell culture depends 
upon the presence of live infectious virus in the clinical specimens. The loss of infectivity 
during transport and contamination of the samples with other micro-organisms may render 
them unsuitable for recovery of the virus in cell culture. Further, the identity of the viral 
isolate is established using other techniques such as immunofluresence. The whole 
procedure may take several weeks to achieve a diagnosis. Histopathology can be useful to 
aid the diagnosis. The demonstration of acidophilic intranuclear inclusion bodies may be 
suggestive of herpesvirus infection.
Election microscopy can be a useful rapid diagnostic aid but it is time consuming and is 
not practical for analysis of a large number of specimens. Also, the final identity of the 
virus is established by additional procedure. The equipments and expertise are not 
available in most of the diagnostic laboratories.
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DNA fingerprinting technique has been used to differentiate between field isolates of 
EHV-1 and EHV-4. In fact, this technique initially led to differentiation of these viruses 
as separate entities (Studdert et al. , 1981; Sabine et al., 1981; Turtinen et al. , 1981). This 
technique is also time-consuming, requires specialised equipments and expertise. 
Therefore, it cannot be used for rapid routine diagnosis.
Pools of EHV-1 and EHV-4 specific monoclonal antibodies in enzyme immunofiltration 
and indirect immunofluorescence assays have been used to type field isolates within 3 h 
after isolation (Yeargan et al., 1985).
Fluorescent antibody technique has been used for direct detection of EHV-1 antigens in 
frozen foetal tissue sections (Platt et al., 1980). The technique has limitations in that the 
fluorescent signal is transient and there is need for fluorescent microscopy. For urgent 
screening of the aborted foeti, an indirect immunoperoxidase method has recently been 
developed (Whitewell et a l, 1992). This method is suitable for both paraffin-embedded 
and frozen sections. An antigen capture ELISA to detect EHV-1 antigens in nasal swab 
specimens has also been described (Sinclair and Mumford, 1992). Although all these 
methods are used for direct detection of viral antigens in the clinical samples, they are less 
sensitive than the virus isolation.
Several serological assays have been developed to diagnose EHV-1 and EHV-4 infections 
viz complement fixation (Thomson et al., 1976), virus neutralisation (Doll and Bryans, 
1962), ELISA (Dutta et al., 1983; Stokes et al., 1991a), radial immunodiffusion enzyme 
assay (Gradil and Joo, 1988). The serodiagnosis is less dependable, requires paired serum 
samples and is achieved when the samples are analysed by more than one assay.
With advancements in molecular biology, molecular approaches have been followed to 
detect the nucleic acid sequences in the clinical specimens. One such method, nucleic acid
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hybridisation is based on hybridisation of labelled nucleic acid probes to the specific DNA 
sequences present in the samples. This method is thus, specific and can be used to detect 
both infectious and non-infectious virus. Based on this approach, Belak and Linne (1988) 
developed a rapid method to detect DNA sequences of pseudorabies virus in the nasal and 
tonsilar specimens from experimentally and naturally infected pigs by filter hybridisation 
using a cloned fragment of PRV DNA as a probe. On similar lines, Morris and Field
(1988) described Southern and dot blot hybridisation methods to detect EHV-1 DNA in 
the tissue specimens of foeti aborted due to EHV-1 infection using a fragment of EHV-1 
DNA cloned into a plasmid vector as probe. Both the methods though specific, are one 
order of magnitude less sensitive than virus isolation and immunofluorescent staining. The 
dot blot method has the potential for rapid diagnostic test. Chowdhury et al. (1986b) also 
described a method based on blot hybridisation for rapid identification and screening of 
field isolates of EHV-1. The procedure involves the digestion of the viral DNA extracted 
from the infected small scale cell cultures with Bam HI and identification of the restriction 
fragments by Southern hybridisation with ^ -lab e lled  reference EHV-1 DNA as probe. 
This technique is sensitive and can detect viral DNA in field isolates having a titre of 104- 
105 pfu/ml prior to adaptation in cell culture and is relatively economical. The nucleic acid 
hybridisation methods are labour-intensive and require specialised equipment and 
expertise.
The recently developed polymerase chain reaction (PCR) technique (Saiki et al., 1985; 
Mullis and Faloona, 1987) has been widely applied for detection of human and animal 
pathogens. By this technique, the target DNA in the sample can be amplified a million 
folds within a few hours (Saiki et al., 1988). The specificity of the amplified DNA is 
confirmed by hybridisation with specific labelled DNA probes and alternatively by 
restriction fragment length polymorphism (RFLP) analysis in some instances. The method 
is thus rapid, extremely sensitive and utilises minute amount of the crude clinical sample.
145
The work presented in this thesis has been focused mainly at developing polymerase chain 
reaction assay to diagnose and differentiate between EHV-1 and EHV-4 infections and to 
study the pathogenesis of these infections in specific-pathogen-free foals which were 
infected experimentally with these viruses.
The sequence data on EHV-4 generated by the department of Veterinary Pathology, 
Glasgow (Nicolson and Onions, 1990; Nicolson et al., 1990 a,b) has been utilised to 
design type-common primers such that both EHV-1 and EHV-4 specific DNA sequences 
in the sample could be amplified in a single reaction using a single primer-pair. The data 
was also used to select EHV-4 specific oligonucleotide probe sequence. The sequence 
data on EHV-1 (Robertson and Whalley, 1988; Allen and Coogle, 1988) was utilised to 
select EHV-1 specific probe sequence and for comparative analysis. The reaction 
conditions for PCR were optimised using cell culture supernatants obtained from EHV-1 
and EHV-4 infected cell cultures and recombinant plasmid containing EHV-1 or EHV-4 
DNA fragment as targets for amplification and using primers derived from TK, gH and 
gC gene as described in Chapter 3.
The comparative analysis of nasal swab samples obtained from suspected EHV-1 or EHV- 
4 field cases and their in-contacts by virus isolation and PCR revealed a good correlation 
between the two techniques and increased sensitivity of PCR over virus isolation as 
discussed in Chapter 4. Ballagi-Pordany and co-workers (1990) in Sweden have also 
observed a good concordance between the two techniques while analysing aborted foetal 
tissue samples. Inconsistent amplification observed in some instances in the present study 
may be attributable to stochastic effects, a 20 pi aliquot used in the PCR assay may not 
contain a single copy of amplifiable DNA molecules particularly when the amount of virus 
present in the sample is very low. Multiple aliquots of a sample may therefore be 
examined before declaring it negative. Although the PCR technique is rapid, its sensitivity 
makes it prone to false positives. The amplified products of the previous run may
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contaminate the samples in the next or following run, producing false positive results. 
Cross-contamination among samples during collection, processing and preparation can not 
be ruled out as yet another possibility. Rigorous precautions are required to avoid false 
positives; the pre-amplification and post-amplification stages have to be physically 
separated. In the present study, different laboratories were designated for different 
activities, e.g. reagent preparation and storage, sample preparation, addition of first round 
PCR product to reaction mixture containing the internal set of primers in the nested PCR 
assay, analysis of the reaction products. Colour-coded, positive displacement pipettes 
dedicated for different activities were used. Gloves were changed between samples and 
were always put on while entering the storage area. Protective clothing was used and other 
precautions as described by Jarret et a l (1990) in this department and Kwok and Higuchi
(1989) have been followed to prevent contamination. Other anti-contamination strategies 
have also been described. One of these to prevent PCR carry-over products utilises the use 
of dUTP instead of d’lTP in the reaction mixture and pre-treating all subsequent PCR 
reactions mixtures with an enzyme, uracil N-glycosylase (UNG) prior to amplification. 
Products from the previous amplfications are eliminated as the existing uracil residues are 
excised by UNG (Erlich et a l , 1991). The resulting abasic polynucleotide is degraded by 
heat treatment. The amplification process catalysed by Ampli-Taq remains unaffected by 
this process and the resulting PCR products are free of PCR product carry over.
It is evident from the aforesaid, that PCR technique can not be introduced for routine 
diagnosis in an ill-equipped laboratory as it requires extreme care and caution to achieve 
accurate diagnosis . In the present study, y32P-labelled oligonucleotide probes have been 
used to ascertain the specificity of the PCR products. Non-radioisotopic methods can be 
developed in order to introduce this technique in routine diagnosis and for mass screening 
of samples. Ballagi-Pordany et a l (1990) describe the use of biotion-labelled 
oligonucleotide probe to detect EHV-1 specific DNA sequences in the tissues of aborted 
foeti. Colorimetric tests have now been developed to analyse PCR amplified products.
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One such method known as amplified DNA assay (ADA) has been employed to detect 
HIV sequences in samples obtained from AIDS patients (Kemp et al., 1989). The method 
utilizes a nested PCR by which the target DNA is first amplified using one set of primers. 
The second set of oligonucleotides nested between the first set, is incorporated by three or 
more PCR cycles. These oligonucleotides bear legends e.g. one can be biotinylated and the 
other can contain a site for DNA-binding protein GCN-4 expressed as glutathione-S- 
transferase GCN-4 polypeptide in E. coli. This protein is coated onto the wells of a 
microtitre dish. The amplified DNA labelled with avidin-peroxidase can then be detected 
colorimetrically using chromogenic substrate. This procedure has been further simplified. 
Precisely, the DNA is bound to glutathione S-transferase-GCN4 fused polypeptide and 
avidin-peroxidase simultaneously. The DNA amplfied in the wells of a microtitre dish is 
captured and detected via GST-GCN4 immobilized on beads attached to the lid of 
micotitre dish (Kemp et al., 1990).
Alternatively, the oligonucleotide probes may be labelled with acridinium ester (Arnold et 
al., 1989), digoxygenin (Martin et al., 1990) and flurorescent dyes (Chehab et al., 1989) 
and alkaline phosphatase (Wages et al., 1993).
The PCR technique has been introduced as a routine diagnostic procedure in Sweden to 
detect many animal viruses (Belak and Ballagi-Pordany, 1993) and it has been concluded 
that the PCR diagnosis is economical as compared to virus isolation and can serve as good 
compliment to virus isolation.
The PCR method as routine diagnostic test can particularly be useful in determining mixed 
infections of EHV-1 and EHV-4. Such infections are difficult to detect by virus isolation 
and other routine procedures. This can be achieved by designing virus specific primers as 
well as probes. The primers may be derived from the most divergent regions of the same 
gene. Recently, Kirisawa et al. (1993a) described the use of type-specific and type-
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common primers in a one-step reaction to amplify EHV-1 and EHV-4 specific DNA 
sequences from a mixture of EHV-1 and EHV-4 DNAs. The amplified products were 
distinguishable by the expected fragment sizes.
Studies on the pathogenesis of experimental EHV-1 and EHV-4 infections in SPF foals 
and the effect of homologous and heterologous (EHV-4: EHV-1) challenge are described 
in Chapter 5. Following primary infection with either virus, the foals exhibited classical 
signs of EHV-1 and EHV-4-induced respiratory disease. EHV-4 caused a milder disease. 
The earlier studies on pathogenesis of EHV-4 infections suggest that they are confined to 
respiratory tract and draining lymph nodes (Allen and Bryans, 1986), the virus can also 
infect alveolar macrophages (Patel and Edington, 1983) and that the infection does not 
progress any further.
The present study provides definitive evidence that EHV-4 is capable of infecting 
peripheral blood mononuclear cells (PBMCs) and causes cell-associated viraemia as 
demonstrated by the detection of EHV-4 specific DNA sequences in the PBMCs of 
infected foals by PCR. The infectious virus was however, not demonstrable by co­
cultivation of the blood leucocytes with permissive cells which may be due to the low 
sensitivity of this procedure. EHV-4 may be transported to the uterus via infected 
leucocytes to induce abortion as is thought to be one of the mechanisms for transportation 
of EHV-1. Endothelial cell tropism of EHV-1 in maternal endometrium, placenta and 
foetus (Edington et al. , 1991; Smith et al., 1992) and in central nervous system (Edington 
et al., 1986) has been shown to be central in the pathogenesis of abortion and neurological 
disease. Such tropism for EHV-4 also needs investigation in light of the present findings.
The study also provides a definitive evidence of establishment of EHV-4 latency in 
PBMCs of the infected foals. The EHV-4 specific DNA sequences were detectable in the 
PBMCs of infected foals by PCR 82 days after primary infection or two days prior to
challange with EHV-1. The virus persisted in the PBMCs of the host foals as the viral 
DNA was detectable up to 5 days after EHV-1 challenge and not thereafter. The latter 
observation is particularly interesting in that there is a possibility that some of the 
persisting EHV-4 may be reactivated by EHV-1 which is then cleared by the immune 
system. However, the virus persisted further as demonstrated by the detection of EHV-4 
specific DNA sequences in the PBMCs of the foals following dexamethasone treatment. 
EHV-1 specific DNA sequences were also detected in the PBMCs of these foals following 
such treatment providing the evidence for establishment of latent state by these viruses. In 
fact, use of high levels of corticosteroids has been an approach in the recent past to obtain 
evidence for EHV-1 and EHV-4 latency (Edington et al. , 1985; Browning et al. , 1988b).
The heterologous (EHV-4:EHV-1) challenge studies revealed that EHV-4 afforded partial 
protection against EHV-1. A slow onset of EHV-1 viraemia with relatively lower 
proportion of PBMCs infected with the virus was observed in heterologously challenged 
foals. Edington and Bridges (1990) found a slight reduction in nasal excretion of the virus 
and pyrexia in ponies which received two sequential infections with EHV-4 five months 
apart and a challenge with EHV-1 four months later. However, they observed a complete 
protection when the infection pattern was reversed. Based on these observations, the use of 
monovalent EHV-1 vaccine has been suggested to cover against EHV-1 and EHV-4. 
Contrary to the observations made by Edington and coworker, two sequential infections 
with EHV-1 eighteen days apart failed to protect ponies when challenged 147 days later 
with EHV-4 (Stokes et al., 1991). A two-way cross-protection has however, been 
demonstrated by Allen and Bryans (1986) in foals which were given two consecutive 
exposures of the virus at six-month interval on challenge with heterologous virus four 
weeks later. A very little cross-protection was however, observed when foals were 
challenged after a single exposure.
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Full protection was observed in foals that received homologous EHV-1 challenge. Viral 
DNA was not detected in the PBMCs of the infected foals 82 days after primary EHV-1 
infection i.e. at two days prior to second infection as well as upon reactivation following 
dexamethasone treatment. Two possibilities exist to explain this situation: first, the virus 
might have been completely eliminated by host defences and second, the proportion of 
latently infected PBMCs might be very low and hence, undetectable at the present level of 
detection. The latter possibility can be investigated by performing PCR on DNA extracted 
from the PBMCs of the infected foals collected at necropsy.
The studies can be further extended to identify the type(s) of PBMCs harbouring the latent 
virus by performing PCR on different cell-types sorted by FACS. Also, the tissues 
collected from the SPF foals at termination of the experiment can be investigated for sites 
of latency. The precise identification of cell-type harbouring latent EHV-1 and/or EHV-4 
can be accomplished by conducting in situ PCR on tissue specimens. New conclusions 
about the sites of latency of EHV-1 and EHV-4 can thus be obtained particularly for 
investigation of paralytic syndrome caused by EHV-1. The earlier studies relied on the 
isolation of the virus by co-cultivation of nervous tissue to demonstrate EHV-1 latency. 
The failure to isolate infectious virus from the nervous tissue negated it as a probable site 
of latency. A single study to demonstrate EHV-1 latency in experimentally infected 
ponies using PCR and co-cultivation studies on peripheral blood leucocytes, lymphoid 
tissues and ganglia of V cranial nerve collected from the ponies ten weeks after primary 
infection suggests that PBLs and the lymphoreticular tissues are the sites of latency (Welch 
et al., 1992). These workers detected the presence of EHV-1 specific DNA sequences in 
the ganglia of one pony by PCR but failed to recover the virus by co-cultivation of the 
ganglionic explants with permissive cells. They also obtained similar results while 
analysing nervous tissues from naturally infected horses. One argument that has been put 
forward for such detection is that the nervous tissue might be contaminated by blood. The 
establishment of latent state in ganglia is thought to be yet another possibility. However,
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these workers could not recover infectious virus in cell culture on co-cultivation of the 
explant. This finding cannot completely rule out the possibility of viral latency in the 
nervous tissue since the cocultivation procedure may be less sensitive. This aspect 
therefore, merits further investigation. In situ PCR technique may be useful in resolving 
this problem.
The PCR assay described in this thesis has another practical application in that it can be 
employed to determine the proportion of latently infected horses in a population 
particularly Thoroughbreds. A survey of EHV-1 latency in pregnant mares might be 
useful in determining whether the abortion is induced by recredescence of latent virus or is 
the result of a recent infection. It would also be useful in determinig whether risk or carrier 
animals exist in a population. A single study conducted on tissue specimens obtained from 
abattoir horses suggest that the prevalence rate of EHV-1 and EHV-4 latency is very high 
as 87% (Edington et al., 1993).
The studies on molecular mechanisms governing establishment, maintenance and 
reactivation of important alphaherpesviruses are under way (Section 1.6) which would 
provide useful information for designing control strategies. Such studies on EHV-1 and 
EHV-4 latency can be pursued using suiable small animal models. Field et a l (1992) have 
conducted some reactivation studies in mouse model using stimuli such as X-irradiation 
and corticosteroid treatment. Following such treatments, they were able to recover 
reactivated virus from peripheral blood leucocytes and respiratory tract of some of the 
infected mice. The mouse model has many features common to the natural EHV-1 
infection (Awan et al., 1990, 91). In acutely infected mice, the virus replicates in the 
respiratory tract and causes cell-associated viraemia. The inoculation of the pregnant mice 
with the virus results in premature birth of a dead or abnormal offspring.
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PCR together with RFLP analysis has recently been applied to study the epidemiology of 
circulating field stains of PRV. Banks (1993) developed a PCR method to discriminate 
between the established strains and a new strain of PRV that was introduced in 1981. The 
new strain had a different DNA restriction pattern with Bam HI. The method utilises the 
use of primers that were derived from the region bracketting a novel Bam HI restriction 
site. The viral genotype was identified by RFLP analysis of PCR products digested with 
the Bam HI. With this study, it was possible to trace the spread of new virus type which 
was found responsible for 65% of the outbreaks in England and Wales during 1982 by 
relating the results to pig movement records. As more information on RFLP analysis of 
neurovirulent, abortigenic and respiratory field strains of EHV-1 and EHV-4 or on 
markers of their virulence become available such approach might prove useful for 
differentiating them.
For control of EHV-1 and EHV-4 infections, both inactivated or live modified virus 
vaccines have been developed to vaccinate horses (Campell and Studdert, 1983). In 
general, the killed vaccines require repeated administration to achieve effective levels of 
protective immunity, the important epitopes may be lost during inactivation process, and 
these vaccines are generally unable to induce cytotoxic T cells (Monaco, 1992). Although 
live attenuated vaccines are better inducers of protective immunity, they suffer from 
several drawbacks: they may cause clinical disease if not attenuated properly or their over­
attenuation may lead to their inability to generate immunity in the host. The major 
concern in the use of live vaccines has been that there is a possibility of reversion of 
vaccine strains to virulent phenotype with potential to cause clinical disease. In fact, some 
of the abortion outbreaks in the field are thought to be consequence of live-attenuated 
vaccines.
The commercial inactivated vaccine, Pneumabort K (Fort-Dodge, Iowa, U.S.A.) has been 
used extensively to vaccinate mares in Kentucky (Allen and Bryans, 1986). With
introduction of this vaccine, the abortion rate dropped to less than 0.2 percent in 1987 as 
against 0.74 percent prior to introduction of vaccination in 1977. These figures suggest 
that widespread vaccination over a prolonged period can reduce the abortion rate. This 
vaccine is also in use in U.K to vaccinate Thoroughbreds. Under experimental conditions 
and during field trials, abortions have been observed in mares despite vaccination with 
Pneumabort K on challenge with virulent EHV-1 (Burrows et al., 1984; Burki et al., 
1990,91) or with EHV-4 (Mumford and Bates, 1984). Burki et al. (1990) observed higher 
serum neutralizing antibody titres induced by the Pneumabort K than those induced by 
vaccination with the live vaccine, Pre-vaccinol. Both these vaccines, however, did not 
prevent disease. The vaccinated and control groups developed viraemia, five out of ten in­
foal mares aborted following virulent challenge. The use of Pneumabort K vaccine to 
immunize adult horses has been abandoned in Austria as the vaccine caused severe local 
side reactions after repeated vaccinations with this vaccine (Burki et al., 1991).
Sub unit vaccines although safe, are costly and poorly immunogenic. Vaccinia virus 
recombinants expressing EHV-1 gB and gC glycoproteins have been shown to induce 
protective immunity in hamsters (Guo et a l, 1989; 90). These glycoproteins are potential 
candidates for vaccine development.
Thymidine kinase negative (TK") mutants of various herpesviruses have been produced by 
selective use of mutagenic agents. EHV-1 has been used to vaccinate horses. Comick et 
al. (1990) developed such mutant by serially passaging the vero-cell adapted TK+ EHV-1 
strain RQ in media that contained ara T (l-(3-D arabinofuranosyl thymine) and 
bromodeoxyuridine. The vaccine was safe when administered by either intramuscular or 
intravenous route. Nasal shedding of the virus was not observed for 12 days after 
inoculation and the vaccinees had significant antibody titres in their sera. HSV mutants 
produced in a similar manner are less virulent and are capable of establishing latency in 
mice (Klein, 1982). The TK' mutant of infectious bovine rhinopneumonitis (IBR) virus
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prevented respiratory disease in pregnant cows when challenged with virulent IBR virus 
strain (Kit et al., 1986). A temperature sensitive and TK' strain of PRV is highly 
immunogenic in pigs and prevents clinical signs of pseudorabies, reduces the amount the 
virus and duration of its excretion following challenge exposure (Shibata et al., 1992).
A hepesvirus 1247 isolated from an aborted bovine foetus has been used to vaccinate 
pregnant pony mares (Crandell et al., 1980). Following vaccination, the mares did not 
exhibit adverse clinical signs and the virus was not recovered from nasal swabs for two 
weeks. Full-term healthy foals were delivered by four mares and the dead foal delivered 
by the fifth did not have a viral etiology. The mares developed 13-250 fold increase in 
serum neutralizing antibody titres.
The preparations of Immune stimulating complexes (ISCOM) that contained major 
glycoproteins of EHV-1 induced neutralizing antibodies in hamsters and protected them 
against a lethal challenge (Cook et a l, 1990). These preparations have been further 
evaluated in horses. They induced serum neutralizing antibodies to glycoproteins gp 10, 
13, 14, 17, 18, 21/22 which persists for 14 weeks (Hannant et al., 1993). Although a 
significant reduction in clinical signs, cell-associated viraemia and nasal exretion of the 
virus was observed in vaccinated horses, they did not fully resist the challenge with a 
homologous strain of EHV-1.
Recent studies with mutants of PRV have demonstrated that it is possible to develop a 
nonspreading live herpesvirus vaccine (Heffner et al., 1993). The glycoprotein gp 50 of 
PRV which is gD homologue of HSV-1 is essential for entry of the virus into target cells 
and is dispensable for direct cell-to-cell spread in cell culture. Heffner and co-workers 
(1993) infected mice by intranasal inoculation of gp 50' or gpll" mutants of PRV after 
prior phenotypic complementation by propagation on cell lines providing essential 
glycoproteins in trans. The mutant lacking gpll, which is gB homologue of HSV did not
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cause any disease or symptoms whereas gp50" mutants derived from two different PRV 
stains were fully virulent leading to death of mice. Free infectious virus was however, not 
recovered from either gp50" or gpll" PRV infected animals. It was inferred from these 
studies that direct cell-to -cell spread of gp50" mutants of PRV is sufficient for full 
virulent phenotype. After infection of pigs with phenotypically complemented gp50" 
PRV, mild symptoms were produced in the infected animals whereas gpll" mutant was 
totally avirulent. On challenge with a highly virulent strain of PRV, gpll" PRV infected 
pigs exhibited severe symptoms whereas gp50" PRV infected animals exhibited significant 
protection. The gp50" mutant of PRV which is incapable of forming infectious virus can 
thus confer on pigs protection against challenge and forms a basis of nonspreading live 
herpesvirus vaccine.
A new approach in vaccine methodology has recently been developed in which the genes 
encoding protective antigens can be directly injected into tissues of the host. Potential for 
such DNA injection has been demonstrated for influenza in a mouse model (Ulmer et al. , 
1993). This approach has recently been adopted by Cox and coworkers (1993) in which 
mice were injected with plasmids encoding glycproteins gl, gill and gIV of BHV-1 and 
calves with the plasmid containing gIV. Specific neutralising antibody responses to these 
glycoptoteins were observed in these studies. The vaccinated calves shed less virus than 
did the control unvaccinated calf following challenge with virulent BHV-1.
The current strategy for the development of genetically engineered effective vaccines 
against EHV-1 and EHV-4 are based on the generation of deletion mutants that lack one or 
more genes which are involved in virulence and or viral pathogenesis. Selection of such 
genes for deletion is based on studies with other herpes viruses. Ribonucleotide reductase 
(RR) and thymidine kinase (TK) are two candidate genes for deletion. RR catalyses the 
reduction of ribonucleotides to deoxyribonucleotides and is essential for DNA synthesis in 
prokaryotic and eukaryotic cells (Erikson and Sjoberg, 1989). Like other herpesviruses
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viz. HSV, VZV and PRV, EHV-1 also induces RR activity in the infected cells (Cohen et 
al., 1977b; Telford et al., 1990). The ribonucleotide reductase activity of HSV is essential 
for pathogenicity in mice (Cameron et al., 1988). EHV-1 also induces virus-specific TK in 
the infected cell during lytic phase (Allen et al., 1978). This enzyme is operative in 
salvage pathway of pyrimidine biosynthesis (Kit, 1985). TK' herpesviruses are less 
nurovirulent than TK+ herpesviruses because of their reduced capacity to replicate in 
resting cells in vitro (K it, 1985).
The strategy for development of TK' or RR* mutants involves the cloning of TK or RR 
genes of EHV-1 or EHV-4 into plasmid vector which is then rendered non-functionnal by 
deleting part of the cloned gene, the plasmid containing the target gene is then incubated 
with viral DNA and used for transfection of equine cells. Some of the DNA gets inside the 
cells and the recombination between the viral DNA and plasmid DNA occurs such that 
some of the virions released from the cells into the culture contain genomes without 
functional gene.
Glycoprotein and other genes that are involved in virulence or pathogenesis are also target 
for deletion. Although the latter have not yet been identified in case of EHV-1 and EHV-4, 
deletion mutants lacking such genes of other herpesviruses have been characterised and 
evaluated. PRV mutants that functionally lacked one of the non-essential genes in the 
unique short region of the geneome revealed that gl contributes to virulence by facilitating 
the spread of the virus through nervous system (Kimman et a l,  1992). The gl and gX 
mutants confered on pigs complete protection against virulent challenge whereas 
incomplete protection was observed when pigs were inoculated with gp63 and protein 
kinase mutants.
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The studies on determination of markers that would permit differentiation of live virus 
vaccine and the field viral isolates would be of great importance from epidemiological 
point of view. Meyer et al. (1992) have described a rapid method for such differentiation 
between the field isolates of EHV-1 and the vaccine strain Rac-H. The method utilizes the 
hyridisation of a digoxigenin-labelled DNA probe derived fromt he inverted repeat region 
of EHV-1 genome and cloned into a plasmid vector to the Bam HI restriction fragments of 
field isolates as well as the vaccine strain. The probe hybridises specifically to the 
sequences of the inverted terminal repeat region which in the vaccine strain includes a 
deletion of 0.8 kb. The migration patterns after blot hybridisation are then compared to 
that of the vaccine strain.
The PCR technique will have its practical application in differentiating the field isolates 
from the genetically engineered live vaccines and to monitor the epidemiology of such 
vaccine strains. In such differential PCR technique, one primer pair can be designed from 
the deleted gene and the other from a gene present both in the vaccine and wild type or 
challenge virus strains. Such approach has recently been followed to differentiate cell 
culture propagated PRV strains from those present in latently infected neural tissues of 
mice and swine (Haesbe et a l , 1993).
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S um m ary
T he po lym erase  chain  reaction (PC R ) is a  sensitive technique 
used to detect DNA of viral pathogens. We have applied  the 
technique  to the  detection of E quid  h e rp esv iru se s-1 and  -4 
(EHV-1 and  EHV-4) DNA w ithin n aso p haryngeal sw ab 
sam ples from  horses. N inety-eight sam ples from  suspected 
field cases an d  in -contact horses w ere analysed . T he assays 
w ere conducted  b lind  and  later decoded and  com pared  w ith 
v irus isolation d a ta . O u r results ind ica te  th a t PC R  is a 
sensitive and  ra p id  technique for the d iagnosis of EHV-1 and  
EHV-4 infection.
In tro d u c tio n
EQUID herpesviruses 1 and 4 (EHV-1 and EHV-4), formerly 
known as Equid herpesvirus 1 subtypes 1 and 2 respectively, are 
alphaherpesviruses responsible for great economic losses within 
the horse breeding industry. EHV-1 is associated with abortion, 
respiratory disease and neurological disease. EHV-4 is primarily a 
causative agent of respiratory disease although occasional EHV-4 
induced abortions (Allen and Bryans 1986) and neurological 
disease have been reported (Meyer, Thein and Hubert 1987).
Diagnosis of EHV-l or EHV-4 infection in live animals is 
achieved by virus isolation from nasopharyngeal secretions and 
blood, or from foetal tissue in the case of abortions. Diagnosis by 
serological methods is less definitive and requires both acute and 
convalescent serum samples. Alternative diagnostic methods such 
as DNA fingerprinting in combination with Southern blot 
hybridisation and monoclonal antibody typing have been used for 
efficient screening of large numbers of field isolates (Yeargan, 
Allen and Bryans 1985; Chowdhury e t  a l  1986).
Like other members of the herpesvirus family, EHV-1 and 4 
may establish latent relationship within their equine host as 
reflected by co-cultivation (Scott. Dutta and Myrup 1983; Allen 
and Bryans 1986) and reactivation studies (Edington, Bridges and 
Huckle 1985; Browning e t  a l  1988). The shedding of virus by 
silently infected carrier animals with appropriate stimulation 
makes total disease eradication highly unlikely, diminishes the 
effectiveness of disease control by chemotherapy or 
immunotherapy and complicates the design for control of these 
infections by vaccination. Rapid and more sensitive tools are 
required for identifying carrier horses in an equine population.
In the present study, we describe the application of the 
polymerase chain reaction (PCR) technique to the detection of EHV- 
1 and EHV-4 DNA sequences in the nasopharyngeal secretions of 
clinically affected and asymptomatic in-contact horses.
Polymerase chain reaction is a method whereby specific DNA  
sequences are amplified using minute amounts of target DNA^as 
the template. Two oligonucleotide primers are selected sucff that
they flank the region of DNA to be amplified with one derived 
from the upper DNA strand and the other from the lower strand. 
The amplification process involves repeated cycles o f heat 
denaturation, annealing and DNA extension steps in which the 
oligonucleotides bind to target DNA and act as primers for DNA  
synthesis catalysed by thermostable DNA polymerase. 
Amplification o f a specific DNA sequence leads to a double 
stranded DNA band of defined size on electrophoresis of the PCR 
products. The specificity of amplification can be verified further 
by hybridisation of a probe derived from the target sequence to 
the reaction products (Fig 1). The use of nested primer sets 
increases the sensitivity and specificity of the amplification 
process.
Ballagi-Pordany, Klingebom, Flensburg and Belak (1990) 
applied PCR technique to the detection of EHV-1-specific DNA  
sequences in aborted foetuses employing primers derived from 
the EHV-1 gp 13 gene and found a good correlation between PCR 
and virus isolation.
In the present study, specific regions o f EHV-1 and EHV-4 
gene homologues of HSV-1 genes encoding thymidine kinase 
(TK) and glycoproteins gC and gH were amplified using primers 
derived from conserved regions of these genes (Allen and Coogle 
1988; Robertson and Whalley, 1988; Nicolson, Cullinane and 
Onions 1990a, b; Nicolson and Onions 1990). The amplified 
products were distinguished by type specific probes derived from 
the EHV-1 and EHV-4 gp l3  (gC) and gH genes. On completion 
of PCR analyses o f 98 nasopharyngeal swab samples, the samples 
were decoded and results compared with virus isolation data.
M ateria ls and  m ethods
S a m p l e s
Ninety-eight nasopharyngeal swab samples were collected from 
horses with suspected EHV-1- or EHV-4-induced respiratory or 
neurological disease and in-contact horses. In-contacts o f a mare 
that suffered EHV-1-induced abortion also were sampled. 
Seventy-nine horses were sampled, 10 of which were sampled at 
intervals. Nasal swab samples were collected in 5 ml transport 
medium (PBS supplemented with penicillin streptomycin, 
fungizone and 2 per cent foetal calf serum), sonicated and stored 
at -20°C. Virus isolation and serological analyses were performed 
by the Irish Equine Centre. Sample aliquots were transported, on 
ice, to the Glasgow Veterinary School. Aliquots (20 |il) o f each 
sample were stored at -70°C until required for PCR analysis.
V i r u s  i s o l a t i o n
Subconfiuent monolayers o f rabbit kidney cells (RK13: Flow 
Laboratories) and equine embryonic lung cells (EEL: Dr. J.
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TABLE 1: N ucleo tid e  s e q u e n c e s  of p rim e rs  a n d  p ro b e s  u se d
Left Right
gH Primers 
Outer se t
EHV-4 5’-AACGCGGAGATGGGCGTC-3' 
I 11 I I I I I I I II  I I I I I
1987-2004 5'-GACCGCTCAAACGTCCA-3' 
II  I I I I I I I 11 I I I I II
662-678
(Set 1) EHV-1 5'-AACGCCGAGATGGGCGTC-3' 2135-2152 5'-GACCGCTCAAACGTCCA-3' 2835-2851
gH Primers 
Inner set
EHV-4 5'-ACAACCGT ATCTA AAAAT-3' 
I I I I I I I I I I I I I I I I I
190-207 5'-TTATCCTGTCATACCTGGTT-3' 
I I 11 I I I I I II I I I I I I I I
343-362
(Set 2) EHV-1 5'-ACAACCGT ATCGAAAAAT-3' 2384-2401 5'-TTATCT TGTCATACCTGGTT-3' 2516-2535
gC Prim ers EHV-4 S'-AACCAGCGCACCCCATTTTC-S* 
I I I  I II I II II I I I  I I I  I I I 
5'-AACCAGCGCACCCCA I I I IC-3'
709-809 5'-ACGG TAACGCTGGTACTGTTA-3'1083-1103 
I I I I I I I I I I I I I I I I I I I II 
5'-ACGG TAACGCTGGTACTGTTA-3' 744-764EHV-1 454-473
gH Probes EHV-4-specific 5'-AACAAACAAAATTGCACTAT-3' 
EHV-1 -specific 5’-GCCACTCCGTCCTGGCG-3'
282-302
2459-2478
gC Probes EHV-4-specific 5'-CCGCACATTCTAGCGCGA-3’ 
EHV-1 -specific 5’-AACGGCAGAGAGGAAAA-3’
887-904
549-565
S equence  d a ta  and  num bering taken from Nicolson and O nions (1990) (gC primers); Nicolson e t al (1990a; EHV-4 gH outer, left) (1990b 
other EHV-4 gH primers), Allen and Coogle (1988) (EHV-1 gC) and  R obertson and Whalley (1988) (EHV-1 gH primers)
TABLE 2: R eac tio n  c o n d it io n s  u se d  in PCR re a c tio n s
D enaturation Annealing Extension
Temp. Time Temp. Time Temp. Time No. of
Primers (°C) (secs) (°C) (secs) (°C) (secs) Cycles
gC 94 10 50 10 72 30 35
Inner gH 94 10 50 10 72 30 35
N ested gH
i) O uter gH 94 10 50 10 72 40 20
ii) Inner gH 94 10 45 10 72 30 25
Mumford, Anim al Health Trust, Newmarket) were inoculated 
with nasal secretions and maintained in MEM supplem ented with 
non-essential am ino acids, 2 mM glutamine, 100 iu/ml penicillin, 
100 pg/m l streptomycin, and 2 per cent foetal ca lf serum. 
Sam ples were passaged for a minimum of two weeks and the 
cultures exam ined daily for cytopathic effects. Virus type was 
identified by im m unofluorescence with a pool o f  EHV-1 or EHV- 
4-specific m onoclonal antibodies (Yeargan e t  a l  1985) provided 
by Dr J. Mumford.
P o l y m e r a s e  c h a i n  r e a c t i o n
The methods o f  M ullis and Faloona (1987) and Saiki e t  a l  (1988) 
were follow ed with suitable m odification. The position o f primers 
and probes used in the study are presented in Table 1. Primer sets 
were derived from 1) the C-terminal coding region o f TK gene  
(upper strand) and from the gH gene (lower strand) (outer gH 
primers); 2) the gH gene (inner gH primers) and 3) the gp 13 (gC) 
gene (gC primers). Reactions with nested primer sets comprised  
first round amplification with outer gH primers (set 1. Fig. 1) and 
second round amplification with the inner gH primer set (set 2. 
Fig 1). Probes were derived from the gC and gH genes.
A 20 pi sample aliquot was steamed for 10 mins to disrupt cell 
membranes and denature virion proteins. PCR mix (30 pi) was 
added such that the reaction contained 50 pmol o f each primer, 
200 pM dNTP, 3 units o f  TSP-II (Cam bio) or 1.75 units o f 
Amplitaq (Cetus) enzym e and an appropriate reaction buffer with 
M gC U  at a final concentration o f 1.5 mM (gC and inner set o f gH 
primers) or 2.5 mM (outer pair o f nested gH primers). Thermal 
cycling was carried out in a H ybaid-intelligent heating block. 
Reaction conditions were optimised for each set o f  primers using 
EHV-1 strain AB1 (Meredith e t  a l  1989), provided by the Institute
o f Virology. G lasgow, and EHV-4 strain 1942 (Cullinane. Rixon 
and Davison 1988) as amplification targets. Reaction conditions 
are detailed in Table 2. Sam ples were analysed blind initially. 
After decoding the results, PCR-positive samples and other 
samples o f interest were further investigated.
P o l y m e r a s e  c h a i n  r e a c t i o n  q u a l i t y  c o n t r o l
As a consequence o f the sensitivity o f the PCR technique, 
contamination o f reaction m ixes or samples with previously 
amplified DNA can cause false positive results. Therefore, in this 
study, strict protocols (ours and those o f  Jarrett, Clark. Josephs 
and Onions 1990) were follow ed to avoid contamination. 
Synthesis and purification o f  oligonucleotide primers and 
preparation o f DNA-free reaction m ixes were performed outside 
the University. Within the Department separate laboratories were 
designated for 1) storage o f reagents and material for PCR; 2) 
aliquoting o f reaction m ixes. 3) preparation o f samples and 
m ixing o f boiled samples and reaction m ixes, 4) preparation o f 
second round amplification reactions (nested primer reactions 
only) and 5) addition o f  positive control virus and DNA to 
reaction m ixes and analysis o f  PCR am plified products. Positive 
displacement pipettes were used wherever possible and gloves 
were changed between sam ples. In each PCR experiment, 
appropriate negative controls and a DNA-free control or reagent 
control were always included.
P o l y a c r y l a m i d e  g e l  e l e c t r o p h o r e s i s  a n d  e l e c t r o h l o t t i n g
A sample (12 pi) o f the PCR product was loaded onto a 6 per cent 
polyacrylamide gel and electrophoresis carried out at a constant 
current o f  35 mA. The gel was stained with ethidium bromide and 
DN A bands visualised on an ultra violet transilluminator.
The gel was soaked in denaturation buffer pH 12 to 14 (0.5 M 
NaOH and 1.5 M N aC l) for 35 m ins follow ed by neutralisation 
for 35 mins with neutralisation buffer pH 8.0 (0.5 M Tris base. 3 
M N aC l, 0 .38 M HC1). Finally, it was immersed in lxTAE buffer 
for 15 mins. The DNA was electroblotted onto Hybond-N at 15V 
overnight. The membrane was washed with lxTAE. dried 
between filter pads and baked at 80°C for 2 h.
L a b e l l i n g  o f  o l i g o n u c l e o t i d e  p r o b e s
O ligonucleotides were labelled to high specific activity with 
crude gamma J2ATP (ICN) using T4 polynucleotide kinase in
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TABLE 4: D etails of EHV-1- and  EHV-4- Positive  sa m p le s  a s  
d iag n o sed  by PCR and /o r v irus iso lation
Sample
no. Horse
Virus isolation 
data
Nested
gH
PCR Data: 
Inner se t 
of gH g c
81588 A EHV-4 EHV-4 EHV-4 EHV-4
85324 B1 EHV-4 EHV-4 EHV-4 EHV-4
85325 B2 Negative EHV-43 EHV-4 EHV-4
85326 B3 Negative EHV-4 EHV-4 EHV-4
85327 B4 Negative EHV-4b EHV-4 EHV-4
85328 B5 EHV-4 EHV-4 EHV-4 EHV-4
85329 B6 Negative EHV-4 EHV-4 EHV-4
84615 C EHV-4 EHV-4 EHV-4 EHV-4C
87313 D1 EHV-4 EHV-4 EHV-4 EHV-4d
87319 D2 EHV-4 EHV-4 EHV-4 .  e
84747 E Negative EHV-1* - -
84916 E EHV-1 EHV-19 - -
Sam ples from cohorts are grouped and each  horse identified by a 
cohort-specific letter (A-E) and a  horse-specific num ber (within the 
cohort). a> bProcessed  four times with nested  gH, once with inner 
gH and twice with gC primers. Negative on one occasion with 
nested  gH, otherwise positive. cProcessed three times with nested 
gH. once with inner gH, and 3 times with gC primers. Negative on 
one occasion using gC primers, otherwise positive. dProcessed  as 
for 84615. Negative on two occasions using gC primers, otherwise 
positive. P ro c e s se d  as for 84615. Positive using gH primers; 
negative using gC primers. P ro c e sse d  six tim es with nested gH, 
twice with inner gH, and once with gC primers. Positive on one 
occasion only, using nested gH primers. ^P rocessed  five times with 
nested  gH once with inner gH, and once with gC primers. Positive 
on one occasion only, using nested gH primers
C o m p a r i s o n  o f  P C R  a n d  v i r u s  i s o l a t i o n  d a t a
The results of analysing the samples by PCR and virus isolation 
are shown in Table 3. Six cases o f EHV-4 and one o f EHV-1 
infection were diagnosed by virus isolation. All six EHV-4 - 
positive samples were PCR-positive and typed as EHV-4 (Table 
4). The EHV-1 virus isolation-positive sample, 84916, was PCR- 
positive (EHV-1) on only one occasion. Attempts to re-isolate 
virus from this sample in cell culture were unsuccessful.
Ten cases of EHV-4 infection and two o f EHV-1 infection 
were diagnosed by PCR. O f these, one EHV-l and four EHV-4 
samples were negative by virus isolation.
Two cases of inconsistent amplification o f EHV-1 DNA  
(84747, 84916) and five of EHV-4 DNA (85325, 85327, 84615, 
87313, 87319) occurred (Table 4).
D iscussion
In this study PCR was applied to the detection o f EHV-1 and EHV-4 
DNA in 98 nasopharyngeal swab samples, which had been defined 
previously as negative, EHV-1- positive, or EHV-4 positive by virus 
isolation followed by immunofluorescence with EHV-1 - or EHV-4- 
specific antisera. Primers were selected from conserved regions of 
EHV-1 and EHV-4 DNA. To distinguish amplified EHV-l and 
EHV-4 DNA, oligonucleotide sequences selected from divergent 
regions o f the genomes were used as hybridisation probes. These 
probes hybridised specifically to either EHV-1 or EHV-4 DNA  
amplified in positive control (A B 1 or 1942) or field samples.
Ninety-three of the 98 samples were diagnosed identically by 
PCR and virus isolation. Therefore, there was a general 
concordance between the PCR and virus isolation data. The five 
other samples comprised five virus isolation-negative/PCR-
positive cases.
O f 91 samples defined as EHV-1- or -4-negative by virus 
isolation, 86 were negative, four typed as EHV-4 and one typed as 
EHV-1 by PCR. The four PCR-positive samples, virus isolation- 
negative for EHV-4 DNA. 85325. 85326, 85327 and 85329, were 
taken from horses housed in the same yard as two horses 
identified as EHV-4-positive by both virus isolation and PCR 
(samples 85324 and 85328). All horses in G ro u p  B exhibited 
clinical signs o f upper respiratory tract disease. This result is 
encouraging in that it indicates increased sensitivity o f PCR over 
virus isolation as a diagnostic tool. The additional EHV-1-positive 
sample, 84747, is discussed below.
Analysis o f samples from H orse E proved particularly 
interesting. Sample 84747, taken after seroconversion o f the horse, 
was virus isolation negative. Yet we detected EHV-1 DNA in one 
sample aliquot by PCR. This suggests that EHV-1 infection was in 
progress but that insufficient infective virus was present in the 
sample to produce a cytopathic effect within 2 weeks in tissue 
culture. As for the G ro u p  B horse cases this is indicative o f the 
greater diagnostic potential of PCR. A sample taken 19 days later, 
84916, was EHV-1-positive by virus isolation and one aliquot was 
PCR-positive. Re-isolation of this virus in cell culture was 
unsuccessful. There are two possible explanations for this situation. 
The amount of viral DNA might be so low that DNA was present in 
only one PCR sample aliquot: whereas 20 pi o f sample is used per 
PCR reaction, 500-fj.l is used for virus isolation. Alternatively, it is 
possible that the EHV-1 strain involved, a paralytic isolate, may 
possess sequence variation across the primer sites. This option 
could be investigated by cloning and sequencing o f amplified DNA.
Sample 87319, which proved positive by PCR with inner and 
nested sets o f gH primers, could not be amplified with gC 
primers. Samples from a cohort, (H orse  D l; sample 87313), and 
from H o rse  C (sample 84615) were EHV-4-positive by virus 
isolation and by PCR using gH primer sets. However, 
amplification using gC primers was inconsistent. These results 
suggest H o rses C, D l and D2 were infected by an EHV-4 strain 
with variation in the gC gene sequence relative to that of strain 
1942 from which the primers were derived.
Our results indicate, as do those o f Ballagi-Pordany e t  a l  
(1990), that PCR used on crude clinical samples can be applied to 
the rapid diagnosis o f EHV-1 and -4 infection. We also have 
evidence that, as might be expected, PCR is the more sensitive 
diagnostic technique. In addition to its increased sensitivity and 
decreased sample analysis time, a PCR diagnostic laboratory 
probably would be more economical than existing virus isolation 
and serological facilities. However, it is essential that strict 
procedures are followed as detailed here and elsewhere (Jarrett e t  
a l  1990) to avoid contamination. A typical PCR reaction can 
generate as may as 1012 molecules o f amplified DNA (Mullis and 
Faloona 1987). In other words, a 100 (il aliquot from an Olympic 
size swimming pool in which reaction products had been 
distributed would yield 400 molecules o f amplified DNA (Kwok 
and Higuchi 1989). Therefore, PCR reaction products serve as a 
source o f contamination that could yield false positive results.
The PCR technique ultimately could be used to identifiy 
particular strains o f virus using primer sets to divergent parts of the 
EHV-1 genome. Thus, strains associated with paralytic and 
abortigenic disease could potentially be differentiated. Given its 
sensitivity, PCR also has particular application to the study of EHV- 
1 and -4 latency. To obtain a good comparison of the relative 
sensitivity o f PCR versus virus isolation, sequential studies of virus 
excretion during the course of infection are planned.
A cknow ledgem en ts
We thank Catherine Naughton for her excellent technical 
assistance and M. Riddell, A. May and J. Fuller for their help in 
the preparation o f the manuscript and diagrams. We are grateful 
for the generous support o f the Horserace Betting Levy Board.
EQUINE VETERINARY JOURNAL 25
R eferences
Allen. G. P. and Bryans. J. T. (1986) M olecular epizootiology. pathogenesis and 
prophylaxis o f equine herpesvirus-1 infections. Prog. vet. microbiol. Immunol. 2. 
78-144.
Allen. G. P. and Coogle. L. D. (1988) Characterization o f an equine herpesvirus type 
I gene encoding glycoprotein gp(13) with homology to Herpes Simplex Virus 
glycoprotein C. 7. Virol. 62. 2850-2858.
Ballagi-Pordany, A.. K lingebom , B., Flensburg, J. and Belak. S. (1990) Equine 
herpesvirus type 1: detection o f viral DNA sequences in aborted fetuses with the 
polymerase chain reaction. Vet. Microbiol. 22. 373-381.
Browning, G. F.. Bulach. D. M., Ficorilli. N.. Roy. E. A.. Thorp, B. H. and Studdert. 
M. J. (1988) Latency of equine herpesvirus 4 (Equine rhinopneumonitis virus). 
Vet.Ree. 123.518-519.
Chowdhury, S. I., Hammerschmidt, W„ Ludwig. H.. Thein, P. and Buhk, H. J. (1986) 
Rapid m ethod for the identification and screening o f herpesviruses by DNA 
fingerprinting com bined with blot hybridization. 7. Virol. Methods. 14. 285-291.
Cullinane, A. A.. Rixon. F. J. and Davison, A. J. (1988) Characterization of the 
genom e of equine herpesvirus 1 subtype 2.7 . Gen. Virol. 69, 1575-1590.
Edington. N ., Bridges. C. G. and Huckle, A. (1985) Experimental reactivation of 
Equid herpesvirus 1 (EHV-1) following the adm inistration o f corticosteroids. 
Equine vet. J. 17. 369-372.
Jarrett. R. F., Clark. D. A.. Josephs, S. F. and Onions. D. E. (1990) Detection of human 
herpesvirus-6 DNA in peripheral blood and saliva. 7. Med. Virol. 32. 73-76.
Kwok, S. and H iguchi. R. (1989) Avoidance of false positives with PCR. Nature 
I London) 339 . 237-238.
M eredith. D. M.. Stocks. J.-M., Whittaker, G. R., Halliburton, I. W„ Snowden, B.
W„ K illington. R. A. (1989) Identification o f the gB homologues of equine 
herpesvirus types I and 4 as disuiphide-linked heterodim ers and their 
characterization using monoclonal antibodies. 7. Gen. Virol. 70. 1161-1172.
Meyer. H., Thein, P. and Hubert (1987) Characterization o f two equine herpesvirus 
(EHV) isolates associated with neurological disorders in horses. 7. Vet. Med.
B 34. 545-548.
M ullis, K. B. and Faloona. F. A. (1987) Specific synthesis of DNA in vitro via a 
polym erase catalyzed chain reaction. M ethods Enzymol. 155. 335-350.
N icolson. L. and Onions, D. E. (1990) The nucleotide sequence o f equine 
herpesvirus 4 gC gene homologue. Virology 179. 378-387.
Nicolson. L., Cullinane, A. A. and Onions. D. E. (1990a) The nucleotide sequence of 
the equine herpesvirus 4 thym idine kinase gene. 7. Gen. Virol. 71. 1801-1805.
N icolson. L.. Cullinane. A. A. and Onions. D. E. (1900b) The nucleotide sequence of 
equine herpesvirus 4 gene homologue of the herpes simplex virus I glycoprotein 
H gene. 7. Gen. Virol. 71. 1793-1800.
Robertson. G. R. and Whalley, J. M. (1988) Evolution of herpes thym idine kinase: 
identification and com parison o f the equine herpesvirus 1 thymidine kinase gene 
reveals similarity to a cell encoded thym idylate kinase. Nucleic Acid  Res. 16. 
11303-11317.
Saiki, R. K., Gelfand. D. H.. Stoffel. S.. Scharf. S. J.. Higuchi. R.. Horn. G. T.. 
Mullis, K. B„ Erlich. H. A. (1988) Primer-directed enzymatic am plification of 
DNA with a thermostable DNA polymerase. Science  239, 487-491.
Scott, J. C., Dutta. S. K., Mvrup, A. C. (1983) In vivo harboring o f equine herpesvirus- 
1 in leucocyte populations and sub-populations and their quantitation from 
experimentally infected ponies. Am. 7. vet. Res. 44, 1344-1348.
Yeargan, M. R., Allen. G. P. and Bryans. J. T. (1985) Rapid subtyping o f equine 
herpesvirus 1 with monoclonal antibodies. 7. Clin. Microbiol. 21. 694-697.
Recieved fo r  publication: 25.2.91  
Accepted: 15.7.91
Equine Reproduction Short Course
San Antonio, Texas, USA 10th-12th August, 1992
The American College of Theriogenologists is presenting an Equine 
Reproduction Short Course for veterinarians in San Antonio, Texas, U.S.A., 
10th-12th August, 1992. This will im m ediately precede the annual m eeting of 
the Society for Theriogenology, 14th-15th August, 1992 in San Antonio.
The programme will consist o f the m ost up-to-date topics involving the mare 
and stallion and will be presented by internationally Known theriogenologists. 
The short course also will include a one-day laboratory with limited enrollment.
For further information, p lease contact: Dr Walter R. Threlfall, The 
Ohio Sate University, Veterinary Hospital, 1935 Coffey Road, 
Columbus, Ofl 43210-1089 , USA. Tel: (614) 292-6661.
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